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Abstract 
Cancer is one of the most challenge diseases to treat around the world. Drug 
delivery system, as one of the chemotherapeutic treatments has received enorrmous 
attention from researchers. This thesis is to develop amphiphilic diblock copolymer 
protected nanoparticles loaded with anti-cancer drug, with small size and high drug 
loading, to achieve selective drug delivery using EPR effect. Chapter 1 briefly describes 
the motivation and novelties of this research pursuit. Chapter 2 introduces a modified 
confined impingement jets mixer with dilution (CIJ-D mixer), using flash 
nanoprecipitation to produce nanoparticles made of hydrophobic drugs. The CIJ-D mixer 
was evaluated by the sizes of β-carotene nanoparticles at varied flow conditions 
compared to these made by multi-inlet vortex mixer. The CIJ-D mixer provides higher 
efficiency and easiness of handling for nanoparticle preparation. That is why CIJ-D mixer 
was used for all the work presented in the following chapters. In Chapter 3, we made the 
first attempt to produce PEG-b-PLGA protected paclitaxel loaded nanoparticles but 
failed, because paclitaxel is too hydrophilic to be captured in particles. Thus, a series of 
silicate ester derivatized paclitaxel were synthesized by Hoye research group and 
successfully encapsulated into nanoparticles. Several nanoparticle post-treatments, such 
as filtration, hollow fiber diafiltration, and ultracentrifugation were used and assessed, in 
order to purify nanoparticles. Lyophilization was found to induce nanoparticle 
aggregation due to the freezing process. The addition of sucrose as cryoprotectant was 
studied to prevent aggregation and recover nanoparticle. Chapter 4 focuses on developing 
in vitro drug release protocols, for more accurate quantification of highly hydrophobic 
paclitaxel prodrugs. Different dialysis devices were used such as dialysis tubes, dialysis 
vi 
 
cassettes, and dialysis mini capsules. Infinite sink and limited sink conditions were 
compared as well to provide sufficient concentration gradient across dialysis semi-
permeable membrane. At last, a reverse drug release experimental protocol was 
customized to determine the remaining drug left in dialysis mini capsules while the sink 
condition was maintained by frequently refreshing buffer solution during in vitro drug 
release study. Chapter 5 mainly presents the pharmacokinetics of paclitaxel prodrug 
nanoparticles loaded with different silicate ester derivatives, at different pH, both inside 
nanoparticles and in buffer solution. Chapter 6 includes a series of Cryo-TEM images of 
nanoparticles collected at different time, such as fresh nanoparticles immediately after 
being prepared by CIJ-D mixer, nanoparticles after ultracentrifugation, after 
lyophilization, 0hr, and 24 hr during drug release study. These images not only showed a 
reverse liner relation of average particle size and hydrophobicity of the loaded drug, but 
also displayed a core-shell internal structure of nanoparticles prepared via flash 
nanoprecipitation and potential particle disassembly after 24hr drug release. Finally, 
Chapter 7 summarizes the key results and conclusions obtained from previous chapters, 
lessons learned from mistakes and failures, and future directions for this project, in order 
to prepare nanoparticles with better controlled size and drug release kinetics and to 
understand deeply on nanoparticle formation and release mechanisms.   
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Chapter 1 Overview and Motivation 
1.1 Drug Delivery and EPR Effect 
Cancer is the second deadly disease globally, causing about 13% of all human 
death
1
. Numerous researchers have endeavored for decades to find effective treatments 
for cancer. Currently, several methods have been developed, such as surgery, radiation 
and chemotherapy. However, chemotherapy, as the most effective and widely used 
treatment, has severe side effects on patients, mainly due to undesirable and non-specific 
anticancer drug delivery to normal tissues in human body. Accordingly, a goal of 
chemotherapeutic treatment is to achieve specific drug delivery allowing drug localized 
only in tumor tissues. Methods to achieve specific delivery can be categorized in two: 
active targeting and passive targeting
2
. Active targeting usually involves functionalizing 
drug delivery systems with particular functional groups which can be attracted to receptor 
on cancer cell surface. However, in this research work, we focus on drug delivery system 
via passive targeting. It means that specific drug delivery relies on nano-scale systems 
being uptaken via selective size and transport. It is called the enhanced permeation and 
retention effect, or EPR effect discovered in 1986
3-6
.   
Utilizing the EPR effect, macromolecular particles are first delivered by 
intravenous administration and circulated in blood as shown in Figure 1.1. When they 
reach normal tissue vasculature, normal endothelial cells are compactly aligned, and drug 
molecules or very small particles less than 50 nm in diameter can penetrate them. On the 
other hand, tumor tissues are poorly aligned with defective endothelial cells. Researchers 
have found open cell fenestrations range approximately between 50-400 nm depending 
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on different tumor types and their locations. Particles in this size range will penetrate 
through and localize in tumor tissues. Also vascular structure is poorly organized with 
dead ends. Moreover, tumor tissues typically lack effective lymphatic drainage system. 
Both factors mean particles lodging in tumors will have an elongated retention time.  
There is a growing trend of tailoring particles smaller for the EPR effect. Several 
researchers have claimed that particle sizes below 30 nm are desirable in some cases
4-6
. It 
is also stated that sizes within 10-100 nm are able to deliver drug efficiently and to 
facilitate long circulation in blood and higher uptake of drug in tumor
7
. Meanwhile, there 
is a limit since particles smaller than 20 nm cannot be prevented from renal clearance
8-10
. 
It is pointed out that the reduction in size increases uptake by both dissolution and 
particulate pathways, but the increased self-agglomeration of small particles can, 
paradoxically, lead to reduced uptake
11
. Researchers have also shown that different 
tumors have different pore sizes and they also change as a function of time
12
.  
 
 
Figure 1.1 Specific drug delivery via the enhanced permeation and retention effect
103
. 
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It is clear that there is no universally accepted standard, in regards to particle size 
for the EPR effect. Because pore sizes vary greatly, future development of nanoparticles 
for drug delivery must be customized in size depending on cancer type and position. 
Therefore, more specific particle size control is desired, we should be prepared to be able 
to produce nanoparticles with desirable sizes. There is a need for manufacturing 
processes, in which size of the resulting nanoparticles can be at least predicted and 
controlled. In order to utilize EPR effect, our goal was first to prepare nanoparticle in 50-
400 nm and control their size by mixing condition, solvent systems, selection of drug and 
polymer.  
1.2 Nanoparticles and Flash Nanoprecipitation 
Nearly 40% of active pharmaceutical ingredients are hydrophobic, thus it is very 
challenging to deliver them in aqueous solution for clinical evaluation
13
. That is why 
nano-scale systems such as emulsion
14
, micelle
15-20
, liposomes
21
, and polymersomes
22
, 
draw enormous attention as drug delivery tools. Nevertheless, their loading capacities are 
typically low (less than 20%
23-25
, and frequently less than 5% for paclitaxel) and limited 
by the solubility of drug in hydrophobic moiety of surfactant or polymer excipient
26
. Pure 
drug particles can overcome these limitations and have been widely used in industrial 
production and laboratory experiment. Industrial processes are usually in the top down 
category include media milling, grinding and high pressure homogenization. The 
disadvantages are large particle size, broad distribution, long processing time, 
contamination and high power source required. In laboratory studies, nanoparticles are 
often prepared from molecular level via bottom up processes, such as traditional drop-
wise precipitation etc. But, these methods also have trouble producing nanoparticles 
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below 200 nm and need long processing time from a few hours to weeks
27-31
 in order to 
reach thermodynamic equilibrium
32, 33
. To overcome this limitation, a kinetic process, 
flash nanoprecipitation, is introduced in this work. 
 
Flash nanoprecipitation was developed by Prud’homme et al via vortex mixer and 
confined impingement jets (CIJ) mixer
34-39
 and further improved in our laboratory via CIJ 
with a dilution (CIJ-D) mixer
40
. In this process as shown in Figure 1.2, amphiphilic block 
copolymer and hydrophobic drug are first dissolved in a water miscible organic solvent, 
which is impinged rapidly with antisolvent, typically water. The supersaturation 
condition drives organic solutes to precipitate out of the solvent mixture, nucleate and 
grow into particles. A diblock copolymer is added to provide steric stability to these 
particles. The hydrophobic block of copolymer co-precipitates with drug to form particle 
cores, while the hydrophilic block of copolymer arrests particle growth via steric 
stabilization. The solvent mixing can be achieved in a few seconds, which is obviously 
      
Figure 1.2 Schematic of flash nanoprecipitation to form hydrophobic drug loaded block 
copolymer protected nanoparticles
67
. 
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more efficient that overnight drop-wise precipitation. Nanoparticles are kinetically 
formed which makes it possible to control particle size in a range of 50-400 nm by 
micromixing condition. The drug loading is extremely high which is beyond the 
capability of all thermodynamic equilibrium systems such as micelle, emulsion, or 
liposome. Therefore, flash nanoprecipitation has already been applied to anti-cancer drug 
formulation
41
 and bioimaging
42-45
 nanoparticles. 
1.3 Paclitaxel Formulation and Controlled Drug Release 
In this work, paclitaxel was chosen as the anti-cancer drug for nanoparticle 
chemotherapeutic formulation development. It was first discovered by Monroe E. Wall 
and Mansukh C. Wani in 1967, by isolating from the bark of the Pacific Yew tree
46
. It 
promotes polymerization of tubulin, stabilizes microtubules and interferes with the 
normal breakdown of microtubules in cell division, resulting in cell cycle arrest and 
eventually cell death. It is a mitotic inhibitor in chemotherapy, widely used for patients 
with ovarian, breast, non-small cell lung cancers and AIDS-related Kaposi’s sarcoma46, 47.  
Current paclitaxel-based formulations have several limitations. For instance, in 
Taxol
®
, paclitaxel is dissolved in Cremophor EL
®
, a 1:1 mixture of polyethoxylated 
castor oil and ethanol, whereas Cremophor EL
®
 is toxic with a large amount needed to 
enhance the low solubility of paclitaxel
48-51
. It causes non-specific delivery of paclitaxel 
during blood circulation with severe side effects
52
. Another formulation, Abraxane
®
 is a 
nanoparticle formulation with albumin
53
. Although it eliminates the use of Cremophor 
and its toxicity, FDA approved its use only for certain types of patients at certain 
stages
54,55
. Also Taxol
® 
is now generic, Abraxane
®
 is more expensive
56
 than Taxol
®
 due 
to engineering challenges in formulation production. Genexol
®
 uses block copolymer to 
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solubilize paclitaxel with much less toxicity related to delivery agents, but it is now 
facing neurotoxicity safety issues in phase II trials
57
. Briefly, those paclitaxel 
formulations have common problems, such as non-specific drug delivery, toxicity of 
delivery agent and low drug loading in 1-10 wt%
53, 58
.  
In order to improve paclitaxel delivery, the goal of this work was to use 
biodegradable amphiphilic block copolymer as delivery agent to prepare paclitaxel 
containing nanoparticles with high drug loading made via flash nanoprecipitation. More 
importantly, this thesis focused on characterizing drug delivery and controlling drug 
release by several strategies, such as controlling particle size, and prodrug modification 
of pacltiaxel, with customized hydrophobicity and hydrolytic lability etc. 
1.4 Thesis Outline and Novelty 
In Ch.2 we describe a simple and efficient mixer to prepare nanoparticles via flash 
nanoprecipitation. A modified version of Prud’homme’s confined impingement jets (CIJ) 
mixer
34, 37
 is introduced here with the addition of a dilution stage. The new design of CIJ-
D mixer was manufacturing in our laboratory. β-carotene was used as a model drug. It is 
inexpensive and highly hydrophobic. The amphiphilic block copolymer (PEG-b-PLA) 
was used to stabilize nanoparticles in size and stability. To understand the importance of 
dilution stage, β-carotene nanoparticles were first prepared without dilution, or with an 
immediate or delayed dilution. Also, the dilution volume was varied. Particle sizes at 
different conditions clearly demonstrated that dilution is very necessary to quench 
particle growth and high supersaturation level is substantial to create multiple nuclei 
resulting smaller particle size. We have also compared sizes of nanoparticles prepared by 
7 
 
CIJ-D mixer and multi-inlet vortex mixer (MIVM). At varied flow rates, particle size 
decreased as flow became more turbulent, characterized by Reynolds number (Re). At the 
same Re, nanoparticles from CIJ-D mixer were slightly smaller, which indicated that 
head-on impingement in CIJ-D mixing provided better micromixing condition.  
The novelties of this chapter are that 1) the confined impingement jets mixer was 
first modified with a dilution stage, to overcome the limitation on supersaturation level by 
equal volume impingement of solvent and antisolvent. 2) The effect of dilution was 
investigated in terms of particles nucleation and growth. The dilution needs to occur < 5s 
after mixing and > 5 fold in volume in order to create sufficient supersaturation. 3) The 
relation of particle size vs. flow conditions was established, and the threshold of 
sufficient turbulent condition was identified and estimated with Re>1000, to produce 
small and stable particles. Briefly, as an alternative to vortex mixer, CIJ-D mixer is 
simpler, cheaper, and more efficient to produce nanoparticles via flash nanoprecipitation. 
It is a smaller lab scale unit, especially convenient for rapid screening of small quantity of 
new materials.  The research results shown in the following chapters are all based on CIJ-
D prepared nanoparticles. Most of the content of this chapter has been published in the 
Journal of Pharm. Science
40
. 
In Ch.3, nanoparticles were successfully prepared with 2’-triethyl silicate (Si) 
paclitaxel (PTX) and 2’,7-triethyl silicate (Si) paclitaxel (PTX). They are silicate 
derivatized paclitaxel prodrugs with a higher hydrophobicity which was synthesized by 
Wohl et al
59, 60
. Paclitaxel was introduced as a hydrophobic pharmaceutical ingredient for 
chemotherapy, and silicate paclitaxel prodrugs as prodrug of paclitaxel, return to be 
active anti-cancer ingredient. They were characterized by dynamic light scattering (DLS), 
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nanoparticle tracking analysis (NTA), scanning electron microscopy (SEM), Cryogenic-
transmission electron microscopy (Cryo-TEM) and high performance liquid 
chromatography (HPLC) in terms of size, distribution, morphology and drug loading.  In 
order to determine drug loading more accurately, nanoparticles were purified using 
several techniques, such as membrane filter, hollow fiber diafiltration and 
ultracentrifugation. Ultracentrifugation was found to be the best method to remove un-
encapsulated drug molecules and empty polymer nanoparticles. Another advantage of 
using ultracentrifugation was that drug loading levels of the ultracentrifuged 
nanoparticles were higher than the initial formula due to the removal of empty polymer 
particles. For long-term storage, nanoparticles were then lyophilized to remove solvent 
content from nanosuspension. The resulting product was particles in dry powder. 
However, we encountered a problem to recover particle size when redispersing particles 
in aqueous solution. Thus, sonication was studied in the relation of particle size reduction. 
Also, cryoprotectant, sucrose was used to protect particles from aggregation during 
freezing process. Based on the shelf life concern of our prodrugs and nanoparticles, aging 
studies were conducted for 32 weeks to monitor composition change of prodrug affected 
by hydrolysis in dry state and in aqueous state for the entire nanoparticle preparation 
process, from the very beginning of prodrug synthesis, to CIJ-D mixing, 
ultracentrifugation, lyophilization and redispersing in aqueous solution for 24 hr.  
The novelties of this chapter are that 1) paclitaxel containing nanoparticles were 
successfully formulated and characterized with an average size of 120 nm and high drug 
loading above 50%. 2) The performance of filtration techniques were compared in terms 
of purifying particles and concentrating particle suspension. 3) Hollow fiber diafiltration 
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was first introduced, but it was not able to separate prodrug loaded and polymer particles. 
It is very efficient to concentrate nanoparticle solution and can be used for dispersion 
containing other micro- and nano-scale systems such as carbon nanotubes and graphene. 
Compared with simple filter filtration and hollow fiber filtration, ultracentrifugation was 
found to be the best method to separate prodrug loaded nanoparticles from prodrug 
molecules, polymer nanoparticles, and prodrug loaded small nanoparticles. 4) The size 
and composition of nanoparticles and the distribution of drug/prodrug were first analyzed 
among supernatant and final pellet after each time of ultracentrifugation. It clearly 
demonstrated that a great amount of free molecules were removed along with empty 
polymer nanoparticles. The loading of prodrug loaded nanoparticles collected from pellet 
increased to over 70% in particle mass. One downside was particle mass loss during 
ultracentrifugation. 5) Aging studies were first carried out to monitor hydrolysis rate of 
paclitaxel prodrug in solid compound state for months and in the entire process of 
nanoparticle preparation and post-treatments. Prodrugs hydrolyzed quickly after 
nanoparticles were in aqueous solution within 24 hr, and even hydrolyzed significantly 
after 5 week in dry state.  Meanwhile, we have found that empty polymer nanoparticles 
degraded at pH 5.0 only after several days, which ruled out the possibility that polymer 
degradation leaves particles less protected and induces prodrug hydrolysis more quickly. 
In summary, paclitaxel with more hydrophobic silicate esters were encapsulated in PEG-
b-PLGA nanoparticles and they have an extraordinary high loading compared to current 
PTX-based formulations in the market. In the following chapters, a standard procedure 
was established to prepare nanoparticles using CIJ-D mixer, followed with 
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ultracentrifugation and lyophilization. They were lyophilized and kept in dry state until 
nanoparticles were needed for in vitro and in vivo studies.   
In Ch.4, in vitro drug release studies were carried out with a series of silicate (Si) 
paclitaxel (PTX) prodrugs. They were 2’-triethyl Si PTX (1a), 2’,7-triethyl Si PTX (2a), 
2’-trioctyl Si PTX (1b), 2’,7-trioctyl Si PTX (2b), 2’-triisopropyl Si PTX (1c) and 2’,7-
triisopropyl Si PTX, synthesized with different silicate esters either at 2’carbon or both 
2’carbon and 7 carbon position by Wohl et al59, 60. To establish a standard drug release 
protocol, several experimental conditions were used including infinite sink, limited buffer, 
pH at 7.4 and 6.4 to mimic acid environment of healthy tissues and tumor tissues. Several 
dialysis devices were used and evaluated. Among dialysis tube, cassette and capsules, 
dialysis mini capsules were chosen for in vitro drug release study. The drug release rates 
were determined reversely by quantifying the remaining drug left in nanoparticles. The 
effect of silicate ester type and position were studied in terms of controlling particle size, 
morphology and more importantly, drug release rates.  
The novelties of this chapter are that 1) a limited sink condition achieved 
consistent release profiles when compared with infinite sink condition, by frequently 
refreshing buffer. 2) Several dialysis devices were compared to deliver better 
performance of release characterization, and dialysis mini capsules (MWCO: 10kDa) 
were chosen as the best for accurate results and ease of handling. 3) A reverse release 
protocol was established to determine the remaining drug in nanoparticles instead of 
released ones in buffer, to overcome the difficulty of quantifying extremely low 
concentration of drug in buffer due to the limited water solubility. Nanoparticles studied 
in this chapter were unfortunately not ultracentrifuged after CIJ-D mixing, thus the 
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diffusion of un-encapsulated drug mixed with nanoparticles caused a significant burst-
release pattern. However, the release study protocol was established by using mini 
dialysis capsules, with frequently refreshed buffer and by determining the remaining drug 
in nanoparticles by HPLC. 
In Ch.5, seven types of silicate ester were introduced to silicate paclitaxel prodrug 
synthesis. They were 2’-triethyl Si PTX (1a), 2’,7-triethyl Si PTX (2a), 7-triethyl Si PTX 
(3a), 2’-trioctyl Si PTX (1b), 2’,7-trioctyl Si PTX (2b), 2’-triisopropyl Si PTX (1c), 2’,7-
triisopropyl Si PTX (2c), 2’-ditert butyl/ethyl Si PTX (1d), and 2’-trimenthyl Si PTX (1e). 
Nanoparticles formulated with these prodrugs were ultracentrifuged between CIJ-D 
mixing and lyophilization. The release profiles were more sustained without any drastic 
burst pattern. With a broad range of customized hydrophobicity and hydrolytic lability, 
nanoparticles displayed a trend of smaller nanoparticle size with more hydrophobic 
compounds, and they released slower with more hydrolytic stable prodrugs. To determine 
the accuracy of the reverse release protocol, a series of mass balance studies were 
conducted to determine whether the remaining and the released drug were 
complementary. Meanwhile, the composition of prodrugs, partially hydrolyzed prodrugs 
and PTX obtained from hydrolysis were determined, this helped us understand the release 
mechanism for particles encapsulating with different Si PTX prodrugs and their 
regeneration of PTX. The general delivery of PTX could be contributed by diffusion, 
hydrolysis, and a combination of the two. More hydrolytic labile prodrugs hydrolyzed 
relatively fast, more PTX regenerated from hydrolysis was found, while hydrolytically 
stable prodrugs hydrolyzed very slowly, so the diffusion of the prodrug was dominant. 
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These phenomena are potentially beneficial for our future work in order to control release 
rate by tuning the hydrolytic lability and hydrophobicity.  
 The novelties of this chapter are that 1) mass balance studies demonstrated that 
the reverse release protocol was able to provide release profiles as accurate as the 
traditional release protocol directly determining the released drug in buffer. 2) 
Composition change of drug and prodrug were different in nanoparticles and in buffer, 
which indicated prodrug hydrolysis was affected by the microenvironment of 
nanoparticles. 3) Nanoparticles with all prodrugs displayed a higher release rate when in 
vitro drug release studies were carried at pH =5.0. It implied that pH-responsive 
hydrolysis contributed to general release in varied levels, and potentially can be a strategy 
to control drug release and regeneration of PTX.  
In Ch.6, nanoparticle size and morphology were mainly characterized by DLS, 
NTA and Cryo-TEM. Hundreds of Cryo-TEM images which obtained by Lee
61
 were 
used to determine particle size and distribution as well. They clearly showed morphology 
change of nanoparticles from fresh state, to lyophilized and redispersed for release 
studies. The novelties of this chapter are that 1) DLS, NTA and Cryo-TEM gave 
consistent particle size. 2) The visualization of core-shell structure was obtained for the 
first time and it confirmed nanoparticles were kinetically formed via nucleation and 
growth. 3) Particle shrinking and disassembly was observed after 24 hr release, which 
lead to a speculation that polymer might degrade or particle collapsed and caused 
irregular shape of nanoparticles over time.  
In Ch.7, key results in previous chapters are summarized. Recommendations for 
future research are discussed including loading two or more prodrug and other functional 
13 
 
ingredients in nanoparticles, using other block copolymer, drug release study in cell 
culture or serum (in vitro or in vivo)  which is closer to biological condition, and polymer 
degradation study.  
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Chapter 2    
Flash Nanoprecipitation: Multi-Inlet Vortex Mixer vs. 
Confined-Impingement Jets Mixer 
Abstract: Johnson and Prud’homme34 introduced the confined impingement 
jets (CIJ) mixer to prepare nanoparticles loaded with hydrophobic compounds (e.g., drugs, 
inks, fragrances, or pheromones) via flash nanoprecipitation (FNP). We have modified 
the original CIJ design to allow hand operation, eliminating the need for a syringe pump, 
and we added a second antisolvent dilution stage. Importantly, the dilution stage 
overcomes the need to operate the original CIJ mixer at equal flow rates of solvent and 
antisolvent. This new CIJ-D mixer (confined impingement jets with dilution) is simple, 
cheap and efficient to produce nanoparticles. We have made 55 nm diameter β-carotene 
nanoparticles using the CIJ-D mixer. They are stable and reproducible in terms of particle 
size and distribution. We have also compared the performance of our CIJ-D mixer with 
the vortex mixer, which can operate at unequal flow rates
39, to make β-carotene-
containing particles over a series of turbulent conditions. Based upon dynamic light 
scattering (DLS) measurements, the new CIJ-D mixer produces stable particles of a size 
similar to the vortex mixer. Our CIJ-D design provides an easily operated and 
inexpensive tool to produce nanoparticles via FNP and to evaluate new nanoparticle 
formulation.  
Key words: CIJ mixer, nanoparticles, flash nanoprecipitation, drug delivery, β-
carotene 
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2.1 Introduction 
Nanoparticles have recently received enormous attention as a drug delivery tool
2, 
62-65
. Flash nanoprecipitation (FNP) is a simple technique that is used to prepare 
polymeric nanoparticles with a high loading of hydrophobic compounds, including 
drugs
34, 37, 66
. As shown in Figure 2.1
67
, a hydrophobic drug and an amphiphilic block 
copolymer (e.g. PEG-b-PLA, polyethylene glycol-b-polylactic acid) are co-dissolved in a 
water miscible organic solvent (e.g. THF), which is then impinged at high velocity 
against an antisolvent (water) to create turbulent mixing and high supersaturation. The 
supersaturation promotes co-precipitation of the hydrophobic drug and the hydrophobic 
block of the copolymer to form nanoparticles
38, 39, 68, 69
. Mixing and precipitation occur 
within milliseconds inside the small internal mixing chamber. 
  
Johnson and Prud’homme34 first described FNP using a confined impingement 
jets mixer (CIJ). In this design, a syringe pump was used to drive two opposing liquid 
streams (A and B in Figure 2.1) at high velocity into the mixing chamber. Prud’homme 
             
                Figure 2.1 Schematic of flash nanoprecipitation process. 
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and others
34-36, 59, 70-72
 used this device to successfully make a variety of nanoparticles. 
The CIJ design was inspired by the simple T mixer that is commonly used to mix liquids 
or act as a chemical reactor
73, 74
. T mixers have also been used to mix monomers and 
oligomers for reaction injection molding
75-77
.  
To avoid reducing the mixing efficiency (via one stream backing up the other), 
the two streams in the CIJ mixer must operate at near equal momentum. In practice, this 
requires approximately a 1:1 volume flow rate, limiting the highest achievable 
supersaturation level. To operate at unequal flow ratios, Prud’homme and coworkers 
developed a multi-inlet vortex mixer
78, 79
. In this design, the mixing chamber is connected 
to four inlets and the liquid streams meet at an angle as opposed to the head-on 
impingement that is characteristic of the CIJ mixer. The vortex mixer can be applied to a 
wide range of solvent ratios and materials. However, the device is time consuming to 
clean and digitally programmed syringe pumps are usually required to control the inlet 
flow rates
80
. In terms of operation, cleaning and cost, the CIJ mixer is preferred. 
Nevertheless, the vortex mixer is able to achieve higher levels of supersaturation.  
In this chapter, we report a modified CIJ design, the CIJ-D mixer, that is simpler 
than the original Johnson and Prud’homme design, yet overcomes the limitation of 1:1 
solvent ratio. To emphasize its simpler design and easier handling with equivalent 
function, we have compared the average size of β-carotene nanoparticles made using our 
CIJ-D mixer vs. the vortex mixer at varied flow conditions. 
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2.2 Design 
2.2.1 Interior Dimensions of CIJ-D Mixer 
Figure 2.2 shows the confined impingement 
jets with dilution (CIJ-D) design. Two features 
distinguish it from the original CIJ mixer: hand 
operation and an antisolvent dilution stage. By using 
relatively small, low friction syringes, turbulent 
flow can be achieved with simple, rapid hand 
motion, eliminating the need for syringe pumps. A 
metal plate connects the two syringes to insure 
simultaneous actuation. To increase the 
supersaturation, the outlet stream from the CIJ-D 
chamber immediately flows directly into a large volume of water.  
The design dimensions for the CIJ 
mixing chamber was first recommended by 
Johnson and Prud’homme34. It has been 
redesigned in our laboratory and 
manufactured here in the physics machine 
shop (University of Minnesota). The 
innovation at UMN is to make an intact unit 
with the complete chamber and flow paths 
there, as composed to Prud’homme’s CIJ 
mixer composed of three pieces merged together that were initially intended to get 
 
Figure 2.2 The CIJ-D mixer, hand 
operated with subsequent dilution. 
 
Figure 2.3 The original design of the CIJ 
mixer chamber by B.K. Johnson and R.K. 
Prud’homme. 
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interior chamber and paths exposed for manufacturing easiness.  The original CIJ mixer 
was described with dimensions shown below
37
. In Figure 2.3, d=0.5 mm, L/d > 8 to 
insure the jets are stable, the chamber height to diameter H=0.8D, and length to diameter 
ratio H+Z=2.0D are held constant to maintain geometric similarity upon scale-up. The 
outlet tube runner is at least ten times the outlet diameter K/δ >10, in order to create a 
pressure drop and ensure that the chamber is filled with liquid during impingement. 
Figure 2.4 shows the dimensions of our CIJ-D chamber. In order to build a 
standard for manufacturing our CIJ-D mixer, a complete specification list was presented 
here for dimensions and raw materials. d=0.5 mm, H=2 mm, Z=3 mm, D=2.5 mm 
(D/d=4.76, H=0.8D, Z=1.2D). A ratio of entrance channel length to diameter L/d=6.1 is 
used to insure stable jets. The chamber volume is 25 µL.  
 
 
                         Figure 2.4 Dimensions of the CIJ-D mixer made of HDPE. 
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2.2.2 Raw Materials and Parts   
The main body of the CIJ mixer is made of high density polyethylene (HDPE). 
All five openings are tapped with 1/4”-28 threads. The two inlets on the top in Figure 2.2 
are threaded with white adapters (IDEX Health & Science, P604) fitted with glass or 
plastic syringes, and one outlet is threaded with green adapter (IDEX Health & Science, 
P205-X), and a blue cap (P-200X) inside threaded with a Teflon tube. Two additional 
side openings resulted when horizontal jet pathways were drilled during manufacturing.  
They are sealed with white plugs (IDEX Health & Science, P203-X) during FNP, but can 
be opened for thorough cleaning. An aluminum metal bar is placed on top of syringes to 
assure stable injection and simultaneous actuation. 
2.3 Methods and Experiments 
2.3.1 Materials 
β-carotene was purchased from Sigma-Aldrich and used as received. PEG-b-PLA 
(MW: 5k-10kDa
81) was synthesized in Hoye’s lab. Water (H2O, HPLC grade) and 
tetrahydrofuran (THF, HPLC grade) were purchased from Aldrich and used as received. 
Multiple 3 mL plastic syringes (Tyco Healthcare, MA) were used for solvent injection. A 
programmable pump (Harvard Apparatus, PHD 2000)
82
 and a mechanical pump (Harvard 
Apparatus, model 945) were used for solvent injection with vortex mixer.  
2.3.2 β-carotene (only) Nanoparticle Preparation  
A typical procedure for making nanoparticles is as follows. β-carotene was used 
as the generic hydrophobic molecule. PEG-b-PLA was used as the amphiphilic block 
20 
 
copolymer. 25 mg β-carotene and 25 mg PEG-b-PLA were dissolved in 2.5 mL of THF 
and transferred to a 3 mL plastic syringe. 2.5 mL of water was loaded in a second 3 mL 
plastic syringe. The mixing occurred for 5 seconds and the co-mixed streams was 
immediately drained into a bottom reservoir pre-loaded with 45 mL of water. The final 
composition of the 50 mL dispersion was THF:H2O = 5:95, containing 0.1 wt% of 
nanoparticles.  
To prepare nanoparticles only composed of β-carotene via vortex mixer, which 
has same dimensions of Prud’homme’s multi-inlet vortex mixer39, 25 mg β-carotene was 
dissolved in 2.5 mL THF. The other three syringes contained 2.5 mL, 22.5 mL and 22.5 
mL water, respectively. The four streams were all injected into vortex mixer at varied 
flow rates in order to complete mixing simultaneously. The resulting mixture was 
collected at the volume ratio of H2O:THF= 95:5. The desired flow rates were 
programmed by digital and mechanical pumps.  
To prepare nanoparticles only composed of β-carotene via CIJ-D mixer, 25 mg β-
carotene was dissolved in 2.5 mL THF and impinged with 2.5 mL water. The mixture 
was diluted in 45 mL water resulting a same volume ratio as that made by vortex mixer. 
When they were prepared at different conditions, the desired flow rates were determined 
by the mixing time for the given volume of solvent when syringes were propelled by 
hand. 
To investigate the effect of dilution stage in CIJ-D mixing, β-carotene 
nanoparticles were prepared without dilution, a delayed dilution or a smaller volume 
dilution. Their particle sizes and stability were compared with particles made by the 
standard procedure above.  
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To test performance of CIJ-D mixer, β-carotene nanoparticles made by the CIJ-D 
mixer were compared to those made by vortex mixer. The flow conditions were varied 
simply by changing hand velocity during CIJ-D mixing and adjusting flow rates on 
digital pumps during vortex mixing. Particle sizes were characterized at each flow rate.  
2.3.3. Particle Size and Distribution 
Mass average particle size and distribution was determined by dynamic light 
scattering (DLS) (ZetaPALS, Brookhaven) with a diode laser BI-DPSS wavelength of 
659 nm, using REPES method
67, 83, 84
. The light intensity correlation function was 
collected at 25 ˚C and a scattering angle of 90˚. 
DLS is based on the technique-photon correlation spectroscopy (PCS) of quasi-
elastically scattered light (QELS), which is dependent on correlating the fluctuations 
about the average, the scattered and the laser light intensity. Light can be treated as an 
electromagnetic wave. The oscillating electro-magnetic field induces oscillations of the 
electrons in a particle. These oscillations change from the source of scattered light. The 
average intensity of the scattered light has been used to determine particle size, in DLS 
measurement. Generally speaking, DLS measurement is based on Stokes-Einstein 
relation, correlating diffusion coefficient with particle size. 
 
D is the diffusion coefficient, kB is Boltzmann’s constant, T is the absolute 
temperature, η is viscosity, R is the hydrodynamic radius of spherical particles. 
When we discuss particle size, the mass average size is mainly used  
                                                                                                    Eq. 2.1 
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            ni is the number of particles with a diameter of di, mi is the mass of a particle with 
a diameter di. 
Intensity Average Size:         
 
ni is the number of particles with a diameter of di. 
2.3.4 Reynolds Number  
Mixer efficiency is typically correlated with Reynolds number, the ratio of inertial 
force to viscous force. The Reynolds number was calculated in 
               Eq. 2.:  
In our case, Reynolds number was calculated by accumulating multiple streams 
when using the CIJ-D or vortex mixer in Eq. 2.5.          
                                                                                                                                                                                                                  
where ρ is the density of the fluid (kg/m3), V is the mean fluid velocity (s), d is the 
stream inlet diameter, µ is the viscosity of the fluid (kg/m∙s), A is the pipe cross-sectional 
area (m
2
) which in our case was the same for all inlets of a given mixer, and Qi is the 
volumetric flow rate (m
3
/s) of the ith inlet stream. 
For example, in CIJ mixing, n=2 for two streams, ρ is 1.0×103 kg·m-3 for H2O, or 
8.89×10
2 
kg·m
-3 
for THF at room temperature, µ is 1.0×10
-3 
Pa·s at room temperature for 
                                       Eq. 2.5 
 
              Eq. 2.2 
 
 4 3
m / /i i i i i i i i id n m d n m n d n d    
                                           Eq. 2.4 
                        
 
                                                                         Eq. 2.3 
 56 iiiiI dndnd
23 
 
H2O, or 4.8×10
-4
 Pa·s for THF, and d is 5×10
-4
m for the CIJ-D mixer. In vortex mixing, it 
has four inlets, each with diameter d=1.45×10
-3 
m. We assumed µ=1.0×10
-3 
Pa·s and ρ = 
1.0×10
-3 
kg·m
-3
 at room temperature, since 95％H2O/5％THF has a similar kinematic 
viscosity to that of water. More Reynolds number calculation are in Appendix B.                                                                                                                                                                        
2.4 Results and Discussion 
2.4.1 Design Comparison between MIV Mixer and CIJ-D Mixer 
Currently, we have two apparatuses to make nanoparticles based on FNP process, 
the multi-inlet vortex (MIV) mixer and the CIJ-D mixer. The vortex mixer was 
manufactured by Prud’homme at Princetion University. The CIJ-D mixer was 
manufactured in our laboratory at University of Minnesota. The two mixers are shown in 
Figure 2.5(a) and (b). Though the CIJ mixer and the vortex mixer are two embodiments 
of flash nanoprecipitation, they are different in several aspects in terms of design. 
 
                        
                       Figure 2.5 (a) the CIJ-D mixer. (b) the multi-inlet vortex mixer. 
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Streams Quantity: The CIJ-D mixer has only two stream pathways, as shown in 
Figure 2.5(a). Two syringes are inserted in the two inlets. The drug and BCP are both 
dissolved in the organic solvent in syringe 1, and water is contained in syringe 2. In the 
vortex mixer, four syringes are connected to four inlets as shown in Figure 2.5(b). One 
inlet delivers the drug and BCP dissolved in organic solvent. The other three deliver large 
amount of antisolvent water to achieve high supersaturation.  
Injection operation: Using vortex mixer, two syringes containing smaller volume 
organic solvent and antisovlent are propelled by a programmable pump. The other two 
syringes containing water in larger volume are propelled by a mechanical pump. Both 
pumps can be digitally set with a wide range of flow rates, up to 120 mL/min, matching 
the solvent with the antisolvent streams to achieve simultaneous mixing. For the CIJ 
mixer, two syringe injections are operated by hand. The metal bar on top of them will 
keep syringes driven simultaneously and steady if a more accurate flow rate is needed, 
the two syringes can also be propelled by a programmable pump.  
The incident angles of incoming streams: in Figure 2.6, the vortex mixer has four 
steams directed into a mixing chamber 
with the incident angle of 90°. They are 
forced to the walls of the mixing 
chamber by centripetal forces, instead 
of impinging with each other. In the 
CIJ-D mixer, two streams are directed 
towards each other with the incident angle of 180°. This essentially increases the mixing 
velocity in micromixing condition. Johnson and Prud’homme speculated that the angling 
 
Figure 2.6 The mixing chamber of (a) the CIJ-D 
mixer and (b) the vortex mixer. 
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of inlet streams can affect the micromixing performance
37
, but we have not gained any 
solid evidence to demonstrate this point.  
Mixing processes: In the vortex mixing, unequal volumes of solvents can be used. 
In our case, syringe 1 contains 2.5 mL THF, and the other three streams contain 2.5 mL, 
22.5 mL, and 22.5 mL of water respectively. This combined mixture has a composition of 
H2O:THF=95:5. This is very high supersaturation level for hydrophobic drug and 
amphiphilic BCP, which can be reached directly in one-step vortex mixing. In the CIJ 
mixing, two identical volumes of solvent and antisovlent impinge with each other and 
collide at equal momentum. For instance, 2.5 mL of H2O and 2.5 mL of THF (50:50 
vol:vol) are impinged. This is far below the supersaturation level in vortex mixing, 
therefore the outlet of the mixer is connected to a beaker containing a large volume (45 
mL) of H2O to further dilute nanosuspension, with a final combined ratio of 
H2O:THF=95:5. The dilution is expected to diminish Ostwald ripening and 
recrystallization of solutes.  
2.4.2 The Necessity of Dilution in CIJ-D Mixing 
When formulating nanoparticles by a “one-step” vortex mixing, the 
supersaturation level is determined by a volume ratio of H2O:THF=95:5. In comparison, 
nanoparticles made by CIJ-D mixer follows a “two-step" process, during which a 
volumetric ratio of H2O:THF reaches 50:50 in the first step of impingement in the mixing 
chamber. Then in the second step, the final ratio of H2O:THF reaches 95:5  by dilution. 
As Prud’homme85 and also Pustulka85, 86 showed, there are two critical time scales 
involved in FNP process, mixing time (τmix) and nucleation and growth time (τng). In 
order to understand their relation, especially to find out where particle nucleation and 
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growth occurs during CIJ-D mixing, β-carotene nanoparticles were prepared by CIJ-D 
mixing either with a complete two-step process, or only impingement or only dilution.  
In Group 1, β-carotene particles were prepared by CIJ mixing followed with an 
immediate dilution. A volume of 2.5 mL THF containing 25 mg β-carotene was impinged 
with 2.5 mL H2O in the CIJ mixer chamber and further diluted in 45 mL H2O. It took 10-
12 seconds to empty the syringes of 2.5 mL THF and H2O simultaneously, thus the flow 
rate (Q) is 12.5~15 mL/min and Reynolds number (Re) = 1500~1800. In Group 2, β-
carotene particles were only prepared by the first-step of impingement. A volume of 2.5 
mL THF containing 25 mg β-carotene was impinged with 2.5 mL H2O in the CIJ mixer 
chamber and collected directly without further dilution. The flow rate was controlled as 
the same as Group 1. In Group 3: β-carotene particles were prepared only by the second 
step of dilution. A volume of 2.5 mL THF containing 25 mg β-carotene and 2.5 mL H2O 
were directly injected to 45 mL H2O without using the CIJ mixer. The flow rate was 
controlled as the same as Group 1. This method is often the case for the traditional drop-
wise precipitation or simple stirring in a tank, but drop-wise addition of solvents often 
takes place for hours. Two batches of β-carotene particles were formulated in each group.  
Their particle size and distribution was measured by DLS and averaged among two 
batches and three measurements in each batch. The mean mass average size in Group 1 
was 60.0±4.0 nm, 412.2±7.2 nm in Group 2, and 69.5±3.3 nm in Group 3.  
β-carotene nanoparticles had very similar size in Group 1 and 3, both of which 
were prepared with dilution. It implied that high supersaturation level is very important to 
make particles with small sizes, even the CIJ mixer is not employed. While CIJ 
impingement was not used in Group 3, the mixing time was longer than that in Group 1, 
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and particle size was slightly bigger in Group 3. Particles prepared in Group 2 were much 
larger than the other groups, because the supersaturation level was a lot less, indicated by 
the volume ratio of H2O:THF=50:50.  The nucleation and growth time was relatively fast 
as opposed to the mixing time, so particles had more chance to grow to a larger size. 
Without the quench effect of dilution, particles probably aggregated as well during the 
time interval about five minutes between mixing and DLS measurement. 
Figure 2.7(a) shows schematically how supersaturation increases as THF (solvent) 
and H2O (anti-solvent) mix during flash precipitation. Supersaturation is defined as 
 
C is total mass of solute divided by the final volume of solvent mixture. C∞ is the 
bulk solubility of drug in solvent mixture.  
Initially, drug and polymer are dissolved in 100% THF where they are soluble. As 
more water is introduced in THF/H2O mixture, the solubility of drug C∞ gradually 
decreases indicated by the red line, while C remains constant indicated by the black line. 
Thus, supersaturation S increases as the distance between black and red lines get longer. 
When 50/50 THF/H2O is mixed in the mixer chamber approximately within 10 ms shown 
by (2) CIJ in Figure 2.7(a), the blue arrow shows the difference of the initial 
concentration and solubility of drug, which is an indicator of supersaturation using CIJ 
mixer. As mixture is diluted in water, the supersaturation continues to increase shown by 
(1) CIJ-D in Figure 2.7(a). In comparison, vortex mixer allows THF and H2O mixing in 
varied volume and achieve the desire solvent mixture ratio shown by (4) vortex. 
                                                             
 
  
                                                              Eq. 2.6 
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Prud’homme35, 39, 78 believed that the nucleation of particles occurs very quickly in 10-20 
milliseconds, which is in the same timescale of mixing shown in Figure 2.7(a).  
 
                
              
Figure 2.7 (a) Supersaturation condition when solubility of drug decreases as H2O% 
increases in THF/H2O mixture during micromixing of flash nanoprecipitation. (b) 
Supersaturation condition via CIJ-D mixing with dilution of (a) 0 mL, (b) 5 mL, (c) 10 mL, (d) 
25 mL and (e) 45 mL.   
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The CIJ-D mixer provides more turbulent mixing in micromixing environment 
than the regular precipitation (simulated in Group 3), the kinetic energy of particles via 
the CIJ mixing is higher to prevent aggregation. Therefore, particle size in Group 1 was 
slightly smaller than that in Group 3. When supersaturation level is relatively low, nuclei 
continue to grow driven by diffusion (Group 2). When the supersaturation level is high, 
particle growth will be quenched by the limited diffusion (Group 1&2) shown in Figure 
2.7. 
2.4.3 The Effect of Varied Dilution 
As mentioned above, the dilution stage allows high supersaturation while 
maintaining the 1:1 flow ratio of the impingement streams in CIJ-D mixer. In order to 
demonstrate the effect of dilution stage, four groups of β-carotene particles were made 
following the standard procedure described previously but with differing dilution. These 
particles showed good short-term (~4 hr) stability due to slightly negative surface 
charge
87
 as judged by zeta potential (ζ) measurements33. 
In group same as 1 above, nanoparticles were made following the standard 
procedure, immediate dilution into 45 mL water as shown by (e) in Figure 2.7(b). The 
resulting mass average size was 55 nm. In group same as 2 above, nanoparticles were 
made without dilution as shown by (a) in Figure 2.7(b). They were unstable, and 
aggregated to micron size in seconds. In group same as 3 above, dilution was delayed 
from ~10 ms (residence time in the mixer and outlet tube) to 5 s. This also resulted in 
unstable microparticles (> 1 µm). In group 4, nanoparticles were made with immediate 
(10 ms) water dilution but less than 45 mL (e.g., (b) 5 mL, (c) 10 mL, and (d) 25 mL in 
Figure 2.7(b) or H2O% in mixture=75.0%, 83.3% and 91.6% or THF/ H2O=0.33, 0.20 
30 
 
and 0.091 shown in Figure 2.8). As shown in Figure 2.8, none of them produced 55 nm 
nanoparticles. Instead, all were much bigger, approximately 1400 nm, 200 nm and 167 
nm, respectively and eventually unstable. These experiments show that immediate 
dilution with a significant amount of water is indispensable to produce small and stable 
nanoparticles.  
 
2.4.4 Performance Comparison 
To test the CIJ-D mixer, β-carotene loaded PEG-b-PLA stabilized nanoparticles 
were prepared following the typical procedure given above. DLS gave mass average 
diameter of 38 nm with polydispersity of 1.6 and standard deviation of 6 nm for three 
measurements on three separately mixed samples. The particles were stable for several 
weeks. In other block copolymer and model drug studies, we have also used PEG-b-PLA 
and PEG-b-PLGA (polyethylene glycol-b-poly (lactic-co-glycolic acid)) with a series of 
molecular weight (5k-b-10kDa, 5k-b-15kDa etc.) to make nanoparticles loaded with β-
carotene. Zhu
67
 used hydrocortisone, paclitaxel, betulin and their derivatives to test the 
 
     Figure 2.8 Mass average diameter of β-carotene particles vs. THF/water ratio in group 4. 
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capability of the CIJ-D mixer for preparing polymeric nanoparticles. They were 
successfully produced, reproducible in terms of size.  
We also compared the sizes of these pure β-carotene nanoparticles made by the 
CIJ-D mixer to those made by the vortex mixer. Particle size was varied by varying the 
flow rate, Q. This was accomplished simply by changing hand velocity during CIJ-D 
mixing and adjusting flow rate on programmable pumps during vortex mixing. The 
micromixing were characterized by Reynolds number. 
 
The mass average diameters shown in Figure 2.9 are averages of three 
measurements on three separately samples prepared under the same conditions. The 
vortex mixing data were obtained from Zhu
67
. The error in the calculated Reynolds 
number came from variation of injection time. In vortex mixing, errors were minor since 
the injection time was mechanically controlled by syringe pumps, but it was relatively 
large in CIJ-D mixing due to uncertainty in timing the hand motion. At the highest 
           
Figure 2.9 Mass average size of β-carotene particles (dm) vs. Reynolds number (Re). 
Particles were made using both the vortex mixer and CIJ mixer.   
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Reynolds number, the injection time of the CIJ-D mixer was 4.2±0.3s. 2.5 mL of solvents 
in two 3 mL syringes were used thus the flow rate was 1.2×10-6m3/s. Considering this 
flow rate and the tubing dimensions (1 mm inside diameter and 15 mm long), the 
residence time in the chamber and outlet tube before dilution was approximately 10 ms. 
For Re<1000, a syringe pump was used with the CIJ-D mixer because hand operation 
cannot be controlled well enough to create steady mixing over minutes.  
The results in Figure 2.9 showed good agreement between the new CIJ-D design 
and the vortex mixer. Because of the rapid injection, the CIJ-D can reach Re>4000, twice 
the limit for the vortex mixer, and particle size of 30 nm, half the smallest size from the 
vortex mixer. At the same Re, particle size for the CIJ-D mixer was slightly smaller. 
A potential problem with hand operation of the CIJ-D mixer is the start-up of flow. 
The Re at the beginning of impingement will be lower due to the time required to 
accelerate the syringes. The same problem occurs with syringe pumps, but because the 
impingement time is longer, it is possible to discard the first part of the product. This 
start-up transient could lead to broader particle size distribution, but we observed broad 
size distribution in both the CIJ-D mixer and the vortex mixer. For example, at Re=1750, 
DLS gave size polydispersity indices
67
 of 0.5−0.8 for both samples. 
2.5 Conclusion 
A simple modification of Johnson and Prud’homme’s confined impingement jets 
(CIJ) mixer has been used to make stable and reproducible nanoparticles. The addition of 
a dilution stage after mixing results in higher levels of supersaturation, and overcomes the 
limitation of equal volume ratios required in the original CIJ design. For our β-carotene 
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particles we found that the dilution needed to be rapid, < 5s after mixing, and 
extensive, >5 fold. Hand-operated impingement with small syringes creates sufficient 
turbulent mixing, ideal for flash nanoprecipitation of hydrophobic compounds with 
diblock copolymers to form kinetically trapped, sterically stabilized nanoparticles. With 
these modifications, the new mixer, called CIJ-D to emphasize the addition of a dilution 
stage, is easy to operate and inexpensive, making it more effective for rapid screening of 
small quantities of new materials, via FNP, compared to alternative mixers and other 
methods. It is especially attractive for evaluation of new drug formulations for their 
stability to produce nanoparticles
88-91
. 
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Chapter 3  
Silicate Paclitaxel loaded Block Copolymer Protected 
Nanoparticles: Preparation and Post-Treatment 
3.1 Introduction 
It is well known that cancer is a leading deadly disease, causing about 13% of all 
human death in the world (2008)
1
. Numerous researchers have dedicated their lives in an 
attempt to find effective methods to treat cancer. Several attractive methods have been 
developed, such as chemotherapy, radiation and surgery. Chemotherapy, is the most 
widely used and effective treatment for cancer. However, its undesirable toxicity causes 
adverse side effects on patients, due to non-specific delivery of anticancer drugs to 
normal tissues. Accordingly, the goal in my work is to develop nanoparticle formulations 
that can act as specific-delivery chemotherapeutic treatment, effective for targeting tumor 
tissues with minimal side effects.  
Paclitaxel (PTX)
47, 92
 is an anti-cancer drug 
approved by U.S. Food and Drug Administration 
(FDA). It was first discovered by Monroe E. Wall and 
Mansukh C. Wani in 1967, by isolating from the bark 
of the Pacific Yew tree
93
. It promotes polymerization 
of tubulin, stabilizes microtubules and interferes with the normal breakdown of 
microtubules in cell division, resulting in cell cycle arrest and eventually cell death. It is a 
 
Figure 3.1 Chemical Structure of 
Paclitaxel
47
. 
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mitotic inhibitor in chemotherapy, widely used for patients with ovarian, breast, non-
small cell lung cancers and AIDS-related Kaposi’s sarcoma47, 93.  
Currently, there are three major commercial formulations of PTX. One is under 
the trademark of “Taxol®”, developed by Bristol-Myers Squibb (BMS). PTX is dissolved 
and delivered in Cremophor EL
®
, a 1:1 mixture of polyethoxylated castor oil and ethanol. 
Cremophor EL
®
 is necessary to overcome the low solubility of PTX in aqueous 
medium
48-51
. Taxol
®
 was completely approved by FDA, but only ca. 1 wt% of PTX in 
Taxol
®
 (6 mg PTX/527 mg Cremophor EL
®
/1 mL solution) is possible for intravenous 
administration
58
. A series of adverse side effects, including hypersensitivity, 
nephrotoxicity and neurotoxicity
52
, occurred with a large amount of Cremophor EL
®
 
accompanying high drug dosage.   
A newer formulation, under the trademark of “Abraxane®” is manufactured by 
Abraxis BioScience. PTX is complexed with albumin to form 130 nm stable particles in 
water solution
53
. Abraxane
® 
avoids all Cremophor-related toxicities, with a notably 
higher loading of PTX, 5mg PTX/ 45mg albumin in 1 mL water solution
54
 (ca. 10 wt% 
PTX in Abraxane
®
). The FDA has approved Abraxane
® 
for treatment of breast cancer but 
only after failure of combination chemotherapy or cancer relapse within 6 months of 
adjuvant chemotherapy
54
, because Abraxane
®
 failed to increase median survival time for 
“first-line” (those have never been treated previously) patients55 and it is more expensive 
than Taxol
®56
.  
In Phase I trial, Abraxane
®
 and Taxol
®
 were administered in doses up to 260 
mg/m
2
 and 175 mg/m
2 
(unit: drug amount/body surface area
94
, respectively). It was found 
in Phase II and III trials that Abraxane
®
 and Taxol
®
 presented different pharmacokinetic 
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parameters, tumor response rates and toxicity profiles. Abraxane
® 
presented no difference 
in overall survival as compared to Taxol
®
. Also, it had a higher incidence of peripheral 
neuropathy, nausea, vomiting, and asthenia, while Taxol
® 
had a higher incidence of 
neutropenia and hypersensitivity reaction
54
. For both of them, the toxicity of PTX on 
normal tissues is serious and worse if higher dosage is used, due to inevitably non-
specific delivery. It strengthens the importance of selective delivery of PTX to tumor.  
Another formulation, Genexol
®
-PM is a paclitaxel-containing polymeric micellar 
system, developed by Samyang Genex Co
95, 96
. Previously, PTX in Taxol
®
 was obtained 
by a semisynthetic process from Taxus baccata, but in Genexol
®
 it was obtained by a 
plant tissue culture technology. This technology enables the production of Genexol
®
 with 
high purity, low purification cost, constant yield and without environmental problems
57
. 
Another advantage of Genexol
®
 is using non-toxic, biodegradable, low molecular weight 
diblock copolymer PEG-b-PLA to solubilize PTX instead of Cremophor EL
®
 in Taxol
®
. 
This potentially will reduce toxicity caused by delivery agent. However, in phase II trials 
of non-small cell lung cancer (NSCLC), along with other anti-cancer agents, it has 
indicated that, though effective for advanced NSCLS patients, neurotoxicity is a safety 
issue for use of Genexol
®57
. Samyang Co. has accepted the investigation of U.S. FDA to 
begin Genexol
®
-PM phase I clinical trials in patients with refractory cancers since 2002. 
Genexol
®
-PM was FDA approved for use in patients with breast cancer
97
. 
Besides formulations mentioned above, there are also liposomal encapsulated 
paclitaxel (by NeoPharm), prodrug paclitaxel polyglumex (Xyotax
®
 by Cell 
Therapeutics), polymeric-micellar paclitaxel (Nanoxel
®
 by Dabur Pharma), paclitaxel 
vitamin E emulsion (Tocosol
®
 by Sonus Pharmaceuticals), and a polymer microsphere 
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paclitaxel (Paclimer
®
 by Gullford Pharmaceuticals). However, none of these has been 
approved by FDA
98
. Despite intense research in drug delivery, it is very challenging to 
develop
 
non-toxic but effective delivery system for hydrophobic compounds like PTX. In 
those cases, researchers have attempted to create Cremophor-free formulation for PTX in 
order to eliminate the increased toxicity associated with solubilization agents. To sum up, 
the encapsulation of PTX into nano-sized non-toxic drug carriers has several advantages. 
First, they can be passively targeted to tumors by enhanced permeation and retention 
(EPR) effect
3
 to improve specific delivery efficiency. Secondly, PTX solubilized in non-
toxic carriers such as polymeric particles reduces side effect by avoiding solubilization 
agents like Cremophor EL
®
, which is associated with increased toxicity when 
administered intravenously. Meanwhile, nanoparticles provide high drug loading which is 
desirable, to achieve more drug localization with higher dosage.  
In order to utilize these advantages, the 
delivery agent studied in this chapter is an 
amphiphilic block copolymer (BCP), 
poly(ethylene glycol)-b-poly(lactic-co-glycolic 
acid) (PEG-b-PLGA) shown in Figure 3.2. As for 
safety of PEG and PLGA, they were both approved by FDA as surgical sutures, 
implantable devices and drug delivery systems
99, 100
, widely used in food, cosmetics and 
therapeutic devices, owing to their biocompatibility and biodegradability.  
We believe that flash nanoprecipitation (FNP), pioneered by Prud’homme et 
al.
34,35
, is a very valuable technique potentially to formulate nanoparticles composed of 
PEG-b-PLGA and paclitaxel in the range of 100-200 nm with high drug loading
70
. FNP 
 
Figure 3.2 Chemical Structure of 
PEG-b-PLGA. 
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shown in Figure 3.3 involves rapid turbulent mixing of organic solutes dissolved in a 
water-miscible solvent (e.g., tetrahydrofuran, acetone, acetonitrile) with the antisolvent 
water in a confined space 
67
. When the solvent and antisolvent streams collide with each 
other, the solutes rapidly precipitate due to the high supersaturation condition
101
.   
 
When PEG-b-PLGA and PTX are dissolved as the organic solutes and co-
precipitate via FNP, the mixing process kinetically controls the aggregation of PTX, with 
the BCP directing self-assembly described in Figure 3.4
35
. The following three time 
scales are important: (1) mixing time (τmix), (2) nucleation and growth time (τng) of the 
solute, and (3) self assembly time of the BCP (τsa). To achieve homogeneous mixing, τmix 
must be much smaller than τng and τsa. If τng and τsa are closely matched, hydrophobic 
block PLGA will deposit on the surface of PTX nuclei, quench growth and aggregation 
of PTX to create small and stable particles. The hydrophilic block PEG will constitute a 
hydrated shell and provide steric stabilization to prevent nanoparticle aggregation and 
       
Figure 3.3 Schematic of flash nanoprecipitation to form hydrophobic drug loaded block 
copolymer protected nanoparticles
67
. 
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protect nanoparticles against macrophage attack during circulation
102
. PEG-b-PLGA 
protected nanoparticles are expected to yield high loading of PTX and to eliminate 
Cremophor-related side effects simultaneously.  
One advantage of 
using FNP is to make small 
particles in the range of 100 
nm, because the controlled 
and relatively small particle 
size is very attractive to the 
application of drug delivery 
in chemotherapy. As 
mentioned before, the 
motivation for tailoring 
particle size is the EPR effect
3
. In order to explain it, the nature of tumor tissues and the 
drug delivery process is shown schematically in Figure 3.5
103
. 
Endothelial cells in normal tissues are regularly aligned, while newly formed 
tumor vessels in cancer are poorly-aligned, defective endothelial cells with wide 
fenestrations
3
, so the vasculature is leaky
104, 105
. During blood circulation, particles loaded 
with drugs below the leakage size can pass through the tumor microvasculature without 
blockage
106, 107
. Also, tumor tissues typically lack effective lymphatic drainage, thus 
particles lodging there are cleared more slowly. The leaky vasculature and the lack of 
lymphatic recovery system will lead to drug-loaded nanoparticles accumulate in tumor 
tissues much more than in normal tissues
8
. This is the EPR effect. In order to exploit it, 
 
Figure 3.4 Flash nanoprecipitation with details of mixing, 
nucleation and growth of solutes, and self assembly of 
polymer
8
. 
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the size of our particles needs to be controlled above the leakage size of normal tissues 
(<50 nm) and below large fenetration of tumor tissues (~400 nm), respectively. This goal 
plays a significant role in delivering the drug selectively to tumors, thereby reducing side 
effects caused by non-specific delivery to normal tissues.  
 
PTX-encapsulated polymeric nanoparticles made by FNP have been attempted 
but failed, ending with rapid aggregation and recrystallization of PTX
67, 92
 shown in 
Figure 3.6. This is due to a sufficiently high water solubility of PTX to promote Ostwald 
ripening
108
. It indicated that PTX is too hydrophobic as a drug to be dissolved in aqueous 
medium, albeit too hydrophilic to be efficiently encapsulated and stabilized in particle 
cores. Thus, strategies must be developed to increase hydrophobicity of PTX in solvent 
mixture. One approach is to increase the ratio of antisolvent over organic solvent. 
However, the ratio used in FNP is 95:5 of H2O vs. THF, which is already very high. 
Second, to choose a poor organic solvent, but options are very limited to water soluble 
        
Figure 3.5 Specific drug delivery via the enhanced permeation and retention effect
103
. 
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organic solvent, i.e, THF, acetone, DMF, and acetonitrile. Moreover, sufficient capability 
of dissolving BCP and drug before FNP needs to be considered as well. Therefore, it 
leads to the strategy of chemically modify PTX with a more hydrophobic moiety.  
 
A novel strategy, the conjugation of paclitaxel with a series of silicate esters (with 
varied –R) was proposed by Hoye et. al59, 109. PTX-OSi(OR)3, is regarded as prodrug of 
PTX. A prodrug
59, 109, 110
 is a pharmacological substance administered in an inactive 
form. Once administered, it is metabolized in vivo into an active drug
110
. Silicate 
Paclitaxel (Si-PTX) prodrug is rendered more hydrophobic, remaining stable as freeze 
dried powder for long-term storage. It will eventually convert to active PTX via 
hydrolysis
109, 111, 112
 during administration (Figure 3.7)
111
. And, the more acidic medium 
in tumor tissues
4
, is potentially beneficial to pH-responsive hydrolysis as well.  
     
Figure 3.6 SEM images of paclitaxel (recrystallization out of nanosuspension in 90 min) 
(left) and stable 2’,7-triethyl silicate paclitaxel nanoparticles
67,92
. 
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Therefore, nanoparticles discussed in this chapter were prepared by CIJ-D mixer 
via FNP, encapsulating Si PTX prodrugs into PEG-b-PLGA. Dynamic light scattering 
(DLS) and scanning electron microscopy (SEM) were used to determine particle size, 
distribution, morphology and stability. They also demonstrated the success of silicate 
paclitaxel strategy in terms of increasing hydrophobicity of PTX and producing stable 
nanoparticles without recrystallization of PTX and aggregation of particles
67
.  
In order to purify nanoparticles and determine their properties with 
pharmaceutical industrial standards, several post-treatments were used, such as 
purification (meaning removing un-encapsulated drug from drug loaded nanoparticle 
dispersion) and lyophilization. Filter filtration, hollow fiber diafiltration and 
ultracentrifugation were employed to purify particles. DLS and HPLC measurements 
were utilized to detect the presence of drug and particles, their sizes in filtrates and waste 
and drug loading levels. The purpose was to find an efficient approach for removing un-
 
Figure 3.7 Silicate prodrug synthesis and hydrolysis (top); Conjugation of paclitaxel to 
paclitaxel silicate prodrug, example: 2',7-(triethyl orthosilyl)paclitaxel. Bz: benzoyl group; Ac: 
acetate group; Ph: phenyl group; Si(OEt)3: triethoxy silicate ester (bottom). 
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encapsulated drug and empty polymer particles from drug loaded nanoparticles. 
Ultracentrifugation proved to be most successful to achieve this goal. Afterwards, 
nanoparticles were lyophilized for storage and future use
113, 114
. We encountered a 
difficulty recovering particle size after lyophilization due to severe aggregation caused by 
the freezing process
85, 115
. Cryoprotectants
113, 116, 117
 like sucrose, trehalose and glucose 
are often used to alleviate aggregation, particles sizes were reduced greatly, but it was 
still very challenging to recover initial size of fresh nanoparticles.  
Since lyophilization was used to store particles in dry state with long term 
stability, we were very interested to find out the stability of Si PTX prodrugs either as 
pure compound or being encapsulated in nanoparticles, because both physical instability 
(e.g., aggregation) and chemical instability (drug leakage of particles, hydrolysis of drug 
and polymer, chemical reactivity of drug) severely limit use of hydrophobic compound 
loaded in nanoparticles. While these instabilities are potentially advantageous for drug 
delivery, they are not ideal for drug formulation storage. Therefore, aging studies were 
conducted by HPLC measurements to determine hydrolysis rate of 2’,7-triethyl Si PTX 
as dry powder for several months. We found insignificant hydrolysis of the dry powder 
over two months. In contrast, after 2’,7-triethyl Si PTX prodrug was encapsulated in 
nanoparticles, ultracentrifuged, lyophilized, and redispersed in aqueous solution, 
hydrolysis occurred fast within 24 hrs. Supporting information for this chapter is 
presented in Appendix C. 
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3.2 Methods and Experiments 
3.2.1 Materials 
Paclitaxel was obtained from Phytogen Life Sciences. PEG-b-PLA (MW: 5k-
10kDa & 5k-15kDa) and PEG-b-PLGA (MW: 5k-10kDa) were synthesized in Hoye’s lab 
as previously reported
81
, β-carotene was purchased from Sigma-Aldrich and used as 
received. Silicate paclitaxel prodrugs were synthesized in Hoye’s lab59 as well. Water 
(H2O, HPLC grade), tetrahydrofuran (THF, HPLC grade) and acetonitrile (ACN, HPLC 
grade) were purchased from Aldrich and used as received. 0.45 μm and 0.2 μm filters 
were purchased from Millipore. Hollow fiber diafiltration column (MWCO: 50 kDa) was 
purchased from Spectrum Lab, Inc. 
3.2.2 Silicate Paclitaxel Strategy 
2'-(triethyl orthosilyl) paclitaxel or 2'-triethyl Si PTX (1a), and 2',7-(triethyl 
orthosilyl) paclitaxel or 2’,7-triethyl Si PTX (2a) shown in Figure 3.8 were synthesized in 
Hoye’s lab as reported59, 109. The addition of silicate ester derivatives was meant to 
increase the hydrophobicity of PTX in order to be successfully encapsulated into 
polymeric nanoparticles. It also determines the diffusion rate of these Si PTX prodrugs 
when they release from nanoparticles due to tuned hydrophobicity. The cleavage of 
silicate ester via hydrolysis was designed for the conversion of prodrugs back to the 
parent drug, PTX, as the active anti-cancer form. The varied hydrolysis rate plays an 
important role in regeneration of PTX. Overall, the silicate ester derivatives can tune the 
hydrophobicity and the hydrolysis rate of Si PTX prodrugs
109, 112
. The hydrophobicity 
was calculated by empirical predictor of calculated logP using ALOPS2.1 program
118
. 
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LogP, is a partition coefficient, as the ratio of the concentrations of a compound between 
octanol and water. The relative hydrolysis rates were determined by a 
1
H NMR 
spectroscopy-based method
109, 112, 119
.  
 
3.2.3 Silicate Paclitaxel Nanoparticle Preparation 
The following is a standard procedure for one batch of nanoparticles prepared 
using CIJ-D mixer. 2,7-triethyl Si PTX (MW: 1178 Da) was weighed 34.5 mg, equivalent 
of 25 mg paclitaxel (MW: 854 Da). It was dissolved in 2.5 mL THF with PEG-b-PLGA 
(MW: 5k-10kDa) and transferred to a 3mL syringe. The other syringe contained 2.5 mL 
water. Both syringes were connected with two top inlets on the CIJ-D mixer. The two 
solvent phases were impinged rapidly by pushing syringes simultaneously within 5 
seconds. The mixture flowed immediately into 45 mL water also described in Ch. 2
40
, in 
order to further quench particle growth. The resulting suspension had total volume of 50 
mL with a ratio of 5:95 THF: H2O and total mass of approximately 60 mg nanoparticles. 
 
      Figure 3.8 Chemical Structure of 2'-triethyl Si PTX (1a) and 2’,7-triethyl Si PTX (2a). 
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3.2.4 Nanoparticle Characterization 
3.2.4.1 Nanoparticle Size and Distribution 
The DLS apparatus (Brookhaven, CA) was used to measure size of 2’,7-triethyl Si 
PTX nanoparticles shown in Figure 3.10. As nanoparticles were made, 2 mL of 
nanosuspension was transferred to glass cuvette. Three identical samples were prepared 
for measurements. The DLS apparatus (Brookhaven, CA) has a diode laser BI-DPSS 
wavelength of 659 nm. The intensity correlation function was collected at 25 ˚C and a 
scattering angle of 90˚. Correlation functions were fit using the REPES model to 
determine average particle sizes and distribution. GENDIST was used for the REPES 
algorithm
67, 83, 84
.  
Another DLS apparatus (Beckman Coulter, CA) was used to measure sizes of β-
carotene loaded PEG-b-PLA nanoparticles filtered by hollow fiber filtration shown in 
Table 3.2 and 2’,7-triethyl Si PTX loaded PEG-b-PLGA nanoparticles and supernatant 
after ultracentrifugation shown in Table 3.3. The apparatus was equipped with a laser 
operating at a scattering angle of 90˚. The refractive index was 1.33, the viscosity of 
solvent mixture was 0.89 mPa•S. The intensity correlation functions were collected at 
25˚C. To prepare samples for DLS (Beckman Coulter, CA) measurements, 100 μL fresh 
nanoparticle suspension was removed by micro pipette, and diluted with 1 mL DI water 
in DLS square tube. The supernatant collected after ultracentrifugation was directly 
measured without dilution. Three identical samples were sealed with a plastic cap for 
measurements. Nanoparticle intensity size was averaged across 150 individual detections. 
The final size and standard deviation were determined by averaging three measurements. 
Size polydispersities were recorded automatically by instrument software.  
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Besides two DLS apparatus, nanoparticle tracking analysis (NTA, Nanosight, 
Malvern Instrument, UK) was also used to determine mass average of particle sizes. 100 
μL fresh nanosuspension was diluted with 2 mL DI water, in order to reach the required 
concentration range: 10
-7
~10
-9
 particles/mL. It was injected via the inlet port into 
chamber. When the instrument was stabilized at room temperature, a 60 second video of 
particle Brownian motion was recorded. The video was replayed with individual particles 
being tracked. The diffusion coefficient of individual particles was calculated and 
converted to particle size based on Stoke-Einstein relation shown in Eq. 2.1.  
All particle sizes were accumulated to create size distribution. The mass average 
size is defined as 
 
where 
in is the number of particles with a diameter id , im is the mass of particles. 
The intensity average size is defined as 
 
Polydispersity index (PDI) is defined as  
            mi is the mass of particles with a diameter of di. 
       
 
  /   
 
                                                                            Eq. 3.3 
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                                                    Eq. 3.1      
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3.2.4.2 Nanoparticle Morphology 
To prepare samples for scanning electron microscopy (SEM), a glass Pasteur 
pipette was first filled with a small amount of the nanosuspension, and then emptied, 
leaving minute amounts of liquid on the inner wall. This was then aspirated onto a silica 
wafer that had been washed with HPLC grade THF and water. After evaporation at room 
temperature, the sample was sputter coated with a 30 Å layer of platinum and imaged 
with a Hitachi S-900 SEM. A small piece of double-side tape was used to place the 
silicon wafer on SEM sample stage.  
The Cryo-TEM imaging was conducted by my colleague, Hanseung Lee
85
. To 
prepare samples for Cryo-TEM, both fresh nanoparticle suspension and re-dispersed 
freeze dried nanopaticles were used. A drop of the suspension was dropped onto the grid 
and frozen under vacuum condition. A lacey carbon Cu grid (01881, 200-mesh, Ted 
Pella, Ltd., Redding, CA) was glow discharged in a vacuum evaporator at 70 mTorr (DV-
502A, Denton Vacuum Moorestown, NJ) for 30 seconds to create a hydrophilic surface 
on the carbon coated side of the grid. A 2 −3 µL of fresh sample was pipetted onto the 
carbon side at 22 °C in a Mark III Vitrobot chamber (FEI Company, Hillsboro, OR) with 
a relative humidity of ~100 %. The excess sample was blotted with 595 filter papers (Ted 
Pella, Ltd., Redding, CA) 1 − 2 times with a ~1.5 mm offset parameter for 5 seconds to 
form a thin liquid film. After the blotting, the sample was relaxed for ~3 seconds and 
immediately plunged into liquid ethane cooled by liquid nitrogen. 
The vitrified sample was transferred to a Gatan 626 Cryo-transfer unit (Gatan, 
Pleasanton, CA) at -194 °C and characterized at -178 °C in the microscope. A 120 kV 
FEI Tecnai Spirit BioTWIN was used and images were taken digitally with Eagle™ 2k 
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CCD camera (FEI Company, Hillsboro, OR) in a low-dose mode. The images were 
processed with TEM Imaging and Analysis software package. (Version 4.2 SP1 build 
816, FEI Company, Hillsboro, OR). To enhance phase contrast, the images were 
observed with objective lens in an under-focused mode (2 – 4 µm).  
3.2.4.3 Nanoparticle Drug Loading 
To prepare standards for high performance liquid chromatography (HPLC), 1 mg 
of PTX and 2’,7-triethyl Si PTX were weighed and dissolved in 1 mL acetonitrile, 
respectively. These solutions were diluted to 100 μg/mL and further diluted in gradient to 
50, 25, 12.5, 6.25, 3.125, 1.56 μg/mL. To analyze nanosuspension samples, 1 mg of 
lyophilized nanoparticles was weighed and dissolved in 1 mL acetonitrile. Three identical 
samples were prepared, to obtain reproducibility. 2’,7-triethyl Si PTX in nanoparticles 
were extracted in acetonitrile for 24 hr before HPLC measurements. To prepare 
acetonitrile and water mixture injected at a volume ratio of 75:25, distilled water was 
filtered and degassed. Acetonitrile was degassed. The drug loading of nanoparticles was 
determined by comparing against the standards samples with known concentration.  
AC-18 column (14.6×25 cm) with 5 µm packing (Beckmann Coulter, CA) was 
used to analyze acetonitrile extract by HPLC. The mobile phase consisted of a mixture of 
acetonitrile and water in a ratio of 75:25, and was delivered at a flow rate of 1 mL/min. A 
30 µL volume of the acetonitrile extract was injected using an autoinjector (Model 508, 
Beckmann Coulter, CA). PTX and 2’,7-triethyl Si PTX were quantified by UV detection 
(System Gold 168 detector) at 228 nm, against a series of PTX and 2’,7-triethyl Si PTX 
standards, with premade concentrations of 1.56-100 µg/mL. The loading level (LL%)was 
calculated using the equation below: 
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3.2.5 Nanoparticle Post-Treatment 
3.2.5.1 Filtration and Ultracentrifugation 
Simple filtration: 0.45 μm and 0.2 μm Millipore filters were used to filter 
nanoparticles. Freshly made nanosuspension was injected through the filter for at least 
three times.  The filtered nanosuspension was collected and measured by DLS and 
compared with non-filtered nanoparticles. 
Hollow fiber filtration (Spectrum Labs, CA
120
): this method is an efficient and 
rapid alternative to traditional methods of nanoparticle purification (ultracentrifugation, 
stirred cell filtration, dialysis or chromatography). It is used to purify liposomes, colloids, 
magnetic particles and nanotubes. The flow process of hollow fiber is shown in Figure 
3.9. When the sample is injected between two syringes back and forth, it is gently 
circulated through a tubular membrane with controlled pore size, which determines the 
retention or transmission of solution components.  The tubular geometry of the hollow 
fiber is beneficial to particle applications due to the phenomenon known as tubular pinch 
effect
121
. Particles migrate to the center of the hollow fiber where flow velocity is the 
highest, while un-encapsulated solutes, in our case drug and empty polymer micelles will 
penetrate out of the membrane and be collected by the third syringe (blue in Figure 3.9). 
                      Eq. 3.4 
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To test the purification performance of hollow fiber diafiltration, two groups of 
nanoparticles were prepared and filtered. Nanoparticles were composed of β-carotene as a 
drug model and PEG-b-PLA as carrier. In experiment 1, 25 mg of β-carotene and 25 mg 
of PEG-b-PLA (MW: 5k-15k Da) were used to prepare nanoparticles by CIJ-D mixer, in 
50 mL solvent mixture of H2O:THF= 95:5. Nanoparticle size was determined by DLS. 
Then, nanosuspension was injected into hollow fiber diafiltration column and filtered for 
10 min, in order to separate β-carotene loaded particles and blank PEG-b-PLA 
nanoparticles. The 
solution collected 
from the waster port 
was transparent and 
clear. The remaining 
β-carotene particle 
suspension was 
concentrated and 
collected from the other outlet. They were both measured by DLS again. In experiment 2, 
two batches of nanoparticles were prepared and characterized by DLS. One was blank 
PEG-b-PLA (MW: 5k-10k Da) nanoparticles and the other was β-carotene loaded PEG-
b-PLA (MW: 5k-10k Da) nanoparticles. They were mixed at an equal volume and 
purified by hollow fiber diafiltration for 10 min. The filtered mixture and waste solution 
were collected and measured by DLS again. 
Ultracentrifugation: 2’7-triethyl Si PTX loaded PEG-b-PLGA nanoparticles 
were prepared and transferred into two 25 mL centrifugation tubes. They were 
 
         Figure 3.9 Schematic of hollow fiber diafiltration
120
. 
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ultracentrifuged (Optima XPN-80 Ultracentrifuge, Beckman Coulter, CA) at 50,000 rpm, 
4˚C for 30 min. The supernatant was removed. The pellet was resuspended in another 25 
mL DI water. Tip sonication was used to redisperse particles using pulse model for five 
minutes, with 15 seconds pause in every minute. The power gradually increased from 3-
9V. Pellet collection, redispersion and ultracentrifugation were repeated for three times, 
to remove free drug and empty polymer nanoparticles. After each ultracentrifugation, 1 
mL nanosuspesion was removed from both redispersed pellet and supernatant. It is used 
to determine particle size and drug loading.   
3.2.5.2 Lyophilization and Sonication 
After 2’,7-triethyl Si PTX nanoparticles were ultracentrifuged, the resulting pellet 
was resuspended in 5 mL water and transferred to 15 mL plastic tubes. They were 
lyophilized using lyophilizer (Freeze dryer system/Freezone 4.5, Labconco, MO) at-45ºC 
under vacuum for 24 hr. The resulting white powder was stored at 4˚C fridge for future 
use. Also, sucrose as cryoprotectant
122
 was added in nanoparticles with a mass ratio of 
sucrose:NPs=1:10
86
, claimed as necessary to achieve size recovery. After lyophilization, 
particles in dry powder were redispersed in DI water at a concentration of 1 mg/mL using 
micro-tip sonication (Misonix Sonicator 3000, NY) and sonication probe (1/8”) in pulse 
mode, 3-9 volt for 5 min. Sonication in each cycle took 1 minute, and the tube containing 
nanoparticles were immersed into ice water for 30s, to remove the heat generated by the 
sonicator. The sonication procedure above was repeated with five cycles. Then, DLS 
measurements were conducted to determine their sizes, SEM and Cryo-TEM to see 
particle aggregation and size distribution.  
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3.2.6 Aging 
2’,7-triethyl Si PTX prodrug(not in NPs) was kept in separate vials right after 
synthesis and purification, sealed with caps and double-layered parafilms (BEMIS, WI) 
and stored at 4 ˚C. At designated weeks and months, 1 mg was weighed out and dissolved 
in 1 mL acetonitrile. Samples were prepared in triplicate and measured by HPLC. The 
amount of 2’,7-triethyl Si PTX, 2’ or 7-triethyl Si PTX prodrugs and PTX obtained from 
hydrolysis were measured. To measure the hydrolysis rate of 2’,7-triethyl Si PTX in 
aqueous solution, 10 mg of the lyophilized 2’,7-triethyl Si PTX nanoparticles were 
redispersed in 10 mL water. At predetermined times (2, 4, 6, 8, 12, 24 hr), an aliquot of 
sample was removed and quantified by HPLC.  
3.3 Results and Discussion 
3.3.1 Silicate Paclitaxel Properties 
The physical properties of two Si PTX prodrugs are listed in Table 3.1
59
. The 
hydrophobicity has been significantly increased from PTX to Si PTX (1a&2a) with 
greasier alkyl groups. The water solubility of PTX was experimentally measured by 
HPLC using supernatant of supersaturated PTX solution. We also attempted to determine 
the solubility of Si PTX prodrugs but failed because their concentration is so low, below 
the detection limit of HPLC (1.5 μg/mL).  Due to the great challenge of solubility 
quantification, the relative hydrophobicity of Si PTX prodrugs was assessed in other 
ways. One is octanol/water partition coefficients (aLogP values calculated by ALOPS 2.1 
software), as an empirical indicator of hydrophobicity. It well predicted that, Si PTX 
prodrugs have more tendency of being captured in nanoparticles, where hydrophobic 
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block PLGA creates hydrophobic microenvironment. Although Wohl et al determined the 
hydrolysis rates in acidic solvent mixture with a measured pH=1.2
59
 in order to monitor 
hydrolysis in a reasonably short time, it indeed demonstrated that Si PTX prodrugs are 
capable of becoming active PTX with varied hydrolytic lability.   
              
3.3.2 Nanoparticle Characterization 
3.3.2.1 Nanoparticle Size and Distribution 
In Figure 3.10, DLS measurements of 2’,7-triethyl Si PTX loaded PEG-b-PLGA 
nanoparticles exhibited an averaged mass average size of 70±3 nm and intensity average 
size of 132±20 nm. Nanoparticles showed a bimodal distribution, where the small size is 
possibly empty polymer micelles (~20-30 nm
67
) and kinetically formed polymer particles 
(~40-50) nm, Si PTX loaded particles were in the range of 100-200 nm.  Because of the 
contribution of polymer micelles and particles, mass average size was far less than 
intensity average size, which was more skewed to larger nanoparticles and aggregates. In 
this case, intensity average size was a better representative of prodrug loaded 
nanoparticles.  
Table 3.1 Properties of PTX and triethyl Si PTX prodrugs 
 
Substrate MW(Da) 
Water 
solubility 
(μg/mL) aLogP
a
 ca. Krel
b
 t1/2(min)
c
 
PTX 854 12 3.20 -- -- 
1a 1016 <1 4.96 18,000 3.7 
2a 1178 -- 6.31 
15,000 (C2’), 
2100 (C7) 
4.6 (C2’), 
33 (C7) 
a:aLogP is calculated by using ALOPS 2.1. 
http://www.vcclab.org/lab/alogps/ 
b: ca. Krel is calculated relative hydrolysis rate detailed in Wohl’s NMR 
method
59,60
.  
c: t1/2 is half time of hydrolysis defined in Wohl’s NMR method
59,60
. 
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3.3.2.2 Nanoparticle Morphology 
SEM images in Figure 3.11 were obtained from fresh 2’,7-triethyl Si PTX 
nanoparticles and those obtained after lyophilization and resuspending in water at the 
same concentration. First of all, fresh nanoparticles Figure 3.11 (a) were spherical with 
size about 75 nm, which was very close to mass average size determined by DLS. 
Secondly, prodrug loaded nanoparticles had more contrast, while nanoparticles with less 
contrast were speculated to be blank polymer micelles and particles, because they were 
easily damaged by electron beam and very difficult to visualize in short time.  
 
   
  Figure 3.11 SEM images of 2’,7-triethyl Si PTX NPs before (a) and after lyophilization (b). 
 
Figure 3.10 Intensity average size (a) and mass average size distribution (b) of 2’,7-triethyl Si 
PTX nanoparticles calculated from DLS data using GENDIST software. 
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It is known that lyophilization can cause nanoparticle aggregation and original 
particle size cannot be recovered
85, 86
. 
Figure 3.11 (b) showed nanoparticles after lyophilization had similar sizes with 
fresh ones but this image was taken from one of few areas. However, aggregates were 
observed in most of other imaging area. Also, Cryo-TEM images shown in Figure 3.12, 
the averaged size from lyophilized particles greatly increased due to aggregation of 
multiple particles. 
 
       
 
Figure 3.12 Cryo-TEM images of fresh (a) and lyophilized 2’-triethyl Si PTX NPs (b), 
fresh (c) and lyophilized (d) 2’,7-triethyl Si PTX NPs. 
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3.3.2.3 Nanoparticle Drug Loading 
Figure 3.13 is a representative of HPLC standard curve for 2;,7-triethyl Si PTX 
nanoparticles. PTX was characterized by the 1
st
 peak with a retention time of 
approximately 2.5 min. The peak area was extremely small, which meant the amount of 
PTX in newly synthesized 2’,7-triethyl Si PTX was negligible. The 2nd and 3rd peak with 
retention time of 4.25 min and 5.60 min indicated the presence of 7- and 2’-triethyl Si 
PTX, hydrolyzed from 2’,7-triethyl Si PTX prodrug with one silicate ester cleavage. 2’,7-
triethyl Si PTX was characterized by the largest peak (the 4
th
 peak) with a retention time 
of approximately 12 min. When Si PTX prodrug was calculated in loading level, both 
mono- (2’ or 7-) and bis (2’,7)-triethyl Si PTX were taken into account because they were 
considered as prodrugs, presumably an inactive form of PTX. The mass of 2’ or 7-triethyl 
Si PTX was converted to 2’,7-triethyl Si PTX, in loading calculation. The standard curves 
of concentration vs. signal of PTX and 2’,7-triethyl Si PTX are show in Figure 3.14. 
                 
 
       Figure 3.13 A representative HPLC analysis for 2’,7-triethyl Si PTX NPs. 
58 
 
According to Eq. 3.4 and 3.5, the loading level of 2’,7-triethyl Si PTX 
nanoparticles was 52.3±.6.5%. This was averaged over three batches of nanoparticles 
with three identical samples prepared in each batch.  The averaged encapsulation 
efficiency was 90.2%. There was about 5% of nanoparticle loss during weighing samples 
and transferring suspension. With measurement error considered, nanoparticles prepared 
via flash nanoprecipitation had very high encapsulation efficiency.  
 
3.3.3 Nanoparticle Post-treatment 
3.3.3.1 Filtration and Ultracentrifugation 
Initially, I did not use dialysis method for purification and concentrating particle 
suspensions because it is very time consuming while the encapsulated Si PTX prodrugs 
are likely to hydrolyze in that period of time. Therefore, we were looking for fast 
approaches to filter particles, so membrane filter, hollow fiber filtration and 
ultracentrifugation were studied.  
Simple filtration: most of particles smoothly passed through the 0.45 μm filter. 
Particles in the filtrate had almost equal size to the un-filtered ones. It implied that 0.45 
 
Figure 3.14 HPLC standard calculation of intensity peak area vs. concentration of (a) PTX and 
(b) 2’,7-triethyl Si PTX in acetonitrile. 
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μm filter was too large to separate particles. Through 0.20 μm filter, a few large particle 
aggregates were filtered out of suspension, and eventually clogged the filter. However, 
particle size was still same as the un-filtered ones, with standard deviation of mass 
average size of 75±3 nm and intensity average size of 127±10 nm. Though nanoparticles 
were polydisperse, they were mostly below 200 nm. Filter filtration was helpful to 
remove aggregates demonstrated by the observation that filter was clogged after 
filtration. Nevertheless, it was not able to purify prodrug loaded nanoparticles from un-
encapsulated prodrug.  
Hollow fiber filtration: in experiment 1, β-carotene loaded PEG-b-PLA 
nanoparticles were freshly made and injected in hollow fiber diafiltration column. The 
filtrated nanoparticle size increased from initially 104 nm to 160 nm shown in Table 3.2. 
Meanwhile, the waste solution showed a size of 91 nm. This indicated that, the waste 
collected smaller particles while the other outlet extracted the population of larger 
particles. 
In experiment 2, β-carotene loaded nanoparticles and blank polymer nanopaticles 
(dI=50 nm) were mixed at equal volume and then filtered by this hollow fiber column. 
The filtrated nanoparticles had insignificant size increase from 104 to 110 nm. The waste 
solution showed almost equal size of what we obtained from the waste in first experiment 
(90 vs. 91 nm). Though hollow fiber column showed consistent filtration performance in 
terms of separating particles into two ranges below and above 100 nm, yet the waste not 
only included blank polymer nanoparticles, but also relatively large β-carotene 
nanoparticles. Therefore, hollow fiber filtration did well in concentrating samples, the 
volume of nanoparticle suspension was reduced to 1/3 of initial volume, and the 
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concentration of nanoparticles increased roughly from 1 mg/mL to 3 mg/mL.  But it still 
failed to purify nanoparticles from free molecules and empty polymer NPs. 
 
Ultracentrifugation: this method was able to separate particles from free prodrug 
left in supernatant, while loaded nanoparticles settled as pellet. However, DLS was able 
to detect strong scattering signals from supernatant, which indicated that there were still 
nanoparticles remaining in supernatant though very dilute.  
                                                                                                              
                                                                                                                    Eq. 3.5 
 
                                        Eq. 3.6  
 
m is particle mass, ρ1 and ρ2 is densities of medium and particle, w is angular 
velocity, r is the radius of centrifugation, f is the friction factor, t is time, D is diffusion  
coefficient, kB is Boltzman constant, T is temperature. 
Table 3.2 β-carotene PEG-b-PLA nanoparticle size comparison via hollow fiber diafiltration. 
 Experiment 1 Experiment 2 
NP type β-carotene PEG-b-PLA β-carotene PEG-b-PLA Blank PEG-b-PLA NPs 
dI&PDI 104 nm/0.15 104 nm/0.15 50 nm/0.18 
concentration 1 mg/mL 1 mg/mL 
Action Filtration Mix & Filtration 
NP type filtrate waste filtrate waste Filtrate waste 
dI&PDI 160 nm/0.18 91 nm/0.27 110 nm/0.17 90 nm/0.27 
concentration ~3 mg/mL n/a ~3 mg/mL n/a 
dI: intensity average size of nanoparticles 
PDI: polydispersity index of particle size. 
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Using Eq. 3.5, with diffusion coefficient D characterized from DLS measurement, 
the friction factor f can be obtained via Stokes-Einstein relation in Eq. 2.1. With known 
r1, r2, t1, t2, w and ρ1, the calculated density of these small particles in supernatant (<80 
nm) had less than 5% difference from that of water, which explained why the particles 
failed to settle after ultracentrifugation. 
For example, nanoparticles obtained from supernatant 1 in Table 3.3 had an 
average size of 72 nm, w is 5000 rad/min, r1 is 5 cm, r2 is 10 cm, ∆t=t2-t1=30 min. Using 
Eq. 3.6, ∆ρ=0.043g/mL, the density difference against to water is 4.3%. In contrast, 
nanoparticles which were able to sediment into pellet had a density difference of 6.9%. 
HPLC measurements showed that a fair amount of prodrug existed in supernatant. 
Though certain amount of prodrug loaded nanoparticles along with free prodrug were 
removed via ultracentrifugation, yet the resulting pellet was nanoparticles heavily loaded 
with 2’,7-triethyl Si PTX loaded nanoparticles. Here is an example of 2’,7-triethyl Si 
PTX NPs particle size and composition in fresh nanosuspension, supernatants and the 
resulting pellets in Table 3.3. Although more prodrug was found in pellet, the average 
particle size of the pellet also increased significantly. As a result, the density of particles 
from pellet calculated via Eq. 3.6 only showed 0.3% density difference from water. The 
same characterization of ultracentrifugation for other Si PTX prodrug loaded 
nanoparticles was also conducted and presented in Appendix C. It was very consistent in 
several aspects: 1) significant mass was lost by the removal of supernatant, 2) smaller 
particles lightly loaded with prodrug were present in supernatant, along with 
unencapsulated prodrugs dissolved in solvent, and 3) the pellet had a higher loading due 
to the removal of empty polymer particles in supernatant. In contrast, supernatant 
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contained very little amount of lightly loaded nanoparticles and free prodrug, the 
solubility of which is so low, far below the detection limit of HPLC. Another related 
phenomenon was that, the ultracentrifuged nanoparticles tended to release in a more 
sustained pattern compared to the non-centrifuged ones, which will be discussed in Ch.5. 
 
3.3.3.2 Lyophilization 
As discussed in section 3.3.2.3, after nanoparticles were freshly made, they were 
immediately freeze dried over 24 hr. Less than 1% of PTX and around 4% of partially 
hydrolyzed Si PTX was detected from 2’,7-triethyl Si PTX nanoparticles. In comparison, 
there was still less than 1% of PTX, but about 10% of partially hydrolyzed Si PTX found 
in nanoparticles when they remained in water solution for 24 hr (Figure 3.15). This 
demonstrated that lyophilization effectively removed water via sublimation and 
prevented occurrence of hydrolysis. This indicated that nanoparticles can be stored in 
long term as lyophilized dry powder.  
     Table 3.3 Physical properties of 2’,7-triethyl Si PTX NPs during ultracentrifugation. 
 
dI(nm) PDI NTA(nm) NP:drug mass(mg) Loading% 
Fresh 132 0.13 109 48.3/27.5 52.3 (0/0/52.3) 
Supernatant 1 72 0.24 91 17.7/7.9 44.5 (33.1/11.4/0) 
Supernatant 2 111 0.18 103 10.9/3.7 34.3 (17.3/14.4/2.6) 
Supernatant 3 150 0.15 105 2.1/0.2 6.6 (1.7/4.1/0.8) 
Pellet 209 0.28 130 15.5/9.4 60.4 (1.6/16.3/42.5) 
dI: intensity average size of nanoparticles measured by DLS. 
PDI: polydispersity index of particle size. 
NTA: mass average size of nanoparticles measured by nanotracking analysis, Nanosight. 
NP:drug is the mass of total nanoparticles vs. drug including Si PTX and PTX. 
Loading is presented as the loading of PTX, 2’-triethyl Si PTX and 2’,7-triethyl Si PTX. 
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DLS measurements exhibited that particle mass average sizes increased 
drastically from 125 nm to 400 nm and above after lyophilization due to nanoparticle 
aggregation. To redisperse lyophilized particles, sonication was utilized to break 
aggregates apart. Micro-tip sonication was more effective than simply putting the entire 
tube of nanosuspension in water bath for sonication. But nanoparicle size was only 
reduced to 250-300 nm. Though the particle sizes in Figure 3.11 were small, aggregates 
above 200 nm were greatly observed from SEM and Cryo-TEM images in Figure 3.12. 
By the naked eye, the freeze dried particles appeared to be cloudy after redispersing in 
water shown in Figure 3.16. Thus, lyophilizaiton brought a great challenge to recover 
initial size. 
 
Figure 3.15 Composition comparison of 2’,7-triethyl Si PTX nanoparticles freeze dried (a) and 
in aqueous solution (b) for 24 hr. 
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To recover particle size, the cryoprotectant, sucrose was added in fresh 
nanosuspesnion right after mixing with a mass ratio of 10:1 sucrose:NPs. Sonication 
beyond 7 min for particles without sucrose and 13 min with sucrose did not reduce 
particle size further as shown in Figure 3.17. With addition of sucrose, lyophilized 
nanoparticles had a reduced size of approximately 180 nm with broad distribution when 
sonicated longer as shown in Figure 3.17. Usually, it was extremely difficult to reduce 
size below 200 nm. Prud’homme et al.122 have claimed that the ratio of sucrose:NP=60:1 
was necessary to retain particle size. 
 One issue related to cryoprotectant was that, such large amount of sucrose was 
undesirable from a drug delivery point of view. High concentration of sucrose will lead to 
a higher osmotic strength than cells and cause cell shrink when nanoparticles along with 
sucrose was intravenously administered into blood. Therefore, nanoparticles with sucrose 
are not practically applicable for injection. Thus, we are still striving to find other 
cryoprotectants with lower concentration and better particle size recovery, or other 
strategies to maintain particle size during lyophilization.   
 
Figure 3.16 The appearance of nanosuspension before and after freeze drying. 
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It will be ideal to use a much lower concentration of sucrose or other effective 
cryoprotectants to achieve a high level of protection during freezing. Pulstulka et. al
86, 123, 
124
 have found that pluronic 
F68 was a better 
cryoprotectant, especially 
for PTX-based particles. 
Further investigation needs 
to continue in search of 
good cryoprotectant or 
developing other strategies 
to protect particles during 
lyophilization, but for the 
following work in this 
thesis, nanoparticles used in vitro and in vivo studies were not prepared with any 
cryoprotectant. Fresh particles dI is 155 nm, after freeze drying without sucrose, 
sonicated for 10 min, 400 nm.  
3.3.4 Aging 
Figure 3.18 showed that 2’,7-triethyl Si PTX gradually hydrolyzed back to PTX 
over weeks when the hydrolyzed prodrug was stored at 4˚C. In short term, the hydrolysis 
was not very significant until one month later.  In long term up to eight months, there 
were only less than 20% of PTX, while the rest was composed of 70% of partially 
hydrolyzed 2’and 7-triethyl Si PTX and 10% of 2’,7-triethyl Si PTX. The hydrolysis 
from 2’,7- to 7-triethyl Si PTX occurred relatively fast, but quite slow from 7-triethyl Si 
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Figure 3.17 The intensity average diameter of 2’,7-triethyl Si 
PTX NPs after lyophilization vs. sonication time. 
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PTX to PTX. There was a significant increase of 2’ and 7-triethyl Si PTX between 5-10 
weeks which indicated the hydrolysis time of 2’,7- to 7-triethyl Si PTX lies in this period 
of time. Once Si PTX prodrugs became PTX, the redispersed nanoparticles loaded with 
PTX will not be stable due to Ostwald ripening of PTX. Therefore, 2’,7-triethyl Si PTX 
loaded nanoparticles were relatively stable with a shelf life of approximately two month 
and nanoparticles are suggested to be used as received and stored within one month. 
 
In contrast, Figure 3.19 showed hydrolysis occurred very fast in short term 
(within 24 hr) when 2’,7-triethyl Si PTX were encapsulated in nanoparticles and 
dispersed in PBS at pH 7.4 and 37˚C. Similarly to prodrug in dry state, prodrug in 
nanoparticles quickly hydrolyzed to 2’or 7-triethyl Si PTX, but the hydrolysis rate was 
much faster in water. At the end of 24 hr, 40% of 2’ and 7-triethyl Si PTX was obtained 
while PTX remained negligible. In comparison, nanoparticles before freeze drying 
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                  Figure 3.18 The aging process of 2’,7-triethyl Si PTX in 32 weeks. 
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contained less than 5% of 2’ and 7-triethyl Si PTX. Thus, the presence of water 
significantly expedited the hydrolysis. The key to store nanoparticles is to remove the 
moisture. Lyophilization is very necessary to maintain the stability of encapsulated 
prodrug, while how to recover nanopartcle size is still under investigation. 
           
 
3.4 Conclusion 
It is not possible to make stable PTX encapsulated nanoparticles due to fast 
Ostwald ripening of PTX, thus silicate esterification of PTX was introduced to increase 
its hydrophobicity by Wohl and Hoye
59, 60. 2’,7-triethyl Si PTX loaded PEG-b-PLGA 
nanoparticles were successfully made to avoid the crystallization of PTX. The 
nanoparticles were stable with an averaged intensity size around 120 nm. They tended to 
have a bimodal distribution where polymer micelles, particles and drug loaded 
 
Figure 3.19 Composition change of 2’,7-triethyl Si PTX during synthesis, flash 
nanoprecipitation, lyophilization, and resuspension. 
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nanoparticles coexisted. In order to remove free molecules un-encapsulated and empty 
polymer micelles/particles, ultracentrifugation was found to be the best method, 
compared to traditional filtration and hollow fiber filtration. The silicate paclitaxel 
prodrug loading levels are above 50% and up to 75% after ultracentrifugation, higher 
than current PTX-based formulations, such as Taxol
®
(~1wt%) and Abraxane
®
(~10 wt%). 
The high drug loading potentially leads more efficient dosing and reduced dosing cycles, 
in order to ease cancer patients’ pain. By lyophilization, nanoparticles were stored in dry 
state, where hydrolysis rate was efficiently reduced but particle size increased 
dramatically since freezing process induced particle aggregation. We attempted to use 
cryoprotectant sucrose to recover particle size after lyophilization but more efforts should 
be made to discover more effective cryoprotectant to maintain initial size with small 
concentration. The aging study indicated 2’,7-triethyl Si PTX prodrug in nanosuspension 
hydrolyzed relatively fast in 24 hr but can be stored as dry powder at 4˚C for a month. 
Beyond one month, hydrolysis will occur even in dry state.  
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Chapter 4  
In Vitro Drug Release Study of Silicate Paclitaxel 
Diblock Copolymer Protected Nanoparticles (un-
ultracentrifuged): Experimental Setting and Release 
Profile 
4.1 Introduction 
To be an effective drug delivery system, evaluation of release is essential during 
development and quality control of the formulations, via in vivo animals or in vitro using 
buffers at 37 ˚C (physical temperature). Due to the labor and expense involved with in 
vivo studies, in vitro drug release study has gained more attention in several aspects: first, 
it provides indirect measurement of drug release and predicts the timeframe of release, as 
preliminary stages for in vivo study. Secondly, it assesses manufacturing methods and 
formulation variables
125
. Thirdly, it screens one or more candidates among several 
formulations. 
In our drug delivery system, the silicate paclitaxel (Si PTX) prodrug loaded PEG-
b-PLGA nanoparticles are designed to be injected via intravenous (IV) administration. 
Once injected, nanoparticles release PTX-containing compounds over a period of time, 
depending on several factors, such as particle size and morphology, drug loading level of 
Si PTX prodrugs, their hydrolytic stability, diffusion of water into nanoparticles, polymer 
degradation etc. This chapter mainly focuses on the development of in vitro drug release 
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protocol, experiment methods and release kinetics characterization. We subjected six Si 
PTX nanopaticle formulations to different pHs and time and measure the release of 
prodrugs with one or two silicate derivatives. 
There are various methods used to measure drug release. They fall into four broad 
categories
126, 127
, in situ methods, continuous flow methods, sample and separate 
techniques and membrane diffusion techniques.    
In situ method: It is intended only for drug with chromophores. When the drug 
system is dispersed in sink, the released drug can be assayed by UV/Vis spectroscopy, 
without separating the dispersion from sink. Unfortunately, it is not suitable for our 
particle system. 
Continuous flow: the drug system is dispersed in a small sink which contained a 
filtration cell. The sink phase is removed for continuous analysis (by UV/Vis and 
fluorescence spectroscopy). Fresh sink is added to the suspension. However, flow rates 
might be varied when filter is clogged during the injection of sample. Though the method 
is not ideal, for Si PTX prodrugs might clog the filter and there is no compound observed 
by spectroscopy. But, the removal and replacement of sink condition is a good alternative 
to perfect sink condition if it can be done sufficiently rapidly.  
Sample and separate: the drug system is dispersed in a medium. Periodically, the 
sample is separated by filtration or centrifugation. The medium is assayed. This technique 
is applicable only if the dispersion and the medium can be completely separated and 
rapidly
128
. However, as we showed in Ch.3, our nanoparticle system with small size 
around 100 nm proved to be extremely difficult to filter off and the time to sediment in 
ultracentrifugation takes hours, which will intervene in the time course of release. 
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Membrane diffusion: One method of in vitro release is to test the formulation in a 
diffusion cell. In this apparatus, the formulation is put in contact with a membrane that is 
immersed in receiving medium. The medium is sampled as a function of time. However, 
this technique is only applicable to the tested drug compound with relatively high 
solubility in the medium. In our case, PTX is poorly water soluble, not to mention Si 
PTX with increased hydrophobicity. The same problems apply to dialysis bag technique. 
The receiving medium, in our case, phosphate buffer solution (PBS) must have a 
sufficient volume to solubilize all possibly released drugs, while the saturated 
concentration is near the lower limit of HPLC, the analysis accuracy cannot be 
guaranteed. If PTX releasing into PBS is first lyophilized and re-dissolved in a small 
volume to a detectable concentration, it can take several days to lyophilize such larger 
volume of buffer. It is inefficient and impractical for in vitro release study in our case, 
which will be performed on several different nanoparticle formulations. And each of the 
formulations needs several days to complete, involving hundreds of samples to be 
processed. 
There are technical problems to use most of the methods described above for in 
vitro release study, because the solubility of these Si PTX prodrugs predicted previously 
112
 were far less than pure paclitaxel (~12 μg/mL). Therefore, in this chapter, I adopted 
membrane diffusion method using dialysis mini capsules to conduct in vitro drug release 
studies with six Si PTX nanoparticles The dialysis mini capsules have a low-binding 
membrane with molecular weight cutoff size of 10kDa. They were tested beforehand to 
see whether the dialysis membrane limits drug diffusion. Pure PTX and 2’,7-triethyl Si 
PTX were first dissolved in water and contained in dialysis capsules, which were 
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immersed in phosphate buffer solution. They completely diffused through membrane in 
1-3 hr quantified by HPLC method shown in Figure 4.7, we do not think dialysis 
membrane limits drug diffusion. 
The drug release mechanism is widely believed to be diffusion from carrier 
matrix, thus using membrane method and sink condition have been proposed a lot for in 
vitro drug release. When drug system is immersed in a continuous phase, drug partitions 
between the carrier phase and the continuous phase, due to the concentration gradient. 
Theoretically, the drug will leave the carrier and partition completely when infinite 
dilution is provided in continuous phase. This is considered as perfect sink condition
127
, 
where true release profile can be measured. However, it is never attainable in practice. A 
finite sink condition is required to obtain valid experimental data. It is recommended that 
drug concentration in sink phase be kept below 10% of saturation
127
. For example, 
Langer’s group has used 20 or 40L PBS to create sink condition for PTX release129, 130. 
However, this poses a problem that as the volume increases, the concentration of drug 
being measured in buffer decreases to an extent that it is too dilute to detect. Eventually, 
the released drug cannot be assayed in buffer.  
It is the very reason that we developed a relatively new method specifically to 
study in vitro Si PTX prodrug and pure PTX release using frequent replacement of sink 
condition of phosphate buffer solution. This improvement has been demonstrated to 
achieve the same release profile obtained using the perfect sink condition. Meanwhile, 
dialysis tubes, dialysis cassettes
131
 and dialysis mini capsules were utilized to verify if the 
geometry design of dialysis devices has any influence on experiment accuracy and use 
convenience.  
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After in vitro release protocol and experimental setup were determined, in vitro 
release studies were first conducted on 2’,7-triethyl Si PTX nanoparticles at pH 7.4 and 
6.4 to study the effect of buffer pH on release rate. The reason for that is, normal tissues 
usually have a neutral environment, while tumor tissues are usually more acidic with a 
pH at 6.4 or lower
4-6
. Thus, it is worth studying whether drug release varies at these two 
conditions, especially when the hydrolysis of Si PTX prodrug captured in nanoprticles 
potentially can be pH-responsive. 
Also, the release profiles were plotted for both 2’,7 and 2’-triethyl Si PTX 
nanoparticles to study the effect of silicate derivatives amount. Lastly, prodrugs with four 
other different silicate derivatives from Wohl et al
59, 60
 were prepared in PEG-b-PLGA 
nanoparticles. With tuned hydrophobicity and hydrolytic lability, their physical and 
pharmacokinetic properties were customized to different levels, specifically in particle 
sizes and release rates.  
4.2 Methods and Experiments 
4.2.1 Materials 
Paclitaxel was obtained from Phytogen Life Sciences. PEG-b-PLGA (MW: 5k-
10kDa) was synthesized in Dr. Hoye’s lab as previously reported 81. Water (H2O, HPLC 
grade), tetrahydrofuran (THF, HPLC grade) and acetonitrile (ACN, HPLC grade) were 
purchased from Aldrich and used as received. Phosphate buffer solution (PBS) was 
prepared by dissolving 3.12 g monosodium phosphate and 20.74 g diasodium phosphate 
in 1 L DI water to achieve pH 7.4, and 10.28 g monosodium phosphate and 6.84 g 
diasodium phosphate in 1 L DI water for pH 6.4. Monosodium phosphate and diasodium 
74 
 
phosphate were purchased from Fisher Scientific. Slide-A-lyzer dialysis cassette 
(MWCO: 10k Da, 0.5-3 mL, 6-12 mL) and dialysis mini capsule (MWCO: 10k Da, 0.5-1 
mL) were purchased from Thermo Scientific. Six Si PTX prodrugs were synthesized in 
Dr. Hoye’s lab as previously reported109, 112. Their chemical structures are shown in 
Figure 4.1. The physical properties and hydrolytic lability are shown in Table 4.1. The 
partitioning coefficient was calculated using several softwares, such as ALOPS 2.1, 
molinspiration and ACD/Labs. They all showed similar trend of values, but those 
obtained by ALOPS 2.1 were most consistent with other hydrophobicity indicators such 
as retention time in LC/MS method and calculated aqueous solubility, discussed,by 
Adam et al
59, 60
.  Thus, only LogP values calculated by ALOPS 2.1 are provided in Table 
4.1. 
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                       Table 4.1 Properties of PTX and Si PTX prodrugs 
Drug MW/Da aLogP
a
 ca. Krel
b
 t1/2/min
c
  
PTX 854 3.20 -- --  
1a 1016 4.96 18,000 3.7  
2a 
 
1b 
2b 
1c 
2c 
1178 
 
1269 
1683 
1058 
1263 
6.31 
 
7.74 
8.59 
5.60 
6.84 
15,000 (C2’),  
2100 (C7) 
5,600 
3,800 
570 
520 
4.6 (C2’), 
33 (C7) 
12 
18 
120 
130 
 
           a: aLogP is calculated by using ALOPS 2.1. 
           b: ca. Krel is calculated relative hydrolysis rate by Wohl’s NMR method
59,60
.. 
           c: t
1/2 
is half time of hydrolysis by Wohl’s NMR method
59,60
. 
 
 
Figure 4.1 Chemical structures of 2’-triethyl Si PTX (1a), 2’,7-triethyl Si PTX (2a), 
2’-trioctyl Si PTX (1b), 2’,7-trioctyl Si PTX (2b), 2’-triisopropyl Si PTX (1c) and 
2’,7-triisopropyl Si PTX (2c). 
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4.2.2 Nanoparticle Preparation 
Nanoparticles made with each of six Si PTX prodrugs were prepared using CIJ-D 
mixer via flash nanoprecipitaiton. For single batch of nanoparticles, 35-40 mg of Si PTX 
prodrugs (with an equivalent of 25 mg PTX) and 25 mg of PEG-b-PLGA were dissolved 
in 2.5 mL THF, contained in a 3mL syringe. It was impinged rapidly with the other 
syringe containing 2.5 mL water within 5 seconds. The mixture was drained into 45 mL 
water, in order to further quench nanoparticle growth. The resulting nanoparticle 
suspension had total volume of 50 mL with a ratio of 5:95 THF: H2O and total mass of 
approximately 60-65 mg nanoparticles. 
4.2.3 Nanoparticle Characterization 
4.2.3.1 Nanoparticle Size and Distribution 
Nanoparticle size was characterized via dynamic light scattering (Beckman 
Coulter, CA). 100 μL suspension was removed by micro pipette, and diluted with 1 mL 
DI water in DLS square tube. The apparatus was equipped with a laser operating at a 
scattering angle of 90˚. The refractive index was 1.33, the viscosity of solvent mixture 
was 0.89 mPa•S. The intensity correlation functions were collected at 25˚C. Three 
identical samples were sealed with a plastic cap and prepared for measurements. 
Nanoparticle size was averaged across 150 individual detections. The final size and 
standard deviation were determined by averaging three measurements. Size 
polydispersity index (PDI) was calculated by instrument software. The mass average 
particle size, intensity average size and size polydispersity index defined as: 
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where in is the number of particles with a diameter id , im is the mass of particles. 
 4.2.3.2 Nanoparticle Drug Loading 
Samples preparation methods for HPLC was described in Ch.3 Section 3.2.3.4. 
Different from Ch.3, the mobile phase consisted of a mixture of acetonitrile and water, 
which was delivered at a flow rate of 1 mL/min in gradient from 100:0 to 50:50 
acetonitrile:H2O in first 4 min, and back to 100:0 in the following 4 min, and decreased to 
50:50 acetonitrile: H2O for another 4 min and remained at that ratio for 5 min in each 
sample analysis . 
Every time new measurements started, new standard samples with known 
concentrations were prepared and calibration was repeated. The Si PTX prodrug loading 
levels in lyophilized nanoparticles were determined by analyzing the acetonitrile extract 
by HPLC. AC-18 column (14.6×25 cm) with 5 µm packing (Beckmann Instruments, CA) 
was used. The loading levels were calculated using the equation below: 
       
 
  /   
 
                                                                        Eq.4.3 
6 5
I /i i i id n d n d                                                                             Eq.4.2  
 
                                                     Eq.4.1      
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4.2.4 In Vitro Drug Release 
4.2.4.1 Sink Condition 
The infinite sink condition is used for extremely hydrophobic drug release. 
Langer et al
130
 used 40 L phosphate buffer solution (PBS) to create sink condition, where 
the extensively large volume of PBS avoided PTX to saturate. The huge volume of PBS 
created sufficient concentration gradient as the driving force for PTX to diffuse out of 
nanoparticles and through dialysis membrane as well.  
 
In order to investigate the effect of sink condition, lyophilized 2’7-triethyl Si PTX 
nanoparticles were redispersed in PBS (pH 7.4) at a concentration of 1 mg/mL. In group 
1, they were put into 500 μL dialysis tubes and multiple tubes were immersed into 40 L 
PBS, at pH 7.4, at room temperature and stirred with an overhead, which is shown in 
 
                           Figure 4.2 Infinite sink condition (40L) for drug release. 
 
                                     Eq. 4.4 
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Figure 4.2. In group 2, dialysis tubes containing same nanoparticle suspension were 
immersed into 1 L PBS magnetically stirred, the buffer of which was periodically 
refreshed at designated time intervals (1, 2, 4, 6, 8, 12, 24 hr) to avoid saturation. At these 
predetermined time, three dialysis tubes were removed from both groups and lyophilized. 
Noted that, at 0hr, the lyophilized nanoparticles were first dispersed and dialyzed against 
buffer. They were removed immediately after being immersed in buffer less than 1 
min.The dry powder of nanoparticles were dissolved in 1 mL acetonitrile and extracted 
overnight. HPLC was used to determine the concentration of PTX and Si PTX prodrugs 
from these lyophilized samples as the remaining/un-released drug from nanoparticles. 
4.2.4.2 Dialysis Devices  
Dialysis tubes, dialysis cassette and dialysis mini capsules were all used to 
contain nanoparticle suspension in drug release study shown in Figure 4.3 (a), (b) and (c). 
(a) Dialysis tube (500 μL) has a cylinder-like membrane compartment with two caps on 
the ends. (b) Dialysis cassette has a tape cassette compartment with two square-shape 
membranes clamped in the middle. (c) Dialysis mini capsule is a 500 μL cup with semi-
permeable membrane on the bottom and sealed with a cap. In order to fully use the 
diffusion area of the membrane, dialysis tube and cassette were completely immersed in 
buffer, while dialysis mini capsule were floating with the bottom membrane immersed in 
buffer. Nanoparticles were injected via inlet port at the corner of dialysis cassette shown 
in Figure 4.3 (d) and placed into dialysis tubes and mini capsules by a pipette shown in 
Figure 4.3 (e).  
To compare the performance of dialysis devices, 2’7-triethyl Si PTX 
nanoparticles were resuspended and put into dialysis tubes, cassettes and mini capsules. 
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In each group, multiple samples were prepared and immersed in PBS pH 7.4 at 37ºC to 
mimic body condition. The release study was conducted using the same protocol 
explained previously. We compared the release profiles obtained from three groups, to 
see if they showed consistent release rates. Or in the other case, different design of 
dialysis devices and varied surface areas immersed in buffer may play a diffusion-
limiting factor. 
 
4.2.4.3 pH 7.4 vs. pH 6.4 
Release studies were conducted in PBS both at pH 7.4 and 6.4 to mimic normal 
tissue and tumor tissue conditions.  The same release study protocols applied to the two 
buffer conditions. Release profiles of 2’,7-triethyl Si PTX nanoparticles were plotted over 
 
Figure 4.3 (a) dialysis tube, (b) dialysis cassette, (c) dialysis mini capsule immersed in PBS at 
37ºC, pH=7.4 or 6.4; (d) sample injection and removal into dialysis cassette, and (e) into mini 
capsule. 
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time in the hope of studying pH-responsive effect on release rates. The protocol of 
nanoparticle preparation, post-treatments and release study protocol are shown in Figure 
4.4. 
 
4.2.4.4 Silicate Derivatives of Paclitaxel Prodrugs 
In this study, 2’,7-triethyl Si PTX and 2’-triethyl Si PTX nanoparticles were used 
to conduct in vitro drug release studies. 15 mg of each were weighed and resuspended in 
15 mL PBS separately, using microtip probe sonication for 5 min. They were put into 
multiple dialysis mini capsules (500 μL) and immersed into 2 L PBS. At predetermined 
time points, triplicate capsules were removed and lyophilized. The dry product remaining 
in capsules was dissolved in acetonitrile and extracted overnight. The extracts were 
 
Figure 4.4 Nanoparticle preparation, size measurement, post-treatment and release kinetic 
characterization processes. 
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analyzed by HPLC to determine the amount of Si PTX/PTX as un-released drug. Release 
profiles were plotted as a function of time. 
The comparison between two derivatives (bis-Si PTX) and one derivative (mono 
Si PTX) were first carried out on prodrugs with triethyl Si derivates. The similar 
comparisons were carried out on triisopropyl and trioctyl Si PTX nanoparticles as well. 
Meanwhile, the comparisons among different derivatives were also observed when the 
prodrugs were chosen with either one (mono-) or two (bis-) Si derivatives.  
4.3 Results and Discussion 
4.3.1 Nanopaticle Physical Properties 
Nanoparticle sizes were measured by DLS apparatus (Beckman Coulter, CA) 
immediately after CIJ-D mixing and before ultracentrifugation. The results were recorded 
using mass average size and intensity average size shown in Table 4.2. Nanoparticles 
usually had a bimodal distribution which showed not only empty polymer nanoparticles 
in a range of 20-50 nm and drug loaded nanoparticles larger than 50 nm. The mass 
average sizes for all the nanoparticles were controlled in the range of 50-90 nm, while the 
intensity average sizes were more skewed towards larger particles, up to 150 nm. The 
size polydispersity index (PDI) values showed that the nanoparticles had a relatively 
broad distribution, which might be due to FNP process and further aggregation. The SEM 
and TEM images in Ch.3 also showed that nanoparticles were spherical with a size range 
of 50-150 nm. There was no obvious trend on nanoparticle size as a function of silicate 
derivatives or molecular weight.  
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Note that nanoparticles prepared in this chapter were not ultracentrifuged, instead 
they were directly lyophilized after preparation. Thus, it is very likely that prodrug loaded 
nanoparticles were mixed with empty polymer particles and un-encapsulated prodrug. 
The loading was determined by the total amount of prodrug possibly including both 
encapsulated and un-encapsulated ones in dry nanoparticles. Therefore, Table 4.2 showed 
that the determined loadings were very close to the initial formulation used in FNP. This 
has been corrected in next chapter when ultracentrifugation was introduced before 
lyophilization, in order to remove all the empty polymer nanoparticles, lightly loaded 
nanoparticles and un-loaded free drug.    
4.3.2 In Vitro Drug Release Setup/Protocol 
Infinite sink condition has been claimed necessary to conduct in vitro release 
study for highly hydrophobic drug. Using Langer’s method130, we prepared 40 L PBS to 
dialyze 15 mg 2’,7-triethyl Si PTX loaded nanoparticles in group 1. Meanwhile, the same 
            Table 4.2 Properties of six Si PTX loaded nanoparticles 
Prodrug aLogP dm(nm) dI(nm) PDI 
Prodrug 
loading% 
1a 4.96 78±13 145±9 0.10 49.1±5.4 
2a 6.31   70±3 132±20 0.13 52.3±6.5 
1b 7.74 77±15 83±6 0.16 55.3±3.5 
2b 8.59 83±29 123±36 0.66 57.8±3.8 
1c 5.60 52±17 136±1 0.17 50.8±2.3 
2c 6.84 46±8 128±4 0.53 53.4±1.8 
Note: aLogP is calculated by using ALOPS 2.1.  
dm & dI:  particle mass average diameter+standard deviation, and particle intensity average 
diameter+standard deviation of three batches of particles and three measurement in each. 
PDI: size polydispersity index of particle intensity average size  
Loading%: total of encapsulated prodrug in nanoparticles (without ultracentrifugation). 
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amount of nanoparticle suspension was dialyzed in 1 L PBS but refreshed at 
predetermined time. Figure 4.5 showed that nanparticles released in a similar rate, but 
uncertainty was huge in both groups. Generally, there was a burst release pattern in the 
first 10 hrs, followed with a more extended and slower release in next 3 days. This burst 
release and large error bars make this study of limited use. But, it indicated that frequent 
buffer refresh provided sufficient sink condition for 2’,7-triethyl Si PTX/PTX, as good as 
the infinite sink condition provided by 40 L PBS.  It can be an alternative to infinite sink 
condition, more economical, practical and easier to prepare. 
 
In comparison of dialysis devices, nanoparticles contained in dialysis tubes (black 
in Figure 4.5) and mini capsules (Red in Figure 4.5) had almost overlapped release rates 
using the same drug release protocol. However, when nanoparticles were contained in 
dialysis cassette, the release profiles showed a burst release pattern in short term as usual, 
but no significant release in long term up to 3 days. The possible reasons are, dialysis 
cassettes had a larger volume (6-12 mL) containing nanoparticles, and they were 
0 10 20 30 40 50 60 70 80
0
10
20
30
40
50
60
70
80
90
100
 pH=7.4 infinite sink
 pH=7.4 limited sink
 pH=6.4 infinite sink
re
m
a
in
in
g
%
time/hr
 
Figure 4.5 Reverse release profiles of 2’,7-triethyl Si PTX NPs in different release conditions. 
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immersed in beaker and placed on a plate shaker with a speed of 100 rpm and in the 37˚C 
incubator, instead of using magnetic stir bar. The rotation of the plate in incubator might 
not be sufficient to achieve flow exchange through dialysis membrane, despite that the 
membrane materials on dialysis cassette and capsules are same, provided by the same 
manufacturer. As a result, the aqueous solution in dialysis cassette was saturated with 
drug/prodrug released from nanoparticles and they crystallized to the bottom of the 
cassette. The release of drug through membrane was greatly inhibited. To investigate it, 
nanoparticle sedimentation with possible PTX crystallization was actually observed in 
dialysis cassette after 36 hrs pointed by the red arrow in Figure 4.6 (b). The 
nanosuspenion in cassette had a fraction of supernatant clear on the top and white 
precipitation accumulated on the bottom. It implied that the aggregation and the 
crystalline bulk of PTX limited the dissolution rate of prodrug/PTX, leading to no 
significant release in long term.  
 
Finally, dialysis mini capsules were chosen for in vitro drug release study in 
future, since they are cheap, disposable, and easy to use. To point out, dialysis mini 
 
Figure 4.6 Redispersed 2’,7-triethyl Si PTX NPs in dialysis cassette (a) right after redispersion 
and (b) 36hr during release study. 
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capsules containing nanoparticles were removed and directly lyophilized, and no 
materials were transferred out of the capsule. This helped us to avoid mass loss during 
sample transfer, which is critical when the following HPLC analysis were usually 
conducted on samples in microliters.  
To sum up, for all further in vitro drug release studies, I chose to use dialysis mini 
capsules and to refresh buffer solution frequently to avoid drug saturation. The drug 
remaining in capsules were mainly analyzed to show a reverse release profile, where the 
encapsulated/un-released drug decreased as a function of time. Temperature was 
controlled at 37 ºC by the incubator rotating at a speed of 100 rpm, and PBS was 
controlled at pH 7.4 and 6.4, to mimic conditions in blood circulation/healthy tissues and 
tumor tissues. PBS was only used to mimic ion, pH and temperature conditions in healthy 
and normal tissues. It is simpler condition than in vivo conditions where clearance of the 
drug during circulation, possible protein binding, and macrophages uptake must be 
considered.  
4.3.3 In Vitro Drug Release Profiles 
4.3.3.1 Diffusion of Drug and Prodrug Only  
To test whether PTX and 2’,7-triethyl Si PTX can diffuse freely through semi-
permeable membrane on dialysis mini capsules, 10 mg of PTX and 2’,7-triethyl Si PTX 
were dissolved in 10 mL DI water, respectively. Based on their aqueous solubility 
estimated by Wohl et al
59, the solution of PTX and 2’,7-triethyl Si PTX were 
oversaturated. The supernatant as saturated solution was removed and placed in dialysis 
mini capsules, which were immersed in 15 mL PBS at pH 7.4 and 37˚C. Each mini 
capsule contained 500 μL solution. PBS was refreshed every 30 min. At predetermined 
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time (0, 1, 3, 6, 8, 10, 24 hr), two dialysis mini capsules and 15 mL PBS were collected 
and lyophilized. The dry product was dissolved in 1 mL acetonitrile and extracted. The 
extracts were analyzed by HPLC to determine the amount of PTX and 2’,7-triethyl Si 
PTX remaining in capsules and diffused in PBS.   
 
As shown in Figure 4.7 (a), about 15% of PTX remained in dialysis mini capsules 
after 1 hr. The retention of this 15% of PTX might be caused by the saturation of PTX in 
PBS outside dialysis capsules before buffer was refreshed. If the experiment was 
conducted in perfect sink condition, the diffusion of PTX should be rapid enough to 
transfer across dialysis membrane immediately. None of it should be detected inside 
dialysis capsules. There was no PTX in capsules detectable by HPLC after 3 hr, which 
meant the capsules were empty then. In PBS, the amount of PTX was not able to be 
identified because larger signal noise in HPLC, until it accumulated to 95% at 24 hr. As 
shown in Figure 4.7 (b), about 30% of 2’,7-triethyl Si PTX remained in dialysis mini 
capsules after 1 hr, while 10% of PTX, 20% of 2’ and 7-triethyl Si PTX were found. 
Similarly, the mini capsules were completely empty after 3 hr. These results 
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Figure 4.7 Percentage of (a) PTX in dialysis capsule and diffusing through membrane into PBS and 
(b) 2,7-triethyl Si PTX, intermediate 2’ or 7-triethyl Si PTX and PTX obtained from hydrolysis 
remaining in dialysis capsule. 
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demonstrated that as molecules, PTX and 2’,7-triethyl Si PTX are able to diffuse out of 
dialysis membrane quickly, possibly shorter than 3 hrs. Their diffusion should not be a 
limiting factor of drug release if they are encapsulated in nanoparticles and able to release 
out of nanoparticles. 
4.3.3.2 pH 7.4 vs. 6.4 
When 2’,7-triethyl Si PTX nanoparticles were dialyzed against PBS at pH 6.4 and 
7.4, the general release rates showed a similar trend in both cases shown in Figure 4.8, 
where a burst release pattern was found in short term, and slow release in long term. 
Overall, nanoparticles released in similar rate in PBS at pH 6.4 and 7.4 both using infinite 
sink condition and limited sink followed with frequent buffer refresh. The possible reason 
is that, the hydrolysis of 2’,7-triethyl Si PTX is not sensitive to such small difference in 
pH. 
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Figure 4.8 Reverse release profiles of 2’,7-triethyl Si PTX NPs in PBS at pH 7.4 and 6.4. 
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4.3.3.3 Silicate Ester Derivatives 
In Figure 4.9, in vitro release studies in PBS (pH=6.4) were first divided into 
three groups, in terms of types of silicate ester derivates. Group 1, they were both triethyl 
Si PTX nanoparticles, but with one silicate derivative at 2’C position (1a) and two silicate 
derivates at both 2’C and 7C positions (2a). The same applied to Group 2, trioctyl Si PTX 
(1b & 2b) and Group 3, triisopropyl Si PTX nanoparticles (1c & 2c). Nanoparticles in 
Group 1 (1a & 2a) had almost complete release in 24 hr, followed by Group 2 (1b & 2b), 
in 48 hr and Group 3(1c & 2c) in 72 hr because their relative hydrolysis rates of silicate 
ester derivatives followed in this order a>b>c shown in Table 4.1. These Si PTX 
prodrugs were hydrophobic enough to be encapsulated in nanoparticles. Once the 
hydrolysis occurred, their hydrophobcities were reduced by 1-2 orders of magnitude, and 
1-5 orders of magnitude indicated by LogP in Table 4.1 if they were converted to be 
PTX. This resulted in faster diffusion of less hydrophobic Si PTX and PTX itself through 
membrane and faster release of drug from nanoparticles.   
4.3.3.4 One vs. Two Silicate Derivatives 
These six Si PTX prodrugs can be also seen as two categories by the number of 
silicate ester derivatives. Group 1 has only one silicate derivative at 2’C position, 1a, 1b 
and 1c. Group 2 has two silicate derivates at 2’C and 7C positions, 2a, 2b and 2c. Across 
all three silicate ester derivatized PTX, nanoparticles loaded with 1a, 1b and 1c have 
consistently released faster than those loaded with 2a, 2b and 2c, because the cleavage of 
2’ silicate derivative by hydrolysis was much faster. In comparison, the cleavage of 
silicate ester at 7C was much hindered. This difference was slightly more obvious for 
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isopropyl Si PTX nanoparticles but not very distinctive for ethyl Si PTX and octyl Si 
PTX nanoparticles. This indicated that while the hydrolytic lability played an important 
role in release rate, the diffusion of Si PTX with one and two silicate derivates was very 
significant. 
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Figure 4.9 Reverse release profiles in PBS at pH 6.4 of a) 1a 2’-triethyl Si PTX and 2a 
2’,7-triethyl Si PTX NPs, b) 1b 2’-trioctyl Si PTX and 2b 2’,7-trioctyl Si PTX NPs and c) 1c 
2’-triisopropyl and 2c 2’,7-triisopropyl Si PTX NPs. 
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4.4 Conclusions 
To sum up, six Si PTX prodrugs synthesized by Wohl et al
59, 60
 were used to 
prepare PEG-b-PLGA nanoparticles. The enhanced hydrophobicity of Si PTX allowed 
nanoparticles to be stable, spherical, size controlled in the range of 50-150 nm. Secondly, 
in vitro drug release protocol was to use dialysis mini capsules, limited sink condition, 
and to frequently refresh buffer at predetermined time. Reverse release profiles were 
determined by analyzing the remaining/un-released drug in nanoparticles contained in 
dialysis capsules. This is meant to overcome detection difficulty of released drug in 
buffer via HPLC, caused by the extremely low solubility of Si PTX and PTX itself.  
With in vitro drug release protocol customized, the general release profiles were 
determined on six batches of nanoparticles loaded with six Si PTX prodrugs, including 
three types of silicate ester derivatives, each of which was derivatized at one or two 
                 
Figure 4.10 Schematic of Si PTX prodrug diffuse and release through dialysis 
semipermeable membrane, (1) diffusion rate>hydrolysis rate, (2) hydrolysis rate>diffusion 
rate. 
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positions. The release rates were attributed to both diffusion of PTX and Si PTX, and 
tuned hydrolysis rates of Si PTX. The release rates were ranked from slowest to fastest 
a>b>c, 1a>2a, 1b>2b and 1c>2c, in an increasing order of the relatively hydrolysis rates 
shown in Table 4.1.  
These possible drug release mechanisms are shown in Figure 4.10. (1), prodrugs 
simply diffuse out of nanoparticles and membrane followed by possible hydrolysis in 
order to achieve regeneration of PTX. Or, (2) prodrugs with more hydrolytic labile 
silicate derivatives first hydrolyze back to PTX first, followed by the diffusion of PTX 
through membrane. Or, (3) prodrugs diffuse and hydrolyze in a similar rate to release 
PTX. Generally, nanoparticles loaded with these prodrugs presented a burst-and-slow 
release pattern, which was probably because, the un-encapsulated prodrug/drug and those 
loosely distributed on the outer region of nanoparticles and diffuse into buffer more 
quickly, while the prodrug/drug captured in the nanoparticle core slowly diffused out of 
polymer matrix of nanoparticles.  
Based on drug release results shown above, it is still unclear how hydrolysis 
occurred during the time course of release study. There are questions that need to be 
answered. For instance, where did hydrolysis take place, in nanoparticles or in PBS? This 
is very much related to the relation between hydrolysis and diffusion. Specifically put, 
which occurred first? Is there a difference in hydrolysis rate in nanoparticles and in PBS? 
Are there any other factors affecting release rates? Many studies have been conducted on 
polymer degradation
132-136
 which can potentially destruct nanoparticle matrix, change 
morphology and influence drug release, but they often occur after 15-30 days, which 
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made it impossible for polymer degradation to affect drug release in 24-48 hrs These 
questions will be discussed in Ch. 5 and Ch.6. 
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Chapter 5   
In Vitro Drug Release Study of Silicate Paclitaxel 
Diblock Copolymer Protected Nanoparticles 
(ultracentrifuged) 
5.1 Introduction 
As shown in previous chapter, we have found all silicate paclitaxel loaded 
nanoparticles had a common burst-and-release pattern. They did not meet one of the 
goals of functionalizing paclitaxel with silicate esters, which was to make the paclitaxel 
prodrugs sufficiently hydrophobic, to let the cleavage of silicate precede the diffusion of 
the compound, and eventually to help obtain a more extended release pattern. The burst 
release phenomenon allowed us to wonder whether any improvement can be made during 
nanoparticle preparation and post-treatment processes, in order to obtain nanoparticles 
with high purity and more accurate characterization. 
It is common in pharmaceutical laboratory using ultracentrifugation
137-139
 to 
separate protein, microparticles and free compounds. As discussed in Chapter 3, we have 
demonstrated that ultracentrifugation is essential to our nanoparticle preparation as well. 
Not only did it separate prodrug loaded nanoparticles away from empty polymer 
nanoparticles and un-encapsulated drug, but also helped to enhance the actual drug 
loading after separation. Therefore in this chapter, different from Ch. 4, all nanoparticles 
were freshly made, immediately ultracentrifuged and lyophilized. The loading levels of 
prodrugs were determined afterwards in the range of 55-75%, which were higher than the 
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initial formula for particle preparation. More importantly, these particles have shown 
much more extended release profiles. 
The six Si PTX prodrugs studied in this chapter are 2’-triethyl Si PTX (1a), 2’-
trioctyl Si PTX (1b), 2’-triisopropyl Si PTX (1c), 2’-ditert butyl/ethyl Si PTX (1d), 2’-
trimenthyl Si PTX (1e) and 2’,7-bis-triethyl Si PTX (2a)59. The first five are paclitaxel 
with only one silicate ester at 2’C position. The last one is paclitaxel derivatized at both 
2’C and 7C positions.  
To investigate the effect of silicate esters on particle physical and 
pharmacokinetic properties in a simpler way, this chapter focuses on mono-Si PTX 
prodrugs with one silicate ester derivative. Because they only have one cleavage of 
silicate at the 2’carbon, they simplified the way to identify diffusion and hydrolysis rates, 
only Si PTX prodrug and PTX were present in buffer and nanoparticles after hydrolysis. 
In contrast, 2’,7-triethyl silicate paclitaxel (2a) was involved with two cleavages of 
silicate derivatives, four compounds in present via hydrolysis. They were 2’7-triethyl Si 
PTX, 2’-triethyl Si PTX, 7-triethyl Si PTX and PTX itself. This multiple-compound 
system clouded the judgment on the completion of the hydrolysis and comparison with 
diffusion. Moreover, the cytotoxicity of the intermediates from 2’,7-triethyl Si PTX, 2’ 
and 7-triethyl Si PTX have not been studied yet.  
In vitro drug release studies were not only conducted in PBS at pH 7.4 and 6.4, 
but also in acetic acid buffer at pH 5.0, in order to compare pH-responsive hydrolysis 
rates. Beside the quantification of drug/prodrug remaining in particles, the exterior buffer 
containing released drug/prodrug was also analyzed. A combination of two allowed us to 
first validate the reverse release protocol as an alternative approach to determine drug 
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release for extremely hydrophobic drugs, and to discover the relative hydrolysis and 
diffusion rates of drug/prodrug in different environments, specifically nanoparticles and 
buffer solution.  
The relative hydrolysis rates of these six Si PTX prodrugs were estimated by 
1
H 
NMR and hydrophobicity by calculated LogP. Nanoparticles loaded with these prodrugs 
were formulated using the confined-impingment-jet-dilution (CIJ-D) mixer. Particle size 
and distribution were characterized by dynamic light scattering (DLS) and morphology 
by Cryogenic-transmission electron microscopy (Cryo-TEM). Prodrug/drug loading 
levels and in vitro drug release kinetics were determined by high performance liquid 
chromatography (HPLC).  
5.2 Methods and Experiments 
5.2.1 Materials 
Paclitaxel was obtained from Phytogen Life Sciences. PEG-b-PLGA (MW: 5k-
10kDa) was synthesized in Dr. Hoye’s lab as previously reported 81. Water (H2O, HPLC 
grade), tetrahydrofuran (THF, HPLC grade) and acetonitrile (ACN, HPLC grade) were 
purchased from Aldrich and used as received. PBS was prepared by dissolving 3.12 g 
monosodium phosphate and 20.74 g diasodium phosphate in 1 L DI water to achieve pH 
7.4, and 10.28 g monosodium phosphate and 6.84 g diasodium phosphate in 1 L DI water 
for pH 6.4. Monosodium phosphate and diasodium phosphate were purchased from 
Fisher Scientific. Dialysis mini capsules (MWCO: 10k Da, 0.5-1 mL) were purchased 
from Thermo Scientific. Silicate prodrugs were synthesized in Dr. Hoye’s lab as 
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previously reported 
109, 112
. Their chemical structures are shown in Figure 5.1 and 
properties in Table 5.1.  
 
5.2.2 Nanoparticle Preparation 
Nanoparticles made with each of Si PTX prodrugs were prepared using CIJ-D 
mixer via flash nanoprecipitaiton. For one single batch of nanoparticles, 35-40 mg of Si 
PTX prodrugs (with an equivalent of 25 mg PTX) and 25 mg of PEG-b-PLGA were 
dissolved in 2.5 mL THF, contained in a 3mL syringe. It was impinged rapidly with the 
other syringe containing 2.5 mL water within 5 seconds. The mixture was drained into 45 
mL DI water, in order to further quench nanoparticle growth. The resulting nanoparticle 
 
Figure 5.1 Chemical structures of 2’-triethyl Si PTX (1a), 2’,7-triethyl Si PTX (2a), 7-triethyl Si 
PTX (3a), 2’-trioctyl Si PTX (1b), 2’-triisopropyl Si PTX (1c), 2’ditert butyl/ethyl Si PTX (1d) 
and 2’-trimenthyl Si PTX (1e).  
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suspension had total volume of 50 mL with a ratio of 5:95 THF: H2O and total mass of 
approximately 60-65 mg nanoparticles. The nanoparticle suspension was further 
ultracentrifuged (Beckman Coulter, CA) at 50,000 rpm, 4 ºC, 30 min for three times. The 
final pellet was removed, lyophilized and stored at 4 ºC fridge.  
 
5.2.3 Nanoparticle Characterization 
5.2.3.1 Nanoparticle Size and Distribution 
As described in Ch.3 and Ch.4, nanoparticles were made via CIJ-D mixer by flash 
nanoprecipitation. The DLS apparatus (Beckman Coulter, CA) was used to measure 
nanoparticle sizes. 100 μL suspension with 0.1 wt% nanoparticles was removed by micro 
Table 5.1 Properties of PTX and Si PTX prodrugs 
Substrate MW/Da aLogP
a
 ca. Krel
b
 t1/2(min)
c
 
PTX 854 3.20 N/A N/A 
1a 1016 4.96 18,000 3.7 
2a 
 
3a 
1b 
1c 
1d 
1e 
1178 
 
1016 
1269 
1058 
1072 
1347 
6.31 
 
5.05 
7.74 
5.60 
7.37 
5.81 
15,000 (C2’), 
2100 (C7) 
2,200 
5600 
570 
1.0 
5.6 
4.6 (C2’), 
33 (C7) 
30 
12 
120 
69,000 
12,000 
a: aLogP is calculated by using ALOPS 2.1 
b:ca. Krel is calculated relative hydrolysis rate by Wohl’s NMR method
59,60
.  
c: t1/2 is half time of hydrolysis by Wohl’s NMR method
59,60
. 
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pipette, and diluted with 1 mL DI water in DLS square tube. Three identical samples 
were sealed with plastic caps. Nanoparticle size was measured and averaged across 150 
individual detections. The resulting intensity size dI was determined by averaging three 
measurements. Size polydispersities and standard deviations were calculated and 
recorded automatically. Nanoparticle sizes were also characterized after lyophilization, in 
order to compare nanoparticle stability and morphology change. 
5.2.3.2 Nanoparticle Morphology 
My colleague Hanseung Lee conducted nanoparticle morphology characterization 
by Cryogenic transmission electron microscopy (Cryo-TEM), either with nanoparticle 
suspension or dried nanopaticle powder. The procedure to prepare samples was described 
in Ch.3. Cryo-TEM images not only enabled us to see nanoparticle morphology, but also 
internal core-shell structure when they were observed with objective lens in an under-
focused mode (2-4 μm). The under-focused mode was intentionally controlled so that 
Fresnel fringe (white rings on the boundary of the structure) can appear and that 
elucidated the core and shell in images. Moreover, hundreds of nanoparticles in Cryo-
TEM images were manually counted and Gatan Digital Micrograph 3.11.1 software 
(Gatan, Pleasanton, CA) was used to analyze sizes of particle core, shell and particle as a 
whole. The number of counted nanoparticles and the resulting size distribution were 
discussed in Ch.6.  
5.2.3.3 Nanoparticle Drug Loading 
Sample preparation methods for HPLC was described in Ch. 3 and Ch.4. When 
HPLC was used to determine the quantity of (1a) 2’-triethyl Si PTX and (2a) 2’,7-triethyl 
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Si PTX, the mobile phase consisted of a mixture of acetonitrile and water with a volume 
ratio of 75:25, and was delivered at a flow rate of 1 mL/min. When HPLC was used to 
determine the quantity of other Si PTX prodrugs (1b, 1c, 1d and 1e), with their increased 
hydrophobicity, the mobile phase consisted of a mixture of acetonitrile and water in a 
continuous gradient between a volume ratio of 100:0 to 50:50 of acetonitrile:H2O, as 
described in Ch. 4. The Si PTX prodrug loading levels of lyophilized nanoparticles were 
determined by analyzing the acetonitrile extract using Eq.4.4 in Ch.4.                                                   
5.2.4 In Vitro Drug Release 
Nanoparticles loaded with each of the Si PTX prodrugs were first lyophilized. 15 
mg of nanoparticles in dry powder was weighed and dispersed in 15 mL PBS (pH 7.4 or 
6.4) or acetic acid buffer (pH 5.0) using microtip probe sonication for 5 min, the 
procedure detail of sonication was described in Ch.3. They were put into multiple dialysis 
mini capsules (500 μL, MWCO: 10 kDa, Thermo Fisher Scientific, IL) and immersed 
into 10 L PBS. At predetermined time points (0, 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120 hr) 
triplicate capsules were removed and lyophilized and 10 L buffer solution was refreshed 
afterwards. The lyophilized samples were dissolved in acetonitrile and extracted 
overnight. The extracts were analyzed by HPLC to determine the amount of drug/prodrug 
remaining in nanoparticle suspension. Reverse release profiles were plotted displaying 
the remaining (or unreleased) drug/prodrug as a function of time.  
5.2.5 Mass Balance 
In order to further validate the reverse release method described above, at each 
predetermined time, 10 L buffer solution, albeit a huge volume, were lyophilized, 
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extracted by acetonitrile and quantified by HPLC to determine the amount of released 
drug. The buffer solution (PBS at pH 7.4 and acetic acid at pH 5.0) of 10 L was 
transferred into several 60 mL tubes and lyophilized by hundreds of batches. Each batch 
contained 8-12 tubes of buffer for 24-48 hr lyophilization. After buffer solution collected 
at one specific time point was completely lyophilized, all the tubes containing dry powder 
of sodium phosphate and the released drug were rinsed by 1 mL acetonitrile for three 
times and extracted for 24 hr. Eventually, HPLC was used to determine the amount of 
released drug obtained from 3 mL acetonitrile extracts. The released drug/prodrug was 
plotted as a function of time, which generally showed an increasing trend of 
drug/prodrug% over time. The plot was constructed by adding the quantity of released 
drug determined at one time point to that obtained from previous time points. It took 
great caution to transfer buffer from beaker to tubes for lyophilization as well as to 
collect acetonitrile used extracting the released drug. It was very likely to lose sample 
during buffer transfer and solvent rinse. Also, when PBS was the buffer solution, a great 
amount of sodium phosphate was obtained, which was mixed with the released drug after 
lyophilization. It made more difficult for acetonitrile to extract the released drug from the 
lyophilized dry powder. After acetonitrile extract was analyzed by HPLC, the error could 
be huge in some cases, especially when some samples contained a fair amount of the 
released drug, some didn’t have any. The unreleased ones obtained from dialysis mini 
capsules were also quantified by HPLC. The procedure described above enabled us to 
check mass balance with the quantity of both remaining/unreleased drug in nanoparticles 
and the released ones in buffer. This experiment was conducted at pH 7.4 and 5.0.  
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5.2.6 pH Variation 
Another addition of in vitro drug release study in this chapter was to investigate 
the influence of pH on hydrolysis of prodrugs. In vitro drug release and mass balance 
studies were conducted at pH 7.4, 6.4 and 5.0. Following the same protocol above, the 
unreleased and released drug/prodrug were plotted against time in three buffer solutions. 
This comparison was meant to discover the pH response of the composition change 
between PTX and Si PTX prodrugs both in particles and buffer solutions. 
5.3 Results and Discussion 
5.3.1 Nanoparticle Size and Distribution 
Fresh nanoparticles immediately made via CIJ-D mixing were encapsulated with 
Si PTX prodrugs and well stabilized by PEG-b-PLGA, in an averaged intensity size range 
of 80-150 nm shown in Table 5.2. Noted that, first of all, Si PTX prodrugs were listed in 
an increasing order of hydrophobicity indicated by aLogP
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 values in Table 5.2, 
1a<1c<1e<2a<1d<1b. Nanoparticle sizes appeared to have a decreasing trend with the 
increasing hydrophobicity of Si PTX prodrugs. It appears to be a linear relation of 
intensity average size with LogP values with 26% deviation. This trend can be explained 
by the nucleation and growth mechanism for particle formation. As the Si PTX prodrug 
was more hydrophobic, its nucleation rate increased but the precipitation rate of 
hydrophobic block of copolymer should remain constant. As a result, more and smaller 
nuclei formed until the deposition of PLGA block arrested the particle growth and PEG 
block stabilized particles. Secondly, 2’,7-triethyl Si PTX (2a) NPs had slightly smaller 
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average particle size than that shown in Table 3.3, but including standard deviation, they 
both lied in the range of 105-135 nm.  
After nanoparticles were ultracentrifuged, lyophilized and dispersed in water, the 
sizes increased significantly due to nanoparticle aggregation driven by the freezing 
process of lyophilization
85, 86
. Their intensity average sizes ranged from 200-450 nm with 
broader size distribution indicated by size polydispersity (PDI). So far, we have not found 
any influence of aggregation on drug release rates, but for nanoparticles which were 
designed for a particular size, ultracentrifugation can be problematic. 
 
Table 5.2 Properties of Si PTX loaded nanoparticles 
Prodrug aLogP
a
 
Before ultracentrifuge After ultracentrifuge 
dI(nm)
b
 PDI
c
 dI(nm) PDI Drug Loading(%)
d
 
1a 4.96 145±9 0.10 423±56 0.25 63.0 
1c 5.60 136±1 0.17 201±32 0.34 58.0 
1e 5.81 95±2 0.08 197±25 0.31 73.5 
2a 6.31 118±13 0.13 312±18 0.65 60.4 
1d 7.37 86±2 0.09 245±27 0.36 73.5 
1b 7.74 83±6 0.16 214±23 0.23 65.0 
a: aLogP is calculated by using ALOPS 2.1. 
b: dI is intensity particle diameter by DLS + standard deviation of averaged particle size within 
three batches of particles prepared in same condition and formula. 
c: PDI is polydispersity index of particle size  
d:Drug loading(%) is total of encapsulated prodrug/drug in nanoparticles (after 
ultracentrifugation) determined by HPLC  
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5.3.2 Fresh Nanoparticle Morphology and Internal Structure 
Freshly made nanoparticles immediately after CIJ-D mixing were imaged via 
Cryo-TEM images shown in Figure 5.2. Sizes and distribution analysis based on these 
images are shown in Figure 5.3. They were fairly consistent, within 2-15% compared to 
dI by DLS. It indicated that, in the increasing order of hydrophobicity, nanoparticles 
became smaller in this order 1a>1c>1e>2a>1d>1b. The number of counted nanoparticles 
is labeled in Figure 5.3. Noted that nanoparticles loaded with 1a and 1c had a significant 
amount of small particles less than 50 nm, these particles were believed to be empty 
block copolymer nanoparticles. It can be explained by nucleation and growth mechanism 
of nanoparticle formation. The Si PTX prodrugs 1a and 1c are less hydrophobic than 
other prodrugs, their nucleation rates during flash nanoprecipitation are slower than 
others while the deposition rate of hydrophobic block PLGA are considered constant and 
similar with other prodrugs. Therefore, the nucleation of 1a and 1c are slower than the 
deposition of polymer so that they form empty polymer nanoparticles first. 
Except size and distribution, the images showed similar internal structure. For 
example, in Figure 5.2 (1a), they showed a clear core-shell structure. The core displayed 
a higher contrast probably due to more electron density of Si PTX, and the shell was 
mostly composed of hydrophobic chains, PLGA while the hydrophilic PEG was likely to 
be swollen with water and invisible after being vitrified. As nanoparticle size became 
smaller, for instance, with the most hydrophobic 2’-trioctyl Si PTX (1b), nanoparticles 
had an average size of approximately 80 nm, where the cores cannot be differentiated, 
probably because particles were too small to be seen with cores.   
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Figure 5.3 Fresh nanoparticle size distribution manually calculated from Cryo-TEM images. 
 
 
Figure 5.2 Cryo-TEM images of fresh Si PTX loaded PEG-b-PLGA protected 
nanoparticles (before ultracentrifugation). 
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5.3.3 Drug Loading Levels 
The drug loadings were determined by dissolving ultracentrifuged and lyophilized 
nanoparticles in acetonitrile and analyzing acetonitrile extracts by HPLC. The drug 
loading included the initial Si PTX prodrug, and possibly PTX and intermediates 
obtained via hydrolysis. The percentage of PTX and intermediates were calculated by 
converting their concentration back to that of equivalent amount of Si PTX prodrugs. For 
example, nanoparticles loaded with (2a) 2’,7-triethyl Si PTX had a 60.4% of drug loading 
vs. nanoparticle mass. It included 1.6% of 2’,7-triethyl Si PTX hydrolyzed to be PTX, 
16.3% to be 2’or 7-triethyl Si PTX and 42.5% of 2’,7-triethyl Si PTX as shown in Table 
3.3.  
Since all nanoparticles in this chapter were ultracentrifuged, the drug loading 
levels were determined only after the un-encapsulated Si PTX and empty polymer 
particles were removed from nanosuspension. Although approximately 50% of initial 
materials used in CIJ-D mixing were removed during ultracentrifugation, the resulting 
nanoparticles were believed to be only Si PTX loaded ones. The loadings were listed in 
Table 5.2 showing a range of 58-75% of prodrug in nanoparticles, which has been 
enhanced greatly from the calculated loading of 55-60% based on the initial formula as 
nanoparticles were made. This implied that as prepared by FNP, nanoparticles not only 
had a distribution in size, but also in loading of Si PTX prodrugs as shown in Table 3.3. 
According to Ch. 3 Eq. 3.7, after ultracentrifugation, nanoparticles loaded with more 
prodrug had a density of 6.9% higher than solvent mixture. They were more likely to be 
separated from solvent. Empty polymer micelles, particles and lightly loaded 
nanoparticles with <4.3% density difference against water, were likely to remain in 
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supernatant of ultracentrifuged suspension. The empty polymer particles and un-
encapsulated prodrugs were discarded by the removal of supernatant. As a result, the 
final loadings were determined by only heavily loaded nanoparticles.  
5.3.4 General Release Rates 
In Figure 5.4, the ultracentrifuged nanoparticles loaded with 2’,7-triethyl Si PTX 
(2a) had no obvious burst-release pattern compared to the reverse release profiles of un-
ultracentrifuged nanoparticles obtained in Ch.4, but the release of ultracentrifuged 
nanoparticles was extended from 24 hr to 48 hr. The similar reduction of burst release 
was also found in other prodrug nanoparticle release studies, the same comparison as 
Figure 5.4 for 2’-triisopropyl Si PTX (1c) and 2’-trimenthyl Si PTX (1e) nanoparticles 
were presented in Appendix C. Therefore, the burst release was likely due to the simple 
diffusion of un-encapsulated prodrugs and those loosely distributed in outer region of 
nanoparticles. 
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Figure 5.4  Comparison of reverse release profiles for ultracentrifuged 2’,7-triethyl Si PTX 
(2a) and un-ultracentrifuged nanoparticles at pH 7.4. 
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The reverse release profiles obtained in PBS at pH 7.4 were shown below in 
Figure 5.5. The general trends were more extended beyond 48 hrs, probably due to the 
removal of un-encapsulated Si PTX. Among six batches of nanoparticles, 2’7-triethyl Si 
PTX (2a) nanoparticles were fastest, with completion of 100% release in 48 hrs. 2’-ditert 
butyl/ethyl Si PTX nanoparticles (1d) were slowest, showing only 55% release in 48 hrs, 
probably due to its most hydrolytic stability. All nanoparticles of Si PTX derivatized with 
one silicate ester (1a-1e) started release at different rates shown with the tangent lines in 
Figure 5.5(a), the rates increased fairly consistent with the increasing hydrolytic lability, 
but the remaining amount all reached the range of 35-45% at the end of 48 hrs. It implied 
that the customized hydrolytic lability has tuned the release rates to some extent due to 
the tuned conversion rates of PTX via hydrolysis along with the varied diffusion rates. 
The release studies were also conducted in PBS at pH 6.4 but the release rates remained 
almost the same as pH 7.4. Note that Figure 5.5 only showed the total amount of 
remaining components in nanoparticles, including both Si PTX prodrugs and PTX, so it 
is worth investigating in detail the compositions of the two components in each batch of 
nanoparticles. This will be discussed in the next section.  
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5.3.5 Mass Balance 
In order to verify the reverse release protocol and check mass balance obtained 
from nanoparticles and buffer solution during in vitro drug release, samples in dialysis 
mini capsules and buffer solution were both collected and lyophilized at predetermined 
time. The extracts as the un-released and the released prodrug/drug were both quantified 
by HPLC.  
The mass balance of 2’7-triethyl Si PTX (2a) nanoparticles were studied using 
PBS at pH 7.4 shown in Figure 5.6. Inside dialysis mini capsule, the components as un-
released prodrug/drug were plotted as a function of time for 48 hrs in. The total amount 
including both Si PTX and PTX showed an almost complete release in 48 hrs. PTX 
obtained from hydrolysis in nanoparticles reached the peak approximately 9% within 1 hr 
 
Figure 5.5 General reverse release profiles of nanoparticles in PBS at pH 7.4 in 20 hrs (a) and 
48 hrs (b). 
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and decreased to none later, because PTX were too soluble to be encapsulated in particles 
so that it diffused into PBS very quickly.  
Meanwhile, almost half of the remaining compounds were triethyl Si PTX with 
one silicate derivative including both 2’-triethyl Si PTX (1a) and 7-triethyl Si PTX (3a), 
but the majority was 7-triethyl Si PTX (3a). They spiked up to 40% within 1-2 hr, and 
slowly diffused out. This indicated that the first step of hydrolysis converting 2’,7-triethyl 
Si PTX (2a) to 2’(1a) or 7(3a)-triethyl Si PTX was relatively fast, and comparable to their 
diffusion rate. Nevertheless, the second cleavage of silicate ester was slower and 
relatively inactive in nanoparticles, that is why only 10% of PTX at most was found.  
Unsurprisingly, the amount of 2’,7-triethyl Si PTX decreased exponentially over 48 hr as 
the hydrolysis occurred. The compositions in nanoparticles had almost equal amount of 
2’,7-triethyl and 2’/7-triethyl Si PTX in 10 hrs, but more 2’/7-triethyl Si PTX appeared 
later as hydrolysis proceeded. The release mechanism appeared to be a combined 
contribution of hydrolysis and diffusion of Si PTX prodrugs.  
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Figure 5.7 Release profile of (2a) 2’,7-triethyl Si PTX nanoparticles in PBS 7.4. 
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Figure 5.6 Reverse release of (2a) 2’7-triethyl Si PTX nanoparticles in PBS 7.4. 
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In PBS where released drug/prodrug were contained shown in Figure 5.7, the total 
release was considered complementary to the remaining profile in Figure 5.6. This 
proved that mass balance was well obtained from two compartments, nanoparticles and 
PBS. The mass balance was summarized in Table 5.3. Also, it confirmed that the reverse 
release protocol was a reliable and convenient approach to determine in vitro release of 
highly hydrophobic drug.   
Interestingly, the amount of 2’,7-triethyl Si PTX in PBS was extremely low. 
Though it appeared to increase, yet remained under 5% during the entire course of drug 
release. The majority of the compounds were still 2’or 7-triethyl Si PTX, while PTX was 
present with slightly smaller but comparable amount. It meant that more cleavage of 2’,7-
triethyl Si PTX to PTX occurred in PBS than in nanoparticles. At the same time, most of 
2’,7-triethyl Si PTX has hydrolyzed with first cleavage of silicate. Apparently, as prodrug 
released into PBS as free molecules, their full contact with buffer led to more hydrolysis. 
In contrast, molecules captured in nanoparticles were mostly surrounded by hydrophobic 
blocks PLGA with limited water access. The hydrolysis was limited to certain extent. The 
huge shift in compositions between nanoparticles and PBS indicated that micro- 
environment has a very significant role in hydrolysis rate.  
Differently, 2’-triethyl Si PTX (1a) nanoparticles had only one possible cleavage 
in hydrolysis. The compounds in nanoparticles were only 2’-triethyl Si PTX and PTX. 
There was 35% PTX in particles when the study started shown in Figure 5.8. It indicated 
that this 2’-triethyl Si PTX was very hydrolytically labile, and a significant amount 
hydrolysis has already occurred during nanoparticle post-treatments, such as 
ultracentrifugation, lyophilization and resuspending in PBS. At the end of 48 hr, PTX 
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decreased to 18%. The amount of 2’-triethyl Si PTX started with 65% and decreased to 
18%. The composition ratio of 2’-triethyl Si PTX vs. PTX changed from 65:35 to 50:50 
as the hydrolysis occurred in particles.  
          
In PBS, the total release shown in Figure 5.9 was also complementary to the 
remaining amount obtained from nanoparticles in Figure 5.8. Again, mass balance was 
well obtained also shown in Table 5.3. There was a significant amount of PTX, due to the 
diffusion of PTX and hydrolysis of 2’-triethyl Si PTX occurring in PBS. However, 2’-
triethyl Si PTX was still the majority of the compositions in buffer solution. The release 
mechanism for this Si PTX prodrug was also a combination of hydrolysis and diffusion, 
but hydrolysis appeared to be faster in this case.  
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Figure 5.8  Reverse release profile of (1a) 2’-triethyl Si PTX nanoparticles in PBS 7.4. 
 
 
115 
 
 
Another triethyl Si PTX was 7-triethyl Si PTX (3a). It is the first intermediate 
obtained after the cleavage of 2’ silicate ester of 2’,7-tri-ethyl Si PTX. This compound 
was also used to prepare nanoparticles and its reverse release result was shown in Figure 
5.10. This experiment was meant to mimic the hydrolysis and diffusion after the first step 
of hydrolysis of 2’,7-triethyl Si PTX. The reverse release rate was similar to 2’-triethyl Si 
PTX but slightly slower, for it is less labile while the hydrophobicity indiated by LogP 
was estimated same as 2’-triethyl Si PTX (1a) shown in Table 5.1. 
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Figure 5.9 Release profile of (1a) 2’ -triethyl Si PTX nanoparticles in PBS 7.4. 
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Due to the hydrolytic stability, nanoparticles were mostly loaded with 7-triethyl Si 
PTX, and only 10% of PTX was found. Suppose 2’7-triethyl Si PTX was resuspended 
and immersed in PBS. As the hydrolysis occurred, it would first hydrolyze to 7-triethyl Si 
PTX very quickly.  Once it converted to 7-triethyl Si PTX, it was more difficult to 
convert to PTX. That is why the majority compositions of 2’,7-triethyl Si PTX 
nanoparticles during release were 7-triethyl Si PTX and 2’,7-triethyl Si PTX. In contrast, 
the composition of 2’-triethyl Si PTX after release contained more PTX. 
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Figure 5.10 Reverse release profile of (3a) 7-triethyl Si PTX nanoparticles in PBS 7.4. 
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In PBS, PTX obtained via hydrolysis of 7-triethyl Si PTX (Figure 5.11) was more 
than that from nanoparticles in dialysis mini capsules, which was consistent with cases of 
2’,7-triethyl Si PTX and 2’-triethyl Si PTX. Nanoparticles cores were surrounded by 
hydrophobic block PLGA, which created relatively hydrophobic microenvironment. But 
in PBS, molecules were fully present in water-based solution, which had more chance to 
hydrolyze.    
Figure 5.12 shows that the reverse release of 2’-trioctyl Si PTX (1b) nanoparticles 
extended beyond 48 hrs. PTX followed a similar trend with that in other Si PTX 
nanoparticles, which spiked up to 10% and reduced to almost zero later due to diffusion 
of PTX. However, over 90% of the composition is 2’-trioctyl Si PTX. Different from 
previous studies, hydrolysis of 2’-trioctyl Si PTX was insignificant in nanoparticles. This 
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Figure 5.11 Release profile of (3a) 7-triethyl Si PTX nanoparticles in PBS 7.4. 
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indicated that release mechanism of 2’-trioctyl Si PTX was dominated by its own 
diffusion.  
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Figure 5.13 Release profile of (1b) 2’-trioctyl Si PTX nanoparticles in PBS 7.4. 
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Figure 5.12 Reverse release profile of (1b) 2’ trioctyl Si PTX nanoparticles in PBS 7.4. 
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In PBS, besides the complementary release trend and mass balance shown in 
Figure 5.13 and Table 5.3, the majority of the components were 2’-trioctyl Si PTX. Only 
less than 20% of PTX was obtained at the end of 48 hrs. This has been so far the smallest 
amount of PTX as released drug, indicating the slowest hydrolysis for 2’-trioctyl Si PTX. 
This is reasonable with the estimated relative hydrolysis rates shown in Table 5.1. 
Therefore, the release mechanism for 2’-trioctyl Si PTX was dominant by the diffusion of 
prodrug. Despite multiple resources of error discussed in 5.2.5, the mass balance 
experiments presented in this chapter were repeated at least twice with samples collected 
at selected time points. The uncertainty of the release and remaining drug lied in a range 
of ±15-20%. The complimentary trend between the remaining and the released drug was 
consistently observed for all. 
 
5.3.6 pH variation 
 Previous two sections were presented based on in vitro release studies in PBS, 
but there was no significant difference between pH 7.4 and 6.4. Thus, in this section, in 
vitro release studies were conducted in acetic acid buffer prepared at pH 5.0, in the hope 
Table 5.3 Percentage of Si PTX prodrugs and PTX during release in PBS at pH=7.4 
Time/hr 
2a, 2’,7-triethyl Si 
PTX 
1a, 2’-triethyl Si 
PTX 
3a, 7-triethyl Si 
PTX 
1b, 2’-trioctyl Si 
PTX 
Reverse Release Reverse Release Reverse Release Reverse Release 
12 45±4 62±5 52±7 40±6 54±6 45±5 57±6 33±5 
24 29±14 68±4 50±6 51±6 50±7 55±10 48±9 40±11 
48 7±11 92±2 35±5 63±7 37±5 65±5 -- 50±5 
Data is shown as total amount of (prodrug&PTX%)±standard deviation. 
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of identifying significant pH-responsive hydrolysis in more acidic buffer. The 
experimental protocols were same with previous ones except pH. 
The first one studied was 2’-triethyl Si PTX (1a) nanoparticles. The total 
remaining drug/prodrug significantly decreased in an exponential pattern in Figure 5.14. 
The amount of PTX started to accumulate as hydrolysis occurred and it reached peak 
value (~20%) with a ratio of 50:50 against 2’-triethyl Si PTX at 4 hrs. At the end of 24 
hrs, the amount of prodrug/drug was negligible, meaning the release was completed when 
both compounds diffused out of particles very quickly. Quite different from release in 
PBS for 48 hrs, the hydrolysis of 2’-triethyl Si PTX at pH=5.0 occurred faster. It 
significantly accelerated the entire release process within 24 hrs, due to a combined 
contribution of hydrolysis and diffusion. 
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    Figure 5.14 Reverse release profile of (1a) 2’ -triethyl Si PTX nanoparticles at pH=5.0. 
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Interestingly in buffer at pH=5.0, only 30% of total loading was detected as 2’-
triethyl Si PTX and it quickly diminished, considered being hydrolyzed to PTX. 2’-
triethyl Si PTX prodrug was not found after 2 hrs. PTX was the only compound detected 
for the rest of release time. Obviously, the hydrolysis of 2’-triethyl Si PTX was greatly 
increased in buffer at pH 5.0. Nanoparticles essentially only released PTX into buffer, but 
the release rate was too fast. Compared with the release profiles in Figure 5.15, the 
acidity of buffer solutions had a significant influence on hydrolysis which leads to the 
possibility of controlled release at varied media conditions. 
The second batch of particles was loaded with 2’-trioctyl Si PTX (1b). The release 
study was carried out for 96 hrs until it was complete. In the reverse release profile in 
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               Figure 5.15 Release profile of (1a) 2’-triethyl Si PTX nanoparticles at pH=5.0. 
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Figure 5.16, the remaining 2’-trioctyl Si PTX and PTX at 48 hrs was only 30%, which 
was 15% less than that observed at pH 7.4 in Figure 5.12. PTX obtained via hydrolysis 
accumulated to a peak of 30% at 8 hr. Obviously, the buffer solution at pH 5.0 induced 
more hydrolysis in nanoparticles, although 2’-trioctyl Si PTX was less hydrolytically 
labile than previous 2’-triethyl Si PTX. Over 96 hrs, the loaded drug was mainly 
composed of 2’-trioctyl Si PTX, except when PTX reached peak at 8 hr. It implied that 
with both compounds present in nanoparticles, the diffusion of PTX was faster than 2’-
trioctyl Si PTX, due to dramatic solubility difference indicated by several orders of 
magnitude in LogP values.  
On the other hand, the released drug/prodrug obtained from buffer almost reached 
94% of initial loading in 96 hrs. PTX was the majority of the compositions in the entire 
time. There was only 15% of 2’-trioctyl Si PTX left in the end. The presence of 2’-
trioctyl Si PTX via diffusion and PTX via hydrolysis acted as counter-productive 
processes, leading to the increased regeneration of PTX. This meant that the release of 
PTX was dominated by the hydrolysis of 2’-trioctyl Si PTX.  
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Figure 5.17 Release profile of (1b) 2’-trioctyl Si PTX nanoparticles at pH=5.0. 
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Figure 5.16 Reverse release profile of (1b) 2’ -trioctyl Si PTX nanoparticles at pH=5.0. 
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The release of 2’-trisopropyl Si PTX (1c) nanoparticles was extended to 120 hrs 
in Figure 5.18. They released in a similar rate of 2’-trioctyl Si PTX, with one more day 
for completion. PTX reached maximum of 34% at 12 hr, followed with a continuous 
reduction. 2’-triisopropyl Si PTX was depleted by both diffusion and hydrolysis. 
In acetic acid buffer at pH 5.0 shown in Figure 5.19, it started with almost equal 
amount of 2’-triisopropyl Si PTX and PTX. After 16 hrs, PTX quickly became the 
majority component, probably because significant amount of PTX diffusion occurred 
when PTX reached the maximum at 16 hr inside nanoparticles. Different from 2’-trioctyl 
Si PTX, the amount of 2’-triisopropyl Si PTX increased instead of decreasing in buffer, 
because it is less hydrophobic, at the same time less hydrolytically labile, so that more 
isopropyl Si PTX was able to diffuse out of nanoparticles before they could be 
completely hydrolyzed to PTX. Therefore, more 2’-trisopropyl Si PTX accumulated in 
buffer solution. 
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Figure 5.19 Release of (1c) 2’-triisopropyl Si PTX nanoparticles at pH=5.0. 
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      Figure 5.18 Reverse release of (1c) 2’-triisopropyl Si PTX nanoparticles at pH=5.0.  
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In order to determine the limiting step of release between diffusion and 
hydrolysis,  nanoparticles loaded with 2’-trimenthyl Si PTX (1e) was used in release 
study at pH=5.0.  2’-trimenthyl Si PTX has similar hydrophobicity with 2’-triisopropyl Si 
PTX (1c) by LogP (5.81 vs. 5.60) but less hydrolytic labile. Dramatically different from 
other particles, the reverse release profile of 2’-trimenthyl Si PTX within particles were 
sustained up to one week shown in Figure 5.20. In 168 hrs, PTX was barely detected. The 
release process was significantly extended, almost two times slower than 2’-trioctyl Si 
PTX (1b), despite 1b was more hydrophobic. The increased hydrolytic stability prevented 
hydrolysis though the buffer was more acidic.  
 
The release profile of 2’-trimenthyl Si PTX shown in Figure 5.21 was quite 
distinctive from others as well. In the first 12 hrs, there was less than 1% of PTX 
observed in acetic acid buffer at pH 5.0, meaning that no significant hydrolysis occurred 
during this time length. PTX started to appear afterward and increased slowly in a linear 
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          Figure 5.20 Reverse release of (1e) 2’-trimenthyl Si PTX nanoparticles at pH=5.0. 
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pattern till 96 hr. Later, the amount of PTX increased linearly in a faster rate while 2’-
trimenthyl Si PTX dropped linearly in a comparative rate. It was obvious that between 
96-168 hr, the regeneration of PTX was mainly contributed by the hydrolysis of 2’-
trimenthyl Si PTX present in buffer. Also, the percentage of 2’-trimenthyl Si PTX 
increased greatly from 96 hr to 168 hr, which indicated in this time period, 2’-trimenthyl 
Si PTX was suddenly able to leave nanoparticles, and it was suspected due to polymer 
degradation especially the study was conducted in more acidic buffer. 2’-trimenthyl Si 
PTX has been so far the only prodrug with no evidence of PTX found inside particles, 
while its hydrolysis was greatly delayed in buffer. Although it is still unknown why 
hydrolysis was triggered suddenly after 96 hr, but 2’-trimenthyl Si PTX indeed showed 
the capability of controlling release rates with customized hydrophobicity and hydrolytic 
lability of silicate esters.  
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          Figure 5.21 Release profile of (1e) 2’-trimenthyl Si PTX nanoparticles at pH=5.0. 
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The reverse release profile of 2’-ditert butyl/ethyl Si PTX (1d) was presented in 
Figure 5.22 as the extreme case with highest hydrophobicity and least hydrolytic lability. 
The release study was conducted for 216 hrs. There was still approximately 46% of 2’-
ditert butyl/ethyl Si PTX left in particles. It is expected to take more than two weeks to 
complete. No trace of PTX was detected at all. 
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      Figure 5.23 Release profile of (1d) 2’-ditert butyl/ethyl Si PTX nanoparticles at pH=5.0. 
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Figure 5.22 Reverse release profile of (1d) 2’-ditert butyl/ethyl Si PTX nanoparticles at 
pH=5.0. 
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In acetic acid buffer at pH 5, the total release in Figure 5.23 was consistent with 
the reverse release profile obtained from nanoparticles in Figure 5.22. 2’-ditert 
butyl/ethyl Si PTX had the most sustained released but hydrolysis was too slow in this 
case, which can be problematic to regenerate active form of PTX. 
To sum up, the total release profiles at pH 5.0 for all particles were presented in 
Figure 5.24. The release time was expanded in the range of 24 hr to 216 hrs (1-9 days) 
with variety of Si PTX prodrugs. The acetic acid buffer at pH=5.0 provided more acidic 
media condition and induced more evident hydrolysis of the hydrolytic labile prodrugs. 
However, the hydrophobicity of these prodrugs was also varied in several orders of 
magnitude indicated by LogP, so the diffusion of these compounds was also a 
contribution to the total release. Although it is known that the customized hydrophobicity 
and hydrolytic lability helped to control release rates in different levels, it is very difficult 
to determine the relative importance of diffusion and hydrolysis because the total release 
included both Si PTX prodrugs and PTX.   
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      Figure 5.24 Total release profile of Si PTX nanoparticles (1a-1e) in buffer at pH=5.0. 
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Compared to total release, it is more important to know how these particles 
regenerated PTX as the active anticancer ingredient. That is why regeneration of PTX 
during release studies at ph 5.0 and 7.4 were summarized in Figure 5.25. This comparison 
mainly demonstrated the hydrolysis lability levels of all Si PTX prodrugs when they were 
encapsulated in polymeric particles and immersed in buffer at different pH. The 
hydrolysis of prodrugs 1a,1b,1c (pH=5.0) and 2a, 1b (pH=7.4) were relatively fast in 
short time. As more hydrolytic stable prodrugs, 1d and 1e were extremely slow and 
sustained in 216 hrs. 1e, as discussed previously only had significant hydrolysis after 96 
hrs. 1d, as the most hydrolytic stable one, had no detectable trace of PTX in the entire 
release time. Despite particles loaded with these prodrugs were able to release PTX-
containing compound into buffer, presumably there will be no anticancer efficacy if the 
active form of PTX cannot be generated. Compared PTX regeneration of 1b, 2’-trioctyl 
Si PTX in buffer at pH 7.4 and 5.0, the more acidic media induced more hydrolysis. At 
96 hr, over 60% of PTX was regenerated at pH=5.0 while only 30% at pH=7.4. This 
result helped us understand more that the availability of PTX can be controlled by 
varying the silicate esters. 
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Inside nanoparticles, the hydrolysis of prodrugs led to an accumulation of PTX in 
10-40% of total drug loading when nanoparticles were immersed in PBS or acetic acid 
buffer, except 2’-ditert butyl/ethyl Si PTX (1d) and 2’-trimenthyl Si PTX (1e), because 
these two prodrugs are most hydrolytic stable. So far, there was no obvious relation found 
between the hydrolytic lability and the amount of PTX accumulated inside nanoparticles.  
More PTX was found when nanoparticles were immersed in acetic buffer (pH=5.0) than 
PBS (pH=7.4). For instance, 30% of PTX in maximum inside nanoparticles was found 
when 2’-trioctyl Si PTX (1b) NPs were immersed in acetic acid buffer, and 
approximately 10% in PBS. 
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Figure 5.25 PTX regeneration from all Si PTX nanoparticles in buffer at pH=7.4 and 5.0. 
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As described in Table 5.4, outside nanoparticles, when prodrugs diffused into 
PBS at pH=7.4, similar amounts of PTX and prodrug were found in the case of 2’-triethyl 
Si PTX nanoparticles (1a) (25% PTX:38% prodrug) shown in Figure 5.9 and 2’,7-triethyl 
Si PTX nanoparticles (2a) (42% PTX: 48% prodrug) in Figure 5.7.  But, for 2’-trioctyl Si 
PTX NPs (1b), the released prodrug had a ratio of 13% PTX vs. 43% prodrug at 48 hr 
shown in Table 5.4. When prodrugs diffused into acetic buffer at pH=5.0, the majority of 
the released drug was PTX in the cases of 2’-triethyl Si PTX (1a), 2’-trioctyl Si PTX (1b) 
and 2’-triisopropyl Si PTX (1c), while 2’-ditert butyl Si PTX (1d) and 2’-trimenthyl Si 
PTX (1e) are too stable to regenerate PTX shown in Table 5.4. As the most labile 
prodrug, 2’-triethyl Si PTX (1a) regenerated PTX completely after 2 hrs they diffused 
into acetic buffer.  
Comparing the relative ratio of prodrug vs. PTX both inside and outside 
nanoparticles, there was more PTX found outside nanoparticles, probably because the 
surrounding medium helped to expedite the hydrolysis while the microenvironment 
Table 5.4 Percentage ratio of PTX vs. Si PTX prodrug obtained from buffer (outside NPs) 
Time/hr 
Acetic acid buffer pH=5.0 PBS pH=7.4 
1a 1b 1c 1d 1e 2a 1b 
12 78/0 37/15 20/15 0.53/31 0/35 25/34 5/28 
24 99/0 41/18 26/15 0.57/39 6/43 28/39 17/34 
48 n/a 61/16 34/16 0.77/41 15/48 42/48 13/43 
1a-1e and 2a are six Si PTX prodrugs encapsulated in nanoparticles and conducted with in 
vitro drug release study, described in Table 5.1. 
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inside nanoparticles were more hydrophobic, rich in hydrophobic block of the block 
copolymer, and the hydrolysis was limited.  
Not only hydrolysis occurred during drug release, hydrolysis of prodrugs and 
PTX also played an important role in regeneration of PTX. The amount of PTX 
hydrolyzed from prodrugs usually accumulated to a maximum of 10-40% and then 
gradually decreased inside nanoparticles, while it continuously increased outside 
nanoparticles. The diffusion of prodrugs varied depending on the hydrophobicity, particle 
size and drug loading. So far, we have found all prodrugs present both inside 
nanoparticles and in buffer, which meant they can diffuse from nanoparticle to buffer 
although their hydrophobicity have been enhanced with several orders of magnitude 
indicated by LogP.  
Although diffusion and hydrolysis are the two main mechanisms for drug release 
discussed in this chapter, we cannot rule out other possibilities. As will be discussed in 
Ch.6, we have found morphology of some nanoparticles changed from spherical to 
irregular shape and nanoparticles did not have a shell region after 24 hr release study, 
which indicated block copolymer core-shell structure might be disassembled possibly due 
to polymer degradation or particle collapse.   
5.4 Conclusion 
To summarize this chapter, nanoparticles encapsulated with Si PTX prodrugs 
showed a decreasing trend of average particle size with their increased hydrophobicity. 
After ultracentrifugation, un-encapsulated prodrugs and empty polymeric particles were 
removed, leaving heavily loaded particles in suspension. As a result, the prodrug loading 
levels of the ultracentrifuged nanoparticles have been greatly increased above 70%, with 
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an average equivalent loading of PTX between 45-60%. This is encouraging, because it 
proved again that flash nanoprecipitation is a powerful technique to produce 
nanoparticles with extremely high loading against other nano-scale systems, the sizes and 
loading of which are controlled by thermodynamic energy. This potentially helps to 
extend anticancer efficacy of paclitaxel and to reduce dosing cycles of nanoparticle 
formulations.   
In order to characterize pharmacokinetic of these particles, a reverse drug release 
protocol was developed to mainly determine the remaining compounds left in particles as 
the un-released drug. When in vitro drug release studies were conducted in PBS at 
pH=7.4 and 6.4, the general release rates of all Si PTX prodrugs were determined in 48 
hrs, only showing a limited range of difference. In order to verify the reverse drug release 
protocol and analyze the composition of drug release, mass balance experiments were 
conducted comparing the remaining drug and the released one extracted from buffer 
solution. We observed that more hydrolytic labile prodrugs tended to hydrolyze to PTX 
first, followed with diffusion of PTX. While prodrugs with medium level of 
hydrophobicity and hydrolytic lability tended to hydrolyze and diffuse in similar rates. 
Those less hydrolytic labile prodrugs contributed to the general release mainly via their 
own diffusion. Therefore, drug release mechanisms can be either dominated by 
hydrolysis or diffusion or a contribution of the two, depending on the selected Si PTX 
prodrugs. Other factors may play a role in drug release as well, such as polymer 
degradation, which will be discussed in Ch. 6. 
In the hope of triggering more hydrolysis, in vitro drug release and mass balance 
studies were also conducted in acetic acid buffer at pH=5.0. The total release rates were 
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significantly accelerated due to faster hydrolysis, and the regeneration of PTX was first 
characterized showing a broad range from 24 to 216 hrs. Consistently across all the Si 
PTX prodrugs, PTX regenerated in nanoparticles always piled up to a peak at certain 
time. For instance, when nanoparticles were immersed in acetic acid buffer at pH=5.0, 2’-
triethyl Si PTX (1a) had a relative hydrolysis rate ca. Krel=18,000 shown in Table 5.1 and 
20% PTX at 4 hr, 2’-trioctyl Si PTX (1b) had a ca. Krel=5600 and 28% of PTX at 8hr, and 
2’-triisopropyl Si PTX (1c) had a ca. Krel =570 and 32% of PTX at 16hr. It was noticed 
that, as the prodrug was more hydrolytic stable, PTX regeneration reached the peak later. 
Though the relation between the two was not clearly defined, it implied that the 
hydrolysis occurring in nanoparticles varied by the choice of silicate ester derivatives. In 
general, the Si PTX prodrug strategy developed by Wohl and Hoye
59, 60
 successfully 
increased the hydrophobicity of PTX-containing compounds, which allowed us to 
prepare stable nanoparticles avoiding the Ostwald ripening and recrystallization that has 
been observed when pure PTX was attempted to be encapsulated in PEG-b-PLGA 
nanoparticles. Secondly, with customized hydrolytic lability, Si PTX prodrugs showed 
the possibility of controlling in vitro drug release and regeneration of PTX by the choice 
of silicate esters.  This is very beneficial to design drug loaded particles with sustained 
release. Among all prodrugs synthesized by Wohl et al
59, 60, 2’-trioctyl Si PTX (1b) is 
able to be encapsulated into PEG-b-PLGA nanoparticles with an average size of 83 nm. 
The size distribution measured and observed from Cryo-TEM images are very narrow. 
As for general drug release, it had an extended time for approximately 96 hrs and we 
successfully observed the regeneration of PTX via hydrolysis. This prodrug is potentially 
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a good candidate for PTX-based nanoparticle preparation, considering particle size, 
morphology, extended release and delivery of PTX.  
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Chapter 6 
Nanoparticle Internal Structure 
6.1 Introduction 
In pharmaceutical industry, nanoparticles are usually characterized by dynamic 
light scattering (DLS) technique and reported with an intensity averaged size and 
distribution
35, 51, 131, 140, 141
. Scanning and transmission electron microscopy are used 
mainly to observe nanoparticle morphology and confirm particle size distribution with 
DLS analysis
35, 51, 131, 140, 141
. It is commonly believed that drug loaded polymeric 
nanoparticles have a core-shell structure
102, 142-144
, but nanoparticle internal structure has 
not been fully investigated to confirm this claim, mostly due to the limitation of 
techniques on nano-scale measurements and imaging.  
Specifically, the problems for these techniques mentioned above are: first of all, 
many nano-scale systems are large in the range of hundreds of nanometers, and it is not 
very difficult to observe their morphology. However, our nanoparticles are approximately 
100 nm, with an even smaller core. The required techniques must be able to differentiate 
structure contrast approximately by 10-20 nm. Secondly, DLS usually provides an 
averaged particle size with a distribution. It cannot tell us structure information of 
individual particles. That is why microscopy is needed to visualize particles internally 
and as a whole, both in size and morphology. Scanning electron microscopy is indeed 
able to image ~100 nm nanoparticles, but particles with coverage of polymer can be 
easily damaged by electron beam. When polymer provides surface coverage for particles, 
the contrast is usually very low against the loading materials, which are also organic. 
138 
 
Plus, the resolution is not high enough to differentiate core and shell regions of particles. 
Therefore, the alternative technique is Cryo-TEM, which freezes particles and assures the 
integrity of particles during imaging process. Although obtaining contrast can be 
difficult, beam damage is helpful to differentiate nanoparticle microstructures. For 
example, the diblock copolymer PEG-b-PLGA used in nanoparticle formation is 
susceptible to the electron beam and they showed a white bubble-like structure. Cryo-
TEM provides higher contrast than SEM and core-shell structure can be visualized. That 
is why results and discussions in this chapter are mainly based on Cryo-TEM images 
obtained by my colleague, Hanseung Lee.  
As nanoparticles are freshly made, they are required to be lyophilized and stored 
in dry state for long-term use and storage. Lyophilization (or freeze drying)
114, 145
 is a 
process that removes water from a frozen sample by sublimation and desorption under 
high vacuum condition. Although, lyophilization is very effective to remove water from 
dispersion, it causes various issues in nanoparticle systems. For instance, after our 
nanoparticles were lyophilized and re-dispersed at a later time, particle sizes often 
increased drastically above 200 nm to micron size, because particles were driven into 
each other during the freezing process, aggregated and even crystallized
86
. To reduce 
particle size growth, nanosuspension was added with cryoprotectant
146
 such as sucrose, 
glucose etc, before lyophilization as discussed in Ch.3. Particles were not completely 
recovered to the initial size, but they were at least being reduced to some extent. 
However, it took 10:1 or higher mass ratio of cryoprotectant vs. nanoparticles to recover 
particle size. When they were redispersed in buffer and administered via IV injection, the 
sugar concentration would be far above glucose level in human blood. That will disrupt 
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the isotonicity and destroy the cells in blood due to concentration gradient between blood 
and cells. Therefore, nanoparticles with high content of sugar cannot be used for in vitro 
cell culture or in vivo animal studies, and certainly cannot be used in clinical practice. 
Other methods must be explored to recover particle size without cryoprotectant. That is 
another reason of using microscopy technique to find out whether particles changed in 
size and morphology and how it occurred during manufacturing and post-treatment.  
Drug loading, as a very critical parameter for drug delivery system, is usually 
determined by the amount of drug loaded with particles. However, it is not always very 
accurate determining it using freeze dried nanoparticles, due to the possibility that the 
unloaded drug exists outside particles. Thus, it is necessary to purify the particles via 
ultracentrifugation to remove the un-encapsulated drug and empty polymer particles. 
Whether the drug has been completely removed can be confirmed by TEM visualization. 
To sum up, the importance of investigating nanoparticle internal structure is 
presented in several aspects: first, nanoparticle internal structure indicates drug 
distribution within particles, which is very critical to drug release kinetics. For instance, 
drug may release faster by simple diffusion and dissolution with less barrier when 
particles have a loosely packed structure with drug distributed in gradient from core to 
shell region. This is often seen when the release profile has a burst pattern in the short 
time. Or release takes longer due to more polymer matrix barrier when drug is mostly 
captured in the tightly packed core region of particles. In that case, the release not only 
depends on diffusion, also water diffusion into particles, polymer degradation, prodrug 
hydrolysis and dissolution, and nanoparticle disassembly.  
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Secondly, imaging particles allows us understand nanoparticle formation 
mechanisms, whether particles made via flash nanoprecipitation are formed by 
nucleation-and-growth where drug and polymer were distinctly phase separated in either 
core or shell region, or nucleation-and-aggregation where particles are formed as a sum 
of multiple aggregates. This is a debating question for many researchers and an improved 
understanding of particle internal structure would help to resolve this puzzle.   
Thirdly, nanoparticle stability is strongly related to its structure. For block 
copolymer particles, it is very important that hydrophilic block (PEG) provides sufficient 
steric stabilization on particle surface, while hydrophobic block (PLGA) creates 
sufficiently hydrophobic micro-environment to kinetically trap hydrophobic drug inside. 
If not, particles might aggregate, or drug diffuses out of particles due to Ostwald 
ripening, just like our first attempt of making paclitaxel loaded PEG-b-PLGA 
nanoparticles
67
.  
 Last but not least, nanoparticle structure might change over time during any of 
these processes: manufacturing, lyophilization, storage, and administration. For example, 
during in vitro drug release study, some nanoparticles were not spherical any more after 
24-48 hrs. They appeared to shrink and change from spherical to an irregular shape. TEM 
indicated some of them had crystalline structure. These observations implied several 
possibilities, polymer degradation, particles disassembly etc. These are worthy studying 
especially when nanoparticles were designed as drug delivery system. It is very important 
to determine shelf life and administration method.  
As mentioned above, nanoparticle internal structure has been hypothesized
35, 44, 67, 
147
 and studied via molecular modeling
68
. Pustulka et al,
85, 86
 showed core-shell structure 
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of only 2’,7-triethyl Si PTX nanoparticles obtained by Cryo-TEM, but nanoparticles 
internal structure has not been fully elucidated. Despite the limitation of imaging 
techniques, nanoparticles loaded with other drug/prodrugs should be studied, in order to 
find relations among nanoparticle structure, size, and loading, and to further understand 
nanoparticle formation mechanisms and drug release kinetics. This will benefit 
researchers on developing nanoparticle technology, controlling nanoparticle size, 
optimizing drug loading, and designing nanoparticles with desirable drug release kinetics.  
6.2 Methods and Experiments 
6.2.1 Materials 
Paclitaxel was obtained from Phytogen Life Sciences. PEG-b-PLGA (MW: 5k-
10kDa) was synthesized in Hoye’s lab as previously reported81. Water (H2O, HPLC 
grade) and tetrahydrofuran (THF, HPLC grade) were purchased from Aldrich and used as 
received. Phosphate buffer saline (PBS) was prepared by dissolving 3.12 g monosodium 
phosphate and 20.74 g Diasodium phosphate in 1 L DI water to achieve pH 7.4, and 
10.28 g monosodium phosphate and 6.84 g diasodium phosphate in 1 L DI water for pH 
6.4. Monosodium phosphate and diasodium phosphate were purchased from Fisher 
Scientific. Si PTX prodrugs were synthesized in Hoye’s lab as previously reported59. 
Their chemical structures are shown in Figure 5.1. The physical properties and hydrolytic 
labilities are shown in Table 5.1.  
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6.2.2 Nanoparticle Preparation and Post-treatment 
Si PTX loaded diblock copolymer PEG-b-PLGA protected nanoparticles were 
prepared using CIJ-D mixer via flash nanoprecipitaiton. The following is a typical 
procedure for one batch of nanoparticles preparation. 35-40 mg of Si PTX prodrugs (with 
an equivalent of 25 mg PTX) and 25 mg of PEG-b-PLGA were dissolved in 2.5 mL THF, 
contained in a 3mL syringe. It was impinged rapidly with the other syringe containing 2.5 
mL water within 5 seconds. The mixture was immediately drained into 45 mL water, in 
order to further quench nanoparticle growth. The resulting nanoparticle suspension had 
total volume of 50 mL with a ratio of 5:95 THF: H2O and total mass of approximately 
60-65 mg nanoparticles.  
Block copolymer nanoparticles were prepared impinging 2.5 mL THF containing 
25 mg PEG-b-PLGA with 2.5 mL water and further diluted into 25 mL water.  
PTX loaded PEG-b-PLGA protected nanoparticles were not able to be prepared 
via flash nanoprecipitation due it Ostwald ripening. Instead, PTX powder was imaged 
using Cryo-TEM.   
Ultracentrifugation (Beckman Coulter, CA) was used to purify nanoparticles at 
50,000 rpm, 4 ºC, 30 min for three times. The final pellet was removed, lyophilized for 
24 hr and stored at 4 ºC refridgerator.  
Micro-tip sonication (Misonix Sonicator 3000, NY) was used to redisperse 
lyophilized nanoparticles by sonicating particle powder in DI water or PBS at 
concentration of 1 mg/mL using microtip probe (1/8”) in pulse mode, 3-9 volt for 5 min. 
Sonication in each cycle took 1 minute, and the tube containing nanoparticles were 
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immersed into ice water for 15-30 seconds, to remove the heat generated by the sonicator. 
Sonication was repeated with five cycles. 
6.2.3 Nanoparticle Size and Distribution  
6.2.3.1 Dynamic Light Scattering (REPES vs. Cumulant) 
In this work, nanoparticle sizes and distribution were measured by dynamic light 
scattering (DLS) using two instruments, either ZetaPALS (Brookhaven, CA) or Delsa
TM
 
Nano (Beckman Coulter, CA). To summarize the DLS characterization method, they are 
both described here, as also mentioned in Ch.3.  
Using ZetaPALS (Brookhaven, CA), 2 mL nanoparticle suspension were 
transferred to round glass cuvettes and sealed with double-layered parafilms. Particles 
were measured using a diode laser BI-DPSS wavelength of 659 nm. The scattering 
intensity correlation function was collected at 25 
o
C and a scattering angle of 90
o
. The 
correlation function is a sum of multiple diffusion coefficients, Di, of each particle, which is 
converted into particle diameter, id , via Stokes-Einstein equation (Eq.6.1),  
 
where bk  is the Boltzmann constant, T is temperature and η is the viscosity of 
the solvent.  
The correlation functions were downloaded from the ZetaPALS instrument and 
manually fit using the regularized positive exponential sum (REPES) program to 
determine averaged particles sizes and distribution. REPES yields a series of discrete 
particle diameters to accumulate the particle size distribution. Differently, most 
                                   
bk
3π
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T
d
D
                                                                      Eq. 6.1 
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commercial instruments use cumulant model to determine size and distribution. The 
software, GENDIST, was used to solve REPES algorithm and yielded an intensity size 
distribution. The averaged intensity particle size Id , is defined in Eq. 6.2, 
  
where in  is the number of particles with a diameter of id . The averaged mass 
particle size, md , is defined in Eq. 6.3,  
 
Using Delsa
TM
 Nano (Beckman Coulter, CA), 100 μL suspension with 0.1 wt% 
nanoparticles was removed by micro pipette, and diluted with 1 mL DI water in DLS 
square tube. Three identical samples were sealed with a plastic cap. Nanoparticle size 
was measured and averaged across 150 individual detections. The resulting size dm was 
determined by averaging three measurements. Size polydispersities and standard 
deviations were also calculated and recorded automatically. When lyophilized 
nanoparitcles were measured by DLS using either of the instruments, particle powder was 
first weighed and reconstituted in water or PBS with a concentration of 0.1 wt% particles. 
When nanoparticles used were measured during in vitro drug release studies, 
nanosuspension with an initial concentration of 0.1 wt% of particles was directly 
transferred from dialysis devices into DLS cuvettes, but over time the concentration may 
be smaller due to drug release. 
       
4 3
m / /    i i i i i i i i id n m d n m n d n d                                                   Eq. 6.3                                                                        
                  
6 5
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6.2.3.2 Nanosight 
Nanoparticle sizes were also measured by nanoparticle tracking system (NTA) via 
Nanosight (Malvern Instrument, UK). Different from dynamic light scattering, sample 
visualization and individual particle tracking are the unique features for NTA. Particles 
were tracked through the virtual of scattered light when illuminated by laser light. The 
light scattered from particles were captured and the Brownian motion of particles were 
recorded frame by frame. Based on a video recorded for 30-60 seconds, the software 
tracked the motion of particles on a particle-by-particle basis, which overcame the 
inherent weakness of DLS as an assemble technique. The hydrodynamic radius of 
individual particles was calculated based on Stokes-Einstein Relation (Eq.6.1). The 
concentration of nanoparticles can be calculated as well when individual particles were 
tracked and counted in camera view with a known volume. Since the video clip is the 
basis of the analysis, particle size for a particular sample can be characterized many times 
with proper adjustments in settings, such as camera levels and detection limits. These 
options enabled us to exclude certain intensity of scattered light such as dust. Also real 
time events can be accurately characterized if aggregation and dissolution are possible.  It 
has been claimed that NTA by Nanosight can accurately analyze monodisperse and 
polydisperse samples, and the presence of small amounts of large particles will not 
compromise the accuracy of the measurements. NTA proved to be suitable to 
characterize drug loaded nanoparticles, complimenting the measurement of DLS
148
.   
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To prepare sample for Nanosight measurement, 100 μL nanosuspension was 
removed and diluted with 2 mL DI water, in order to reach the required concentration 
range: 10
-7
~10
-9
 particles/mL. The nanosuspension was injected via the inlet port into 
chamber. As liquid reached the end of the other inlet port, the chamber was completely 
filled. The chamber was mounted on the stage, with laser plug connected. After the 
temperature control software was opened, the main software was opened. On main 
screen, the “capture” window showed nanoparticles under the camera. The Brownian 
motion was indicated by the movement of scattered light spots. When the instrument was 
stabilized at room temperature, a 60 second video was recorded. The video was replayed 
with individual particles being tracked. Based on particle’s Brownian motion, the 
diffusion coefficient was calculated and individual particle size was determined based on 
Stoke-Einstein relation in Eq.6.1. All particle sizes were calculated and accumulated to 
create particle size distribution. The intensity distribution of nanoparticles was also 
 
Figure 6.1 An example of particle size/relative intensity/particle population 3D plot from 
nanosight. 
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combined to form a 3D figure with particle size, relative intensity, particle population at 
x,y,z axis shown in Figure 6.1. The mass average sizes were automatically calculated, 
along with particle concentration. 
6.2.4 Nanoparticle Morphology 
All Cryo-TEM images shown in this chapter were obtained by my colleague 
Hanseung Lee. To prepare samples for Cryo-TEM, both fresh nanoparticle suspension 
and freeze dried nanopaticles were used. A drop of the suspension was dropped onto the 
grid and frozen under vacuum condition. A lacey carbon Cu grid (01881, 200-mesh, Ted 
Pella, Ltd., Redding, CA) was glow discharged in a vacuum evaporator at 70 mTorr (DV-
502A, Denton Vacuum Moorestown, NJ) for 30 seconds to create a hydrophilic surface 
on the carbon coated side of the grid. A 2 −3 µL of fresh sample was pipetted onto the 
carbon side at 22 °C in a Mark III Vitrobot chamber (FEI Company, Hillsboro, OR) with 
a relative humidity of ~100 %. The excess sample was blotted with 595 filter papers (Ted 
Pella, Ltd., Redding, CA) 1 − 2 times with a ~1.5 mm offset parameter for 5 seconds to 
form a thin liquid film. After the blotting, the sample was relaxed for ~3 seconds and 
immediately plunged into liquid ethane cooled by liquid nitrogen. 
The vitrified sample was transferred to a Gatan 626 Cryo-transfer unit (Gatan, 
Pleasanton, CA) at -194 °C and characterized at -178 °C in the microscope. A 120 kV 
FEI Tecnai Spirit BioTWIN was used and images were taken digitally with Eagle™ 2k 
CCD camera (FEI Company, Hillsboro, OR) in a low-dose mode. The images were 
processed with TEM Imaging and Analysis software package. (Version 4.2 SP1 build 
816, FEI Company, Hillsboro, OR). To enhance phase contrast, the images were 
observed with objective lens in an under-focused mode (2 – 4 µm). The under-focused 
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model was controlled intentionally so that Fresnel fringe (white rings on the boundary of 
nanoparticle structure) can appear and that elucidates the core and shell regions in 
nanoparticles. Bean damage was only used to differentiate the microstructures (e.g, oil, 
surfactant, water). In this case, the diblock copolymer PEG-b-PLGA was susceptible to 
the electron beam and they showed a white edge, making nanoparticles look like bubbles. 
Supporting information for this chapter is presented in Appendix D with more images. 
6.3 Results and Discussion 
6.3.1 Nanoparticle Size and Distribution 
Using dynamic light scattering to characterize particle size, we first found it more 
accurate with calculated average mass size from REPES method than Cumulant model 
used in most commercial instruments to produce average intensity particle size. However, 
our nanoparticles were very polydisperse and the intensity average sizes were more 
skewed to larger particles. In order to understand more about particle size and 
distribution, we presented intensity average size from DLS, mass average size from 
Nanosight, and number average size from Cryo-TEM images in Table 6.1. The sizes of 
all six prodrug nanoparticles decreased as the hydrophobicity of prodrugs increased, this 
has also been discussed in Ch 5.  
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Though Nanosight tracked individual particles by their scattered light, the sum of 
averaged particle size was closely consistent with DLS across all the Si PTX prodrug 
nanoparticles with increased hydrophobicity. Because Nanosight presented mass 
averaged size defined in Eq. 6.3, it is less skewed to larger particles, and overall sizes 
were smaller than that derived from DLS.  
Despite the trend of particle size vs. hydrophobicity, 2’7-triethyl Si PTX (2a) 
didn’t exactly produce nanoparticles smaller with relatively high hydrophobicity 
compared to Si PTX prodrugs 1a, 1c and 1e. It indicated that nanoparticle size was not 
only related to the hydrophobicity of loaded prodrug, but also perhaps to the bulkiness 
and number of silicate ester derivatives. It will be worth studying in future how these 
aspects affect particle size and distribution.  
To analyze particle size based on Cryo-TEM, 200-1000 nanoparticles were 
manually identified and counted. The number average particle size (dn) and core 
       Table 6.1 Nanoparticle sizes of silicate PTX prodrug NPs by DLS, NTA & Cryo-TEM. 
Prodrug  aLogP  DLS (dI)/nm  NTA(dm)/nm             Cryo-TEM (dn)/nm 
particle core 
PEG-b-PLGA n/a 40±10 35±5 20±3 n/a 
1a 4.96 145±9 109±7 174±111 119±63 
1c 5.60 136±1 98±8 251±76 99±75 
1e 
5.81 95±2 76±9 71±44 71±26 
2a 
6.31 118±13 93±12 103±55 92±45 
1d 
7.37 86±2 69±1 63±40 n/a 
1b 
7.74 83±6 75±4 56±20 52±34 
Note: aLogP is calculated by using ALOPS 2.1, same as in Chapter 5.  
Particle sizes are presented as intensity average size ± standard deviation from DLS, mass 
average size ± standard deviation from NTA (Nanosight) and number average size± standard 
deviation from Cryo-TEM. 
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diameter (dc) were measured using all counted nanoparticles and those with visible cores. 
The number of counted nanoparticles, particle and core size are shown in Table 6.2. 
 
An example of how nanoparticle size and core size were analyzed was given in 
Figure 6.2. For each batch of nanoparticles, 200-1000 particles in several images were 
measured to obtain number average size. A line was first drawn across individual 
particles to identify the diameter, and the averaged size was statistically obtained based 
on hundreds of particles with high contrast. Notice that there are a few small particles in 
Figure 6.2, which was expected to be empty polymer particles. They were not counted for 
particle analysis. As for the core size analysis, in high resolution images, the core of 
nanoparticles was identified with even higher contrast than the corona region. Core size 
was a sum of particles with a clear center, which is approximately 15-20% of 
         Table 6.2 Nanoparticle and core sizes obtained from Cryo-TEM images. 
NPs # of  NPs dn(nm) dn
c
(nm) %of NPs
c
 dc(nm) 
BCP n/a 20±5 n/a n/a n/a 
1a 196 110±110 245±80 20 175±65 
2a 453 60±40 100±30 15 70±30 
1b 282 35±15 60±40 15 55±35 
1c 464 100±125 310±90 15 250±75 
1d 147 40±25 85±30 10 60±20 
1e 914 55±40 100±45 5 55±40 
BCP: diblock copolymer PEG-b-PLGA nanoparticles (without drug loading). 
dn: the number average diameter of all counted nanoparticles from Cryo-TEM images. 
dn
c
: the number average diameter of nanoparticles only with visible cores. 
dc: the number average diameter of cores in nanoparticles.  
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nanoparticle population. The calculated standard deviations of particle and core sizes was 
large, because nanoparticles counted in analysis had a broad size distribution as shown in 
Figure 6.2. Also, core size was calculated with nanoparticles only with a visible center. 
For those that didn’t have a core or cannot be imaged with a core, they were not counted 
in analysis either. The selected imaging areas and limited number of counted 
nanoparticles cannot be a complete representative of the entire population of 
nanoparticles. 
 
 
Figure 6.2 An example of particle and core size determination on Cryo-TEM image 
of 2’-triethyl Si PTX (1a) nanoparticles. 
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6.3.2 Fresh Nanoparticle Morphology 
As shown above and also in Figure 5.2, fresh nanoparticles, right after being made 
via CIJ-D mixer, were all spherical, but interestingly their sizes and morphology have 
been changed during the processes of ultracentrifugation, lyophilization, and sonication.   
First of all, fresh nanoparticles in each batch of Si PTX were characterized and 
presented in the following figures. They were only representative of each batch. 2’-
triethyl Si PTX (1a) nanoparticles in Figure 6.3 showed particles had a relatively broad 
distribution. The number average particle size was 196 nm 
from image analysis and a few ones were up to 300 nm which was extreme and rare 
cases. Most of particles showed a clear core-shell structure, some did not. We expected 
that cores with silicate provided more contrast while the shell region with less contrast 
was mainly composed of polymer. However, it is not possible to distinguish between 
hydrophilic block PEG and hydrophobic PLGA because of low electron contrast of 
polymers. The shell region may be only composed of PEG when PLGA was co-
 
            Figure 6.3 Cryo-TEM of fresh 2’-triethyl Si PTX (1a) nanoparticles. 
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precipitated in the core. Or, the shell region was composed of both PEG and PLGA, since 
the radius of gyration of PEG was only 2.58 nm
149
 and they could be extended though. 
There were also 150 nm nanoparticles without a core in contrast, it might be loaded 
without any Si PTX, lightly loaded but failed to show contrast or the electron beam 
destroyed the shell during TEM imaging. Some extremely small particles were 
approximately 20 nm, and it was mostly likely to be empty polymer nanoparticles.  
Most of 2’,7-triethyl Si PTX (2a) nanoparticles were spherical with an average 
intensity size of 118 nm. It has two silicate ester derivatives compared to 1a, and the 
hydrophobicity has been increased significantly indicated by aLogP in Table 6.1, that is 
presumably why particle size were smaller than that of 1a. However, the core size 
distribution was much broader, when some of the particles have a 9:1 of core vs. particle 
ratio and some appeared to have very small cores shown in Figure 6.4. 
2’-trioctyl Si PTX (1b) is the most hydrophobic drug in this synthesized Si PTX 
prodrug family. Unsurprisingly, the nanoparticles had the smallest particles size 
confirmed by DLS, NTA and Cryo-TEM. It was probably because the high 
 
          Figure 6.4 Cryo-TEM of fresh 2’7-triethyl Si PTX (2a) nanoparticles. 
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hydrophobicity drove 1b to precipitate and nucleate faster than other prodrugs during 
FNP. More and smaller nuclei formed until the block copolymer arrested the nucleate 
without further growth. It may also result in stronger cooperative adsorption between 
prodrug and hydrophobic block of the polymer due to similar hydrophobicity, 
which made the particle tightly packed. Thus, these particles had smaller average size and 
narrower distribution. The contrast was relatively high for the whole particle and it was 
very challenging to define the cores in Figure 6.5. 
2’-triisopropyl PTX Si (1c) nanoparticles had second largest average size 
measured by DLS. From Cryo-TEM images in Figure 6.6, it appeared to have a broad 
size distribution similar to 2’-triethyl PTX Si particles, because of the similar 
hydrophobicity. But, the large particles showed a very distinctive core-shell structure. 
The particles were mostly composed of dark core with approximately 10-20 nm of shell 
region, but shell region can barely be seen for some particles. It has also been observed 
that low contrast spot inside particles shown in Figure 6.6, appearing to be polymer 
particles, of which no solid explanation was found yet.   
 
              Figure 6.5 Cryo-TEM of fresh 2’-tri-octyl Si PTX (1b) nanoparticles. 
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2’-ditert butyl/ethyl PTX Si (1d) particles are the second smallest among all the Si 
PTX nanoparticles. Figure 6.7 showed particles were less than 100 nm, which was 
relatively consistent with an average size of 86 nm by DLS. The particles did show a dark 
core but from multiple images obtained, there were insufficient particles with cores to be 
statistically analyzed. However, it is firmly believed that this particular Si PTX was 
successfully encapsulated into nanoparticles, because their sizes were much larger than 
empty polymer nanoparticles and there was no crystalline structure of the prodrug been 
observed in Cryo-TEM. 
 
        Figure 6.6 Cryo-TEM of fresh 2’-triisopropyl Si PTX (1c) nanoparticles. 
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2’-trimenthyl Si PTX (1e) nanoparticle also had relatively small particle size with 
an average of 95 nm, despite the bulkiness of trimenthyl silicate derivative. Core 
structure was observed in Figure 6.8, but oddly the contrast between core and shell 
regions was not as high as other small particles (less than 100 nm), such as 2’-trioctyl Si 
 
            Figure 6.8 Cryo-TEM of fresh 2’-trimenthyl Si PTX (1e) nanoparticles. 
 
       Figure 6.7 Cryo-TEM of fresh 2’-ditert butyl/ethyl Si PTX (1d) nanoparticles. 
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PTX (1b). The size distribution shown below was broader than those two, since 2’-tri-
menthyl Si PTX (1e) was much less hydrophobic and more likely causing more particle 
growth during FNP. 
       
From all the images with silicate paclitaxel prodrugs loaded nanoparticles shown 
above, there were also approximately 20 nm nanoparticles present, which we expected to 
be empty polymer nanoparticles. In order to confirm this assumption, two control groups 
of Cryo-TEM images were obtained, one of which was from freshly made empty PEG-b-
PLGA nanoparticles without any drug in formulation and the other was from paclitaxel 
itself shown in Figure 6.9 
In Figure 6.9 (a), nanoparticles formed by PEG-b-PLGA itself had an average size 
of 20 nm and they were identical with what we have observed in images of prodrug 
loaded nanoparticles. This demonstrated that those unidentified small particles in images 
of prodrug loaded nanoparticles were empty polymer particles. It is reasonable not take 
these particles into consideration for size analysis of particle cores. In Figure 6.9 (b), 
 
Figure 6.9 Cryo-TEM of PEG-b-PLGA nanoparticles (a) and TEM of PTX powder (b).  
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paclitaxel itself forms micron-size crystalline structure which has never been found in 
those prodrug loaded nanoparticles, it indicated that there was no crystallization of 
paclitaxel and prodrugs which were less water soluble. Prodrugs were most likely to be 
amorphous in nanoparticles. This is very encouraging in pursuit of enhancing 
bioavailability and dissolution for drug delivery system.  
6.3.3 Lyophilized Nanoparticle Morphology 
The first time we attempted to lyophilize nanoparticles, fresh nanoparticles via 
FNP were directly sent to be lyophilized without any washing step. As dry powder of 
particles was obtained, they were re-dispersed in DI water, and the redispersion was used 
to prepare TEM samples. Four examples of lyophilized nanoparticles were given below 
in Figure 6.10. Nanoparticles loaded with four different silicate paclitaxel prodrugs did 
not have any clear trend of particle size with hydrophobicity. Though we were able to 
identify individual particles in 100-200 nm with their core-shell structure, they mostly 
aggregated together, which made it impossible to measure particle size accurately by 
DLS or NTA, because the measured sizes were mainly from aggregates as a whole and 
they were up to micron size. The aggregation was widely believed to occur during 
freezing process and Pustulka et al. has proven that by comparing sizes of freeze-and-
dried particles and freeze-and-thawed particles
86
. 
As water freezes and turns into ice during freezing process, nanoparticles in 
suspension are expelled to the area of higher concentration. As a result, particles are 
driven into each other and aggregate together. Also, the crystallization of ice applies a 
mechanical stress on particles leading to their destabilization. Another possible cause of 
particle aggregation was sonication. The micro-tip sonication generates intense energy 
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and heat. When the heat is not dissipated completely in short time and suspension tube is 
immersed in ice/water bath, particles become softer and irreversibly fuse into each other. 
Noted that with our first attempt of lyophilization, ultracentrifugation was not used to 
wash particles, therefore there were also many empty polymer particles and un-
encapsulated prodrug molecules present in suspension, significantly observed in Figure 
6.10. 
 
 
Figure 6.10 Cryo-TEM images of freeze dried and water suspended nanoparticles without 
ultracentrifugation loaded with (a) 2’-triethyl PTX Si, (b) 2’7-triehtyl PTX Si, (c) 2’-trioctyl PTX 
Si, and (d) 2’-trimenthyl PTX Si, respectively. 
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In order to purify nanoparticles, we ultracentrifuged fresh nanosuspension first 
and then freeze dried them in lyophilizer for 24 hrs. The dry powder was redispersed in 
PBS and prepared for in vitro drug release study. Cryo-TEM samples were prepared both 
at 0 hr and 24 hr during the release study. Since samples at 0 hr were prepared right after 
redispersing dry particles, it is a good comparison with Figure 6.10, of which the only 
difference was ultracentrifugation. As shown below in Figure 6.11, the population of 
nanoparticles was dominant by large particle with high contrast in cores. Small polymer 
particles were still present but much more reduced. The calculated density of our prodrug 
loaded nanoparticles were within 5% difference with solution, it is very challenging and 
time-consuming to separate them completely from solvent using ultracentrifugation, and 
polymer nanoparticles were more difficult to remove. However, ultracentrifugation 
indeed removed a significant amount of empty polymer nanoparticles and un-
encapsulated prodrugs. The aggregation still occurred during freeze drying, which would 
continue to be a challenge we strive to overcome.  
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After 24 hrs of in vitro drug release study, nanoparticle suspension was removed 
from dialysis capsules. The attempt of using DLS to measure particle size failed because 
the nanosuspension was too dilute, so DLS cannot collect statistically sufficient amount 
of scattering to calculate particle size. The suspension was further used to prepare TEM 
samples, shown in Figure 6.12. 
 
Figure 6.11 Cryo-TEM images of 0 hr release of nanoparticles loaded with (a) 2’-triethyl 
PTX Si, (b) 2’7-triethyl PTX Si, (c) 2’-ditert butyl/ethyl PTX Si, and (d) 2’-trimenthyl PTX Si, 
respectively. 
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Interestingly, Figure 6.12(a) shows nanoparticles loaded with 2’triethyl Si PTX 
(1a) prodrug 24 hr after immersed in PBS. Compared to Figure 6.11(a) at 0 hr of the 
same suspension, nanoparticle sizes were significantly reduced, and they changed from 
spherical to irregular shape. Particles appeared to shrink without polymer shell 
protection, and it has been hypothesized to be polymer degradation. However, our 
preliminary results showed that polymer degradation occurred evidently only after 16 
 
Figure 6.12 Cryo-TEM images of 24 hrs release of nanoparticles loaded with (a) 2’-triethyl 
PTX Si, (b) 2’7-triethyl PTX Si, (c) 2’-ditert butyl/ethyl PTX Si, and (d) 2’-trimenthyl PTX Si, 
respectively 
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days, which is out of the timeframe of drug release study. Until now, we have not 
identified the reason, albeit it will be part of our future work investigating the influence 
of polymer degradation on particle structure and possible particle collapse over time. 
Another interesting observation is, Figure 6.12(c) and (d) showed nanoparticles loaded 
with 2’-ditert butyl/ethyl Si PTX (1d) and 2’-tri-menthyl Si PTX (1e) at 24 hr, 
respectively. There was no noticeable morphology change like (a). Since these two Si 
PTX prodrugs were most hydrophobic and hydrolytic stable, their release and hydrolysis 
rates were a lot slower than 2’-triethyl Si PTX (1a). It leads to another hypothesis that 
drug release that left particle core more loose or empty might cause particle structure to 
rearrange as well.  
6.4 Conclusion 
In this chapter, six Si PTX prodrugs synthesized by Wohl et al
59, 60
 were 
successfully encapsulated into PEG-b-PLGA nanoparticles. As nanopartiles were freshly 
prepared via CIJ-D mixer, they were characterized by DLS, NTA, and Cryo-TEM. All 
fresh nanoparticles were spherical and mostly loaded with Si PTX prodrugs. The 
intensity average size dI measured by DLS displayed a trend that nanoparticles became 
smaller with increased hydrophobicity of loaded prodrugs. Their size distribution went 
narrower as well. Size analysis from NTA and Cryo-TEM, also done right after CIJ-D 
mixing and before ultracentrifugation, showed mass average size dm and number average 
size dn of particles correspondingly, which were smaller because dm and dn, were less 
skewed by the larger particles. These two measurements also confirmed the trend of 
smaller particles with higher hydrophobicity of the loaded prodrugs.  
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Cryo-TEM technique has clearly demonstrated that nanoparticles have the core-
shell structure with high contrast in the center, which was most likely encapsulating 
silicate prodrugs. Usually, large particles had large cores, but in small ones, it was very 
difficult to visualize cores. Particles were either too small to differentiate the contrast or 
possibly small particles did not have drug loaded in their cores. As control groups, empty 
polymer particles and PTX itself were also imaged by TEM. Polymer particles had a 
relatively uniform size in 10-20 nm. PTX crystallized into micro size. In Cryo-TEM 
images of prodrug nanoparticles, we found a portion of small particles in 20 nm which 
was believed to be polymer particles, and there was no recrystallization found, which 
meant no unencapsualted prodrugs recrystallize outside particles.  
The core-shell structure allowed us to propose a three-layer model
85
 for 
nanoparticle internal structure. With the aid of high resolution in Cryo-TEM, no 
aggregates or primary nucleates were observed in cores of nanoparticles, it also implied 
that the mechanism of nanoparticle formation is more favored towards nucleation and 
growth. During CIJ-D mixing via flash nanoprecipitation, water miscible organic solvent 
(e.g., THF) and water were impinged rapidly creating supersaturation condition for drug 
and polymer, the hydrophobic drug precipitated out of solution and nucleated as particles. 
Once the hydrophobic block of block copolymer co-precipitated and was adsorbed to 
drug particles, it arrested the growth of drug particles. Meanwhile, the hydrophilic block 
stayed in solution, covered particle surface and provided steric stabilization for particles. 
The drug mainly formed the core of particles, while block copolymer formed the shell 
region. In Cryo-TEM images, the hydrophilic block PEG was likely swollen with 
vitrified water with low electron density, so it was probably invisible. Despite that, Cryo-
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TEM has been the most supportive evidence for three-layer core shell structures. Pustulka 
et al
86
 have also used other techniques to identify internal structures such as DSC and 
NMR, they all consistently indicated this three-layer core shell model of block copolymer 
drug loaded nanoparticle internal structure.   
As nanoparticles were lyophilized, particles tended to aggregate because of the 
mechanical stress caused by crystallization of ice during freezing. We have attempted to 
use cryoprotectant like sucrose to eliminate aggregation, however, with addition of 
sucrose (10:1 mass ratio of sucrose vs. NPs), particle sizes were slightly recovered with 
less aggregation, but still problematic. In order to use these particle formulations for in 
vitro and in vivo studies, nanoparticles cannot be redispersed with such high 
concentration of sucrose, because it was much higher than blood sugar level. 
Nanoparticles with sucrose would disrupt the isotonic solution balance in cell culture and 
body fluid. Currently, we are still in search of alternatives without cryoprotectant to 
recover particle size after lyophilization, such as sonication.   
Ultracentifugation was used to remove empty polymer particles and un-
encapsulated drug in suspension. Cryo-TEM images confirmed that nanoparticles were 
purified with less polymer particles. During in vitro drug release study, some of the 
nanoparticles have been through a significant morphology change. They appeared to 
shrink from spherical to irregular shape, of which the reason has not been determined yet. 
We highly hypothesized that polymer might degrade to certain extent, leaving particles 
without shell coverage, or particle shell perhaps collapses. 
  
166 
 
Chapter 7 Summary and Outlook 
Ch.2 described a simpler design of confined impingement jets-dilution (CIJ-D) 
mixer, utilizing flash nanoprecipitation to prepare nanoparticles made of hydrophobic 
materials. The design was modified based on Prud’homme’s confined impingement jets 
(CIJ) mixer. The interior dimensions and specifications on manufacturing CIJ-D mixer 
were listed in details. Our design introduced an addition of dilution stage in order to 
achieve high supersaturation condition above a ratio of 1:1 of anti-solvent/solvent. To 
understand the effect of dilution, β-carotene, as a model drug, was used to prepare 
nanoparticles with varied ratio of anti-solvent/solvent mixing. To test the performance of 
CIJ-D mixer, β-carotene nanoparticles were also formulated by both multi-inlet vortex 
mixer (MIVM) and CIJ-D mixer at varied flow conditions. Particle size and stability were 
consistent between two mixing processes. Smaller particles were produced in more 
turbulent mixing indicated by high Reynolds number. This demonstrated that, it is very 
important, not only to achieve high supersaturation, but sufficiently turbulent mixing in 
order to create small particles made with hydrophobic materials.   
In Ch.3, paclitaxel (PTX), an anti-cancer drug, was introduced to formulate 
nanoparticles via CIJ-D mixer. Diblock copolymer PEG-b-PLGA was used as a particle 
stabilizer. We first encountered difficulty producing stable PTX loaded nanoparticles 
because PTX recrystallized out of dispersion in 90 min due to Ostwald ripening. A 
chemical modification strategy was introduced here to make PTX more hydrophobic in 
an effort to prevent Ostwald ripening. A series of silicate ester derivatized PTX was 
synthesized in Hoye’s lab with enhanced hydrophobicity and tuned hydrolytic lability. 
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These compounds were presumably inactive and considered as prodrug of PTX. Their 
hydrolysis was expected to convert prodrug back to active form of PTX. A series of Si 
PTX prodrugs were used to prepare nanoparticles and they were successfully stabilized 
by PEG-b-PLGA without any significant recrystallization and aggregation. They were 
characterized by DLS, NTA, SEM, Cryo-TEM and HPLC in size, distribution and drug 
loading. Additionally, several purification techniques, such as membrane filter, hollow 
fiber filtration, and ultracentrifugation. And ultracentrifugation was found to be the best 
approach to remove un-encapsulated prodrug and empty polymer particles. Another 
particle post-treatment, lyophilization was investigated as well. It was found that 
nanoparticles tended to aggregate together during freezing process and after lyophilized 
dry powder of particles was redispersed in solution, particles size increased significantly 
due to severe aggregation. To better recover particle size, cryoprotectants like sucrose 
and sonication were used. Although cryoprotectants were able to reduce particle size 
closer to initial size of fresh particles, it is impossible to administer nanoparticles with 
sucrose in vitro and in vivo because the high concentration of sucrose in particle 
dispersion will cause cell shrink as hypertonic effect. While we are still working hard to 
find other cryoprotectants with less concentration to recover particle size, a standard 
procedure of nanoparticle preparation was described as: nanoparticles are first formulated 
via CIJ-D mixer in 95:5 ratio of H2O:THF. They are ultracentrifuged and lyophilized 
without cryoprotectants. They are stored as dry powder and redispersed for 
administration in vitro and in vivo. 
In Ch.4, in vitro drug release studies were first introduced with a series of Si PTX 
prodrug nanoparticles. To customize a drug release protocol for these nanoparticles 
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loaded with highly hydrophobic materials, several experimental conditions were 
explored, such as infinite sink, limited buffer and frequently refreshed buffer. Due to the 
extremely low solubility of these prodrugs in aqueous solution, a dialysis-based reverse 
release protocol was established to determine the remaining prodrug loaded in 
nanoparticles, instead of the released ones in buffer.  Mini dialysis capsules were chosen 
to carry out in vitro drug release study for quantity accuracy and handling convenience. 
The preliminary release results shown in this chapter were based on Si PTX prodrug 
loaded nanoparticles without ultracentrifugation, a significant burst release pattern was 
observed in short time due to the un-encapsulated prodrug in dispersion. However, in the 
following chapter, nanoparticles were all ultracentrifuged and lyophilized before in vitro 
and in vivo studies. 
Ch.5 studied in vitro drug release on nanoparticles loaded with six Si PTX 
prodrugs, respectively, five of which were mono silicate ester derivatized only at 
2’carbon of PTX and one was bis-triethyl Si PTX derivatized at 2’ and 7 carbon of PTX. 
With addition of ultracentrifugation, release profiles of all nanoparticles were more 
extended in a range of 24-96 hrs without obvious burst release. Their release rates 
appeared to increase following an order of increasing hydrolytic lability. To verify the 
reliability of reverse release protocol, mass balance studies were conducted to determine 
the released drugs in buffer and the remaining ones in nanoparticles. Not only did we 
obtain a complementary release and reverse profiles, we were also able to see 
composition change inside nanoparticles and in buffer solution, indicating the hydrolysis 
rates of these prodrugs in different conditions, either encapsulated in nanoparticles or 
surrounded in water. In the hope of observing more hydrolysis of prodrugs, in vitro drug 
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release studies were conducted in PBS first at pH=6.4 and 7.4 to mimic tumor and normal 
tissue conditions, and then at pH=5.0. The general release profiles were significantly 
altered because of pH-responsive hydrolysis.  
In Ch.6, we focused on nanoparticle size and morphology characterization mainly 
by DLS, NTA and Cryo-TEM, which was greatly contributed by my colleague, 
Hanseung Lee. Particle sizes were not only directly measured by DLS and NTA, and also 
hundreds of Cryo-TEM images. The particle size results were consistent among DLS, 
NTA and Cryo-TEM. Besides, morphology of nanoparticles were visualized in Cryo-
TEM, showing a core-shell internal structure, which was the first direct evidence 
confirming nanoparticles were kinetically formed based on nucleation and growth 
mechanism. During in vitro drug release studies, we also found particles became smaller 
and irregular in shape, and seemed to lose shell region. These evidences have inspired us 
to initiate current work on diblock copolymer degradation from nanoparticles.  
Overall the work in this dissertation: 
1) Modified confined impingement jets mixer with a dilution stage and 
demonstrated that CIJ-D mixer can produce nanoparticles composed of hydrophobic 
materials as well as multi-inlet vortex mixer. The dilution step overcame the limitation of 
Prud’homme’s CIJ mixer with equal volume of solvent/anti-solvent mixing and provided 
high supersaturation condition to create small nanoparticles based on nucleation and 
growth. The threshold of flow rates was also identified to create sufficiently turbulent 
mixing condition. 
2) Successfully formulated paclitaxel-based PEG-b-PLGA stabilized 
nanoparticles with a chemical modification strategy. Wohl and Hoye modified paclitaxel 
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with a series of silicate ester derivatives with enhanced hydrophobicity and tuned 
hydrolytic lability.  
3) Established standard nanoparticle formation process with post-treatments, 
including ultracentrifugation, lyophilization and sonication.  
4) Developed a reverse in vitro drug release protocol to determine the remaining 
drug in nanoparticles and confirmed the reliability of this protocol by conducting mass 
balance studies. 
5) Characterized a series of Si PTX loaded nanoparticles by DLS, NTA, HPLC, 
SEM, Cryo-TEM in terms of particle size, distribution, drug loading and morphology. 
6) Characterized in vitro drug release of a series of Si PTX nanoparticles and 
quantified their composition change of prodrug and drug via hydrolysis over time. The 
general release rates increased with more hydrolytic labile prodrugs. With tuned 
hydrophobicity and hydryolytic lability, the choice of prodrug significantly affected the 
release rate of prodrug and regeneration of PTX. Hydrolytic lability appeared to play a 
more important role in regeneration of PTX and general release rate. 
7) The core-shell structure of all Si PTX nanoparticles were visualized by Cryo-
TEM and their morphology change and disappearance of shell during drug release study 
was also observed, which indicated the possibility of in vitro polymer degradation and 
particle collapse. 
Besides the progress achieved in this work, there are also a few lessons I learned 
from our mistakes and omissions. 
1) We started making PTX-based PEG-b-PLGA nanoparticles using (2a) 2’,7-
triethyl Si PTX. This Si PTX prodrug has two intermediates via hydrolysis, which made 
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it more complicated to determine the drug release mechanism. Also, the synthesis was 
very difficult, compared to other Si PTX prodrugs with only one silicate ester derivatives. 
2) At the earlier stage of developing in vitro drug release study, nanoparticles 
were not ultracentrifuged which resulted in a large amount of unencapsulated 
drug/prodrug mixed with nanoparticles in dry powder. As shown in drug release results, a 
burst-release pattern was constantly observed until we realized that the unencapsulated 
drug/prodrug must be removed from nanoparticles in order to characterize drug release 
kinetics more accurate. 
3) As in vitro drug release studies proceeded, polymer degradation was not 
considered as a factor to affect drug release rates until we observed significant 
nanoparticle morphology change on Cryo-TEM images, which indicated nanoparticles 
disassembled or was destructed.  
To anticipate the future development, there are still challenges and research 
interests that have not been explored.  
1) Nanoparticle we have formulated so far only contained one pharmaceutical 
ingredient. To design multi-functional nanoparticles, it will be very interesting to co-load 
two or more ingredients in particles. Those ingredients can be two compounds with 
different release characteristics or varied functions, such as imaging agent, fluorescent 
labels. Appendix E presented a experimental trial of coloading two Si PTX prodrugs 
within nanoparticles at varied mass ratio. Although it was not successful, more systematic 
studies should be planned and more drugs and functional agents should be explored. 
2) Following with Zhu’s work, diblock copolymer PEG-b-PLGA (MW: 5k-
10kDa) was identified as the best particle stabilizer. However, other diblock copolymers 
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and their effect of MW should also be studied. Moreover, triblock copolymer should be 
investigated as well, because they are expected to form either more intense hydrophilic 
region or loops when two hydrophobic blocks embedded in particles. Thus, different 
block copolymers with adjusted MWs are hypothesized to create different internal 
structures. With the powerful tool of Cryo-TEM imaging, these differences might be 
identified. These variables will further play an important role in particle size, distribution, 
drug loading and release profiles.   
 3) Since this thesis has established in vitro drug release protocol for Si PTX 
nanoparticles, in vivo or in vitro release study in other medium such as serum should be 
further developed, in order to mimic biological condition better and to correlate drug 
release rates with other in vitro and in vivo studies, such as cytotoxicity, biodistribution 
and tumor growth inhibition.  
4) We have made a great deal of efforts to visualize nanoparticles, especially their 
internal structure and morphology change during drug release study, we speculate block 
copolymer might degrade in the same course of time. In vitro polymer degradation 
studies should be conducted along with drug release studies, in order to see the effect of 
polymer degradation on drug release. 
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Appendix A: β-carotene loaded PEG-b-PLA Nanoparticles Preparation 
via Vortex and CIJ-D Mixer  
First, empty PEG-b-PLA nanoparticles, without β-carotene were prepared with 
both CIJ-D and vortex mixer. As MW of PLA increased from 2k to 15 kDa, there was 
barely any difference in size (30~35 nm) via the CIJ mixing (Figure A.1(a)). It seems that 
the CIJ mixer is more efficient to make small nanoparticles, when MW of PEG-b-PLA is 
larger. The vortex mixer functions equally well in terms of producing small polymer 
nanoparticles, but exhibiting a linear relation of nanoparticle size vs. MW of PLA. In 
contrast, the sizes of nanoparticles prepared via CIJ-D mixing were affected only by the 
mixing process.  
Second, when PEG-b-PLA nanoparticles were loaded with β-carotene, 
nanoparticle sizes were generally larger than those without β-carotene (Figure A.1(b)). 
By vortex mixing, β-carotene loaded nanoparticles were unexpectedly smallest when the 
MW of PEG-b-PLA was 5k-10kDa. Below MW of PLA=10kDa, nanoparticle sizes 
decreased with longer PLA, probably because β-carotene and hydrophobic PLA 
interacted more strongly. They constructed tighter and smaller nanoparticle cores within 
where PLA chains were more entrapped. Above 10kDa, nanoparticle sizes climbed 
presumably because it’s now dominant for long PLA chain to stretch, rather than being 
entrapped in the cores. However, it’s uncertain if this increase indicated by only one point 
is reliable.  
Third, nanoparticles in saline solution were slightly larger than those in non-saline 
solution, via both vortex and CIJ mixing.  This is because that the addition of 1 wt% of 
NaCl destroyed electrostatic stabilization of nanoparticles, but nanoparticles were still 
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protected by steric stabilization from BCPs. Nanoparticle sizes were reproducible within 
the three batches. 
 
The summary of nanoparticle sizes for Figure A.1 is listed in Table A.1. Figure 
A.2-5 show the mass and intensity average sizes of empty PEG-b-PLA (with varied MW) 
nanoparticle analyzed by DLS (Brookhaven Instrument, CA) and REPES method 
 
 Figure A.1 (a) PEG-b-PLA (polymer-only) NPs.       (b) PEG-b-PLA NPs made via vortex mix. 
  ━in nonsaline solution via vortex mixer                 ━without β-carotene in nonsaline solution 
  ━in saline solution via vortex mixer                        ━without β-carotene in saline solution 
  ━in nonsaline solution via CIJ mixer                       ━with β-carotene in nonsaline solution 
  ━in saline solution via CIJ mixer                              ━with β-carotene in saline solution  
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                    Table A.1 PEG-b-PLA protected β-carotene nanoparticle size by the CIJ-D and vortex mixer. 
PLA-b-PEG 
β-
carot
ene 
NaCl 1wt% 
w/o w/ 
Vortex Mixer CIJ mixer Vortex Mixer CIJ mixer 
d/nm σ/nm d/nm 
 
σ/nm d/nm 
 
σ/nm d/nm  σ/nm 
2k-b-5k 
w/o 16/16/0.02 ±2 33/42/0.20 ±3 20/65/1.12 ±5 33/48/0.35 ±4 
w/ 57/194/3.51 ±8 - 
-
- 61/191/3.67 ±6 - - 
5k-b-5k 
w/o 21/23/0.77 ±2 29/86/0.56 ±3 24/38/0.46 ±3 31/58/1.31 ±5 
w/ 48/112/2.37 ±2 - 
-
- 53/288/4.24 ±2 - - 
10k-b-5k 
w/o 29/88/1.19 ±4 31/100/1.13 ±4 31/102/1.16 ±2 33/91/0.69 ±8 
w/ 24/42/0.62 ±3 27/106/1.24 ±2 29/53/0.88 ±3 49/209/1.37 ±6 
15k-b-5k 
w/o 40/109/1.09 ±10 33/51/0.17 ±7 39/253/4.05 ±4 32/82/0.22 ±6 
w/ 37/62/0.62 ±6 - 
-
- 55/63/0.27 ±7 - - 
 
       Note: Data d is shown as mass average size/intensity average size/span. 
       σ is the standard deviation of the mean mass average size. 
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Figure A.3 Mass average size and intensity average size of PEG-b-PLA (MW: 5k-5kDa) only 
nanoparticles without saline (a) & (b) and with saline solution (c) and (d). 
 
 
Figure A.2 Mass average size and intensity average size of PEG-b-PLA (MW: 5k-2kDa) only 
nanoparticles without saline (a) & (b) and with saline solution (c) and (d). 
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Figure A.5 Mass average size and intensity average size of PEG-b-PLA (MW: 5k-15kDa) only 
nanoparticles without saline (a) & (b) and with saline solution (c) and (d). 
 
 
Figure A.4 Mass average size and intensity average size of PEG-b-PLA (MW: 5k-10kDa) only 
nanoparticles without saline (a) & (b) and with saline solution (c) and (d). 
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     Table A.2 Pure β-carotene nanoparticle size at varied time and saline/non-saline solution. 
          dm/nm           dI/nm 
Pure -carotene 
(10min after mixing) 
47 182 
Pure -carotene 
(60min after mixing) 
40 172 
-carotene+chitosan 
(without salt) 
43 202 
-carotene+chitosan 
(with salt) 
47 330 
 
Since we have found bimodal distribution of block copolymer protected drug 
loaded nanoparticles, we suspected the small portion of nanoparticles with very small 
size was block copolymer nanoparticles or micelles. To determine whether it is 
kinetically formed nanoparticles or micelles at thermodynamic equilibrium state, PEG-b-
     
Figure A.6 An example of zeta pontential measurement of β-carotene only nanoparticles 
188 
 
PLGA micelles were prepared by dissolving 6 mg of PEG-b-PLGA (MW: 5k-10kDa) 
with 1ml acetone, adding 9ml H2O in constant flow rate during 20 hours while stirring 
the solution in the whole process. The sizes were measured by DLS (Brookhaven, CA). 
 
           Table A.3 Sizes of diblock copolymer micelles at varied time. 
time sample dm/nm dI/nm 
1
st
 day PEG5K-PLGA10K 16/8.3 443/543.0/1.2 
2
nd
 day PEG5K-PLGA10K 21/8.0 648/598.8/1.2 
After 1 week PEG5K-PLGA10K 26/7.1 647/607.3/1.2 
 
PEG5K-PLGA10K 27 385 
PEG5K-PLA10K 22   94 
Mass average size dm is shown as Mass size/Mass PDI;   
Intensity average size dI is shown as Size from Repes method/Size from DLS machine/Size PDI 
from Repes. 
 Shaded area is Zhengxi &Haitao’s data. 
 
 
 
          
 Figure A.7 Schematic of diblock copolymer micelle formation experiment. 
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To test nanoparticle stability, PEG-b-PLA nanoparticles in both saline and 
aqueous solution were measured by DLS over time up to one week. They were very 
stable in both cases, without significant particle increase or aggregation. 
 
             Table A.4 Sizes of PEG-b-PLA nanoparticles at varied time. 
 time 
w/o NaCl w NaCl 1wt% 
dm/nm dI/nm dm/nm dI/nm 
PEG5K 
PLA5K 
0.5hr 23/1.8 138/150.2/2.4 28/2.2 191/113.4/2.5 
1hr 25/2.1 180/201.3/5.3 29/2.1 159/135.4/1.7 
48hr 25/1.9 148/118.6/1.6 27/1.9 297/146.6/7.3 
1 week 28/1.7 98/58.3/1.5 33/1.5 78/62.9/1.4 
Mass average size dm is shown as Mass size/Mass PDI;  
Intensity average size dI is shown as Size from Repes method/Size from DLS machine/Size PDI 
from Repes. 
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Appendix B: Reynolds Number Calculation 
Reynolds number is defined as below: 
   
                    
                
  
 
 
 
   
 
                                                                                                                                                                     
In our case,                                                                                                                                 
                         
 
 
             or                                                                             
                       
D is stream inlet 
diameter, W is the 
width of cross-sectional 
area, H is the height of 
cross-sectional area, or 
S is the cross-sectional 
area of inlet pathway. Calculation is separated for round and rectangular cross-section. ρ 
is the density of mixture, Qi is the flow rate of ith stream, ηi is the viscosity of ith stream. 
Reynolds number is calculated as the summation of different stream components.  
Calculation examples are shown below: 
        
  
 
 
  
  
 
   
 
   
  
       
 
   
 
  
  
 
  
  
 
   
 
 
Figure B.1 Interior structures of (a) the CIJ mixer and (b) the 
vortex mixer. 
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1. In CIJ mixing 
Via equation (S5), n=2, Q1=Q2=solution volume/mixing time=2.5×10
-
6
m
3
/mixing time, ρ1=1.0×10
3 
kg·m
-3
(H2O), ρ2=8.89×10
2 
kg·m
-3
(THF), η1=
 
1.0×10
-3 
Pa·s, η2=4.8×10
-4
 Pa·s, D=5×10
-4
m. 
At mixing time= 4.23 s, Q1=Q2=2.5×10
-6 
m
3
/4.23s=5.91×10
-7 
m
3
/s 
Re  (4/π ) ×Σ(ρQ/ η)n=2 = [4/(π×5×10
-4
 m)] ×[(1.0×10
3
 kg·m-
3
×5.91×10
-7
 
m
3
/s)/ 1.0×10
-3
 Pa·s +(8.89×10
2
 kg·m
- 3
×5.91×10
-7
 m
3
/s)/ 4.8×10
-4
 Pa·s] 
    Re= 4292 
2. In vortex mixing 
 Via equation (S5), n=4, Q1=Q2=solution volume/mixing time=2.5×10
-6
 
m
3
/mixing time, Q3=Q4= solvent volume/mixing time=22.5×10
-6
 m
3
/mixing time, 
ρmixture=1.0×103 kg·m-3(≈ρwater), η= 1.0×10
-3
 Pa·s, D=1.45×10
-3
 m. 
       At mixing time= 25.05s, Q1=Q2=2.5×10
-6 
m
3
/25.05s=9.98×10
-8 
m
3
/s, 
Q3=Q4=22.5×10
-6 
m
3
/25.05s=8.98×10
-7 
m
3
/s 
       Re  (4ρ/π η) ×Σ(Q)n=4 = [4×1.0×10
3 
kg·m
-3/(π×1.45×10-3 m× 1.0×10-3 Pa·s)] 
×(2×9.98×10
-8 
m
3
/s +2×8.98×10
-7 
m
3
/s) 
            Re= 1753 
 
 
 
 
 
  
Figure B.2 SEM image of β-carotene 
NPs made by the vortex mixer at 
Re=1753. 
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Table B.1 Reynolds number (Re) vs. Mass average size (dm) via the vortex mixer  
tmix/s QTHF/ m
3
/s Qwater/ m
3
/s Re dm±σ /nm 
25.05 9.98×10
-8
 8.98×10
-7
 1753 67±5 
45.19 5.53×10
-8
 4.98×10
-7
 972 72±7 
60.00 4.17×10
-8
 3.75×10
-7
 744 90±5 
143.08 1.75×10
-8
 1.57×10
-7
 307 98±12 
287.10 8.71×10
-9
 7.84×10
-8
 153 103±8 
570.48 4.38×10
-9
 3.94×10
-8
 77 126±10 
           1156.00 2.16×10
-9
 1.95×10
-8
 38 257±23 
 
             Table B.2 Reynolds number (Re) vs. Mass average size (dm) via the CIJ-D mixer 
tmix/s Q/ m
3
/s Re dm±σ /nm tmix/s Q/ m
3
/s Re dm±σ /nm 
7.62 3.28×10
-7
 2393 48±4 28.76 8.69×10
-8
 643 84±17 
7.92 3.15×10
-7
 2302 57±9 39.58 6.32×10
-8
 461 74±5 
10.50 2.38×10
-7
 1737 56±9 56.71 4.41×10
-8
 321 102±7 
12.50 2.00×10
-7
 1459 49±10 125.00 2.00×10
-8
 145 97±8 
20.48 1.22×10
-7
 890 58±15 180.00 1.39×10
-8
 101 128±7 
22.91 1.09×10
-7
 796 55±8 258.86 9.66×10
-9
 70 137±3 
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Appendix C: Nanoparticle Post-treatment: Ultracentrifugation, 
Sonication and Lyophilization 
In order to purify nanoparticles, two types of nanoparticles were filtered by 450 
nm filters, and the particle sizes were measured before and after filtration. There was no 
clear size difference between these two conditions shown in Table C.1, which indicated 
that simple filter filtration is not able to filter nanoparticles by size.  
Table C.1 Nanoparticle sizes before and after 450 nm membrane filtration. 
NPs dI/nm(before filtration) dI/nm (after filtration) 
2’-triethyl Si PTX (1a) 115 nm 120 nm 
2’-tri isopropyl Si PTX (1c) 136 nm 138 nm 
 
 
                        
Figure C.1 SEM images of 2’,7-tri-ethyl Si PTX (2a) NPs after lyophilization and membrane 
filtration. 
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After the filtered nanoparticles were lyophilized, they were redispersed and 
imaged by SEM. Figure C.1 showed that there were many small nanoparticles in the 
range of 20-50 nm and bigger ones ≥100 nm despite the filtration. It also indicated that 
filter filtration failed to differentiate particles by size. 
When nanoparticles were ultrancentrifuged, nanoparticle sizes were measured 
from supernatants and pellets collected in the end, and the loading of each samples were 
determined by HPLC. 
                    
                  
Table C.3 Physical properties of 2’-trioctyl Si PTX(1b) NPs during 
ultracentrifugation. 
 
dI(nm) PDI NP:drug mass(mg) Loading% 
Fresh 75 0.165 24.5/13.5 55.3 
Supernatant 1 73 0.195 10.8/4.3 39.8 
Supernatant 2 80 0.271 5.6/2.1 37.5 
Supernatant 3 66 0.102 3.2/1.1 34.4 
Pellet 83 0.084 3.9/2.5 65.0 
     dI: intensity average size of nanoparticles measured by DLS. 
     PDI: polydispersity of size. 
 
Table C.2 Physical properties of 2’-triethyl Si PTX(1a) NPs during 
ultracentrifugation. 
 
dI(nm) PDI NP:drug mass(mg) Loading% 
Fresh 109 0.100 36.7/20.0 54.5  
Supernatant 1 44 0.260 9.7/5.1 52.6 
Supernatant 2 48 0.340 2.42/1.0 41.3 
Supernatant 3 40 0.440 1.08/0 0 
Pellet 195 0.260 15.7/9.9 63.0 
     dI: intensity average size of nanoparticles measured by DLS. 
     PDI: polydispersity of size. 
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Table C.6 Physical properties of 2’-trimenthyl Si PTX(1e) NPs during 
ultracentrifugation. 
 
dI(nm) PDI NP:drug mass(mg) Loading% 
Fresh 90 0.080 62.9/38.3 60.9  
Supernatant 1 54 0.221 13.2/7.0 53.8  
Supernatant 2 58 0.281 7.8/4.0 51.2  
Supernatant 3 59 0.270 5.63/2.9 52.3 
Pellet    130 0.172 28.8/21.2 73.5 
     dI: intensity average size of nanoparticles measured by DLS. 
     PDI: polydispersity of size. 
 
Table C.5 Physical properties of 2’-ditert butyl/ethyl Si PTX(1d) NPs 
during ultracentrifugation. 
 
dI(nm) PDI NP:drug mass(mg) Loading% 
Fresh 83 0.071 35.5/19.7 55.5  
Supernatant 1 80 0.159 10.7/2.6 24.1  
Supernatant 2 110 0.130 8.6/2.6 30.0  
Supernatant 3 150 0.173 0/0 n/a 
Pellet    220 0.202 16.3/11.9 73.5 
        dI: intensity average size of nanoparticles measured by DLS. 
        PDI: polydispersity of size. 
 
Table C.4 Physical properties of 2’-triisopropyl Si PTX(1c) NPs during 
ultracentrifugation. 
 
dI(nm) PDI NP:drug mass(mg) Loading% 
Fresh 136 0.084 60.0/30.0 50.0  
Supernatant 1 80 0.229 16.2/6.9 43.0  
Supernatant 2 138 0.221 14.6/3.5 24.1  
Supernatant 3 272 0.136 1.1/0 0  
Pellet 113 0.129 26.4/11.9 58.0  
       dI: intensity average size of nanoparticles measured by DLS. 
       PDI: polydispersity of size. 
 
196 
 
Not only does ultracentrifugation has a significant influence on nanoparticle size 
and loading, but also in vitro drug release profiles. The ultracentrifuged nanoparticles 
release slower than those have not been ultracentrifuged ones in short term. For example, 
2'-triisopropyl Si PTX (1c) and 2'-trimenthyl Si PTX nanoparticles release in PBS at 
pH=7.4 in Figure C.2 and C.3. 
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Figure C.2 Comparison of reverse release profiles for ultracentrifuged 2’-triisopropyl Si 
PTX (1c) nanoparticles and un-ultracentrifuged ones at pH=7.4 
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In order to reduce particle aggregation during freezing of lyophilization, sucrose, 
as cryoprotectant was added in nanosuspension before lyophilization. Combining 
sonication with varied length of time, we studied the effect of cryoprotect and sonication 
time on particle size recovery. 2’,7-triethyl Si PTX nanoparticles were prepared using 
CIJ-D mixer. The nanoparticle suspension was split in half. Sucrose, as cryoprotectant, 
was added in one vial of nanosuspension with a mass ratio of 10:1 sucrose: NPs. The 
other was without sucrose. They were both lyophilized. The nanoparticles in dry state 
were redispersed in PBS at pH=7.4. These two vials of nanoparticles were measured by 
DLS (Beckman Coulter, CA) after 2 and 5 min sonication. They were let sit at room 
temperature for 72 hrs. DLS measurements continued to be taken in 24 hr and 72 hr. 
Particle size are summarized in Table C.7 and size distributions are shown in Figure C.4. 
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Figure C.3 Comparison of reverse release profiles for ultracentrifuged 2’-trimenthyl Si 
PTX (1e) nanoparticles and un-ultracentrifuged ones at pH=7.4 
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Figure C.4 Nanoparticle size distribution of 2’,7-triethyl Si PTX NPs (2a) with sucrose during 
sonication. 
 
Table C.7 2’,7-triethyl Si PTX (2a) NP sizes comparison with and without sucrose. 
particles dI (nm) w/o sugar dI (nm) w/ sugar 
2 min sonication 
308 155 
5 min sonication 
110 96 
24hr 
124 102 
72hr 
157 104 
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Appendix D: Cryo-TEM images of Si PTX Nanoparticles 
 
 
 
 
 
 
 
 
            Figure D.1 Cryo-TEM images of fresh 2’-triethyl Si PTX NPs (1a) after FNP. 
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Figure D.3 Cryo-TEM images of fresh 2’-ditert butyl/ethyl Si PTX NPs (1d) aged in 7 days 
in 95:5 volume ratio of THF/H2O solution. 
 
      
      Figure D.2 Cryo-TEM images of fresh 2’-trimenthyl Si PTX NPs (1e) after FNP. 
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     Figure D.4 Cryo-TEM images of 2’-triisopropyl Si PTX NPs (1c) during ultracentrifugation. 
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                Figure D.5 Cryo-TEM images of 0 hr release of 2’-tri-ethyl Si PTX (1a) NPs. 
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            Figure D.6 Cryo-TEM images of 0 hr release of 2’,7-tri-ethyl Si PTX (2a) NPs. 
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            Figure D.7 Cryo-TEM images of 0 hr release of 2’-trimenthyl Si PTX (1e) NPs. 
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            Figure D.9 Cryo-TEM images of 24 hr release of 2’-tri-ethyl Si PTX (1a) NPs. 
 
 
            Figure D.8 Cryo-TEM images of 0 hr release of 2’-ditert butyl/ethyl Si PTX (1d) NPs. 
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            Figure D.11 Cryo-TEM images of 24 hr release of 2’-triisopropyl Si PTX (1c) NPs. 
 
 
            Figure D.10 Cryo-TEM images of 24 hr release of 2’,7-triethyl Si PTX (2a) NPs. 
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     Figure D.12 Cryo-TEM images of 24 hr release of 2’-ditert butyl/ethyl Si PTX (1d) NPs. 
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            Figure D.13 Cryo-TEM images of 24 hr release of 2’-trimenthyl Si PTX (1e) NPs. 
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Appendix E: Nanoparticles Coloaded with Two Si PTX Prodrugs 
We attempted to prepare nanoparticles coloaded with two Si PTX prodrugs, with 
one of which is more hydrolytical labile and the other one is stable. The goal is to 
develop a nanoparticle formulation which is able to release drug both in short time and 
long time due to two distinctive hydrolysis rate of prodrugs. The nanoparticles were 
prepared by mixing 14.8 mg of 2’-triethyl Si PTX(1a) (with equivalent of 12.5 mg PTX) 
and 15.6 mg 2’-ditert butyl/ethyl Si PTX (1d) and 25 mg PEG-b-PLGA (MW: 5k-10kDa) 
together. All materials were dissolved in 2.5 mL THF, impinged with 2.5 mL DI water 
and diluted by 45 mL DI water by CIJ-D mixer. The resulting nanosuspension were first 
measured by DLS, then ultracentrifuged and lyophilized for 24 hr. The dry powder was 
stored  in 4˚C fridge.  The example of colading nanoparticles has an ideal loading of 
25%:25% when equal mass of two prodrugs were mixed, and the rest of 50% will be 
polymer mass. Shown in Table E.1, A series of mass ratios of prodrugs were used shown 
as 1d:1a, in attempt to achieve nanoparticles with varied loading of coloaded prodrugs. 
Nanoparticle sizes were measured by DLS (Beckman Coulter, CA). The ideal loading of 
PTX% in nanoparticle mass was obtained from the initial materials used for flash 
nanoprecipitation. The actual loading was determined by HPLC using ultracentrifuged 
and lyophilized nanoparticles.  
As seen below, nanoparticle sizes decreased as more 2'-ditert butyl/ethyl Si PTX 
(1d) prodrug was added during flash nanopercipitation. As we know, nanoparticles only 
loaded with 1d were smaller than those with 2'-triethyl Si PTX (1a) shown in Ch.5 and 
Ch.6. Therefore, it is highly likely that nanoparticles were not successfully coloaded with 
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two prodrugs. Instead, one portion of nanoparticles was only loaded with 1d, and the 
other only with 1a.  
In terms of PTX loading, nanoparticles tended to encapsulate more 2'-ditert 
butyl/ethyl Si PTX (1d) than 2'-triethyl Si PTX (1a), which resulted in higher relative 
loading of 1d:1a comparing actual loading with ideal loading. I speculated that 2'-ditert 
butyl/ethyl Si PTX is more hydrophobic, so it nucleates faster during flash 
nanoprecipitation. It is possible that nanoparticles were encapsulated with most of the 
nucluei with 1d and less 1a, or the majority of nanoparticles were only loaded with 1d, 
but not 1a.  
Moreover, the coloading nanoparticles were not successful in terms of combining 
the drug release characteristics of both 1a and 1d nanoparticles. Figure E.1 showed that, 
the coloading nanoparticles release in a similar rate with that of only loaded with 1d, it 
again demonstrated that the coloading nanoparticles are probably composed of 
nanoparticles only loaded with 1d.  
Therefore, in order to achieve coloading two Si PTX prodrugs with very different 
hydrophobicity, new strategies should be developed in terms of mixing condition, 
formulation development etc. 
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               Table E.1 Physical properties of the colaoding nanoparticles. 
1d:1a  Size/nm  Ideal loading%  Actual loading%  
0:100  145  0:47.5  0:47.5 
10:90  145  4.5:33  4.9:40  
30:70  132  15:21  15:32  
50:50  85  21.5:2.5  23:9.5  
100:0  84  53:0  53:0 
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Figure E.1 Reverse release profiles of (1) 1a & 1d coloading NPs, (2) 1a, 2’-triethyl Si 
PTX NPs and (3) 1d, 2’-ditert butyl/ethyl Si PTX NPs. 
